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Abstract  
 
Background: Systematic reviews suggest narrowband UVB (NB-UVB) combined with treatments such 
as topical corticosteroids (TCSs), may be more effective than monotherapy for vitiligo.  
Objective: To explore effectiveness and cost-effectiveness of topical corticosteroid monotherapy 
compared to a) handheld NB-UVB monotherapy and b) handheld NB-UVB/TCS combination 
treatment, in localised vitiligo. 
Design: Pragmatic, 3-arm, randomised controlled trial ith  o ths  t eat e t a d  o ths  
follow-up.  
Setting: 16 UK hospitals – participants recruited from primary and secondary care and the 
community. 
Participants: Adults a d hild e  aged  ea s  ith a ti e o -seg e tal itiligo affe ti g % of 
body area.  
Interventions: TCS (mometasone furoate 0.1% + dummy NB-UVB); NB-UVB (NB-UVB + placebo TCS); 
combination (TCS + NB-UVB). TCS applied once daily on alternate weeks, and NB-UVB administered 
every other day in escalating doses, with dose adjustment for erythema. Treatments were home-
based. 
Main outcome measures: Primary outcome was self-assessed treatment success for a chosen target 
pat h at  o ths a lot less oti ea le  o  o lo ge  oti ea le  o  the Vitiligo Noti ea ilit  “ ale . 
Secondary outcomes included: blinded assessment of primary outcome and % repigmentation; onset 
and maintenance of treatment response; quality of life, side effects, treatment burden and cost-
effectiveness (cost per additional successful treatment). 
Results: 517 participants were randomised (398 adults / 119 children; 52% male; 57% skin types I to 
III, 43% IV to VI).  At 9 months, 370 (72%) participants provided primary outcome data. Median 
percentage of NB-UVB treatment days (actual/allocated) was 81% for TCS, 77% for NB-UVB and 74% 
for combination groups, and for ointment 79% for TCS, 83% for NB-UVB and 77% for combination. 
Target patch location was head & neck (31%), hands & feet (32%) and rest of the body (37%). 
Ta get pat h t eat e t su ess  as 20/119 (17%) for TCS, 27/123 (22%) for NB-UVB and 34/128 
(27%) for combination. Combination treatment was superior to TCS: adjusted risk difference 10.9% 
(95% CI 1.0% to 20.9%; p= 0.032; NNT=10). NB-UVB was not superior to TCS: adjusted risk difference 
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5.2% (95% CI -4.4% to 14.9%; p= 0.290; NNT=19). Secondary outcomes supported the primary 
analysis. Quality of life did not differ between the groups. Participants who used the interventions 
for >75% of expected were more likely to achieve treatment success. Over 40% of participants had 
lost treatment response after a year with no treatment. Grade 3 or 4 erythema was experienced by 
62 (12%) (3 using dummy) and transient skin thinning by 13 (2.5%) participants (2 using placebo). We 
observed no serious adverse treatment effects. For combination treatment compared to TCS, the 
unadjusted incremental cost effectiveness ratio was £2,328.56 (adjusted £1,932) per additional 
successful treatment (from an NHS perspective). 
Limitations: Relatively high loss to follow-up limits interpretation of the trial findings, especially 
during the post-intervention follow-up phase.  
Conclusion: Handheld NB-UVB + TCS combination treatment is superior to TCS alone for treatment 
of localised vitiligo. Combination treatment was relatively safe and  well tolerated, but only effective 
in around a quarter of participants. Whether combination treatment is cost effective or not depends 
how much decision makers are willing to pay for the benefits observed. 
Future work: Development and testing of new vitiligo treatments with a greater treatment response 
and longer-lasting effects are needed.   
Trial registration: ISRCTN17160087 
Funding: NIHR HTA 12/24/02  
  
 
 
5 
 
Contents 
Abstract ...................................................................................................................................... 3 
List of tables ............................................................................................................................. 10 
Abbreviations ........................................................................................................................... 12 
Scientific Summary .................................................................................................................. 14 
Plain English Summary ............................................................................................................. 22 
Chapter 1: Introduction ............................................................................................................. 24 
1.1 Background ...................................................................................................................... 24 
1.2 Rationale for the HI-light Vitiligo trial ............................................................................... 24 
Importance of the topic to patients and healthcare practitioners .......................................... 24 
1.3 Existing Evidence .............................................................................................................. 25 
1.4 Importance of assessing the use of hand-held NB-UVB devices at home ........................... 25 
1.5 Importance of treating early vitiligo .................................................................................. 26 
1.6 Patient reported outcome measures ................................................................................ 26 
1.7 NIHR HTA funding call ....................................................................................................... 27 
Chapter 2: Methods ................................................................................................................... 28 
2.1 Trial Objectives ................................................................................................................. 28 
2.2 Trial Design ....................................................................................................................... 28 
2.3 Trial Setting ...................................................................................................................... 30 
2.4 Participants ...................................................................................................................... 30 
Informed Consent .................................................................................................................... 31 
2.5 Randomisation and blinding ............................................................................................. 31 
2.6 Interventions .................................................................................................................... 32 
Topical Therapy ........................................................................................................................ 32 
Light Therapy ........................................................................................................................... 33 
2.7 Outcomes ......................................................................................................................... 41 
Primary Outcome ..................................................................................................................... 42 
Secondary Outcomes ............................................................................................................... 42 
Safety Outcomes ...................................................................................................................... 43 
Cost-effectiveness analysis ...................................................................................................... 43 
Data collection ......................................................................................................................... 44 
2.8 Sample Size ...................................................................................................................... 45 
2.9 Statistical Methods ........................................................................................................... 45 
Primary Outcome ..................................................................................................................... 45 
Secondary Outcomes ............................................................................................................... 46 
Chapter 3: Results: clinical findings ............................................................................................ 48 
3.1 Recruitment and participant characteristics ...................................................................... 48 
3.2 Adherence to trial treatment and treatment burden ........................................................ 53 
3.3 Blinding ............................................................................................................................ 58 
3.4 Primary Outcome ............................................................................................................. 58 
3.5 Secondary Outcomes ........................................................................................................ 63 
 
 
6 
 
VNS treatment success from blinded PPI reviewers................................................................ 63 
Participant reported VNS treatment success by region of the body (including all assessed 
patches) ................................................................................................................................... 65 
Treatment success - percentage repigmentation .................................................................... 67 
Long-term follow-up (post-intervention) ................................................................................ 68 
Participant reported VNS throughout the trial (treatment and follow-up) ............................ 70 
Quality of life ........................................................................................................................... 71 
Adverse and serious adverse events ....................................................................................... 73 
Chapter 4: Health Economic Evaluation ..................................................................................... 75 
4.1 Introduction ..................................................................................................................... 75 
4.2 Methods ........................................................................................................................... 75 
4.3 Resources use and costs ................................................................................................... 76 
4.4 Identification of outcome(s) ............................................................................................. 78 
4.5 Valuation of outcome(s) ................................................................................................... 79 
4.6 Economic analysis ............................................................................................................. 79 
4.7 Sampling uncertainty ........................................................................................................ 80 
4.8 Subgroup analysis/Analysis of heterogeneity .................................................................... 81 
4.9 Sensitivity analyses ........................................................................................................... 81 
4.10 Results .............................................................................................................................. 82 
4.11 Intervention costs ............................................................................................................. 85 
4.12 Resource use, costs and primary clinical outcome ............................................................. 86 
4.13 Primary Economic Analysis ............................................................................................... 93 
Cost effectiveness analysis of NB-UVB only compared to TCS only ........................................ 93 
Cost effectiveness analysis of combination treatment compared to TCS only ....................... 94 
Sensitivity Analysis ................................................................................................................... 95 
Complete case analysis ............................................................................................................ 96 
The cost of the NB-UVB device ................................................................................................ 96 
Wider cost perspective ............................................................................................................ 97 
Impact of Adherence ............................................................................................................... 98 
Longer term analysis (12 to 21 months) .................................................................................. 98 
4.14 Secondary Economic Analysis ........................................................................................... 99 
Cost utility analysis for those aged 11 and over ...................................................................... 99 
Cost utility analysis for participants aged 11 years and over for NB-UVB only compared to 
TCS only .................................................................................................................................. 101 
Cost utility analysis for participants aged 11 years and over for combination treatment 
compared to TCS only ............................................................................................................ 102 
Cost utility a al sis fo  u de  s ......................................................................................... 102 
NB-UVB compared to TCS: cost utility analysis for participants aged less than 18 years old 
(Table 27) ............................................................................................................................... 105 
Combination treatment compared to TCS: cost utility analysis for participants aged less than 
18 years old ............................................................................................................................ 105 
4.15 Discussion....................................................................................................................... 106 
4.16 Conclusion ...................................................................................................................... 107 
 
 
7 
 
Chapter 5: Process evaluation ................................................................................................. 108 
5.1 Introduction ................................................................................................................... 108 
Aims and objectives .............................................................................................................. 109 
5.2 Methods ......................................................................................................................... 109 
Study Design .......................................................................................................................... 109 
Participants ............................................................................................................................ 109 
Data collection ...................................................................................................................... 111 
Data analysis ......................................................................................................................... 112 
5.3 Results ............................................................................................................................ 113 
Data overview ....................................................................................................................... 113 
Thematic analysis .................................................................................................................. 114 
5.4 Discussion....................................................................................................................... 122 
Trial fidelity ............................................................................................................................ 123 
Population in need ................................................................................................................. 124 
Easy to do but complex to use ............................................................................................... 124 
Treatments may not be suitable for all ................................................................................. 125 
Integrating within the NHS .................................................................................................... 125 
Chapter 6: Patient and Public Involvement .............................................................................. 128 
6.1 Background .................................................................................................................... 128 
6.2 Aims ............................................................................................................................... 128 
6.3 Methods ......................................................................................................................... 128 
6.4 Results ............................................................................................................................ 130 
Contextual factors relating to stakeholder involvement ....................................................... 130 
Stakeholders involved in the HI-Light trial ............................................................................. 131 
Stages of research and opportunities for stakeholder impact .............................................. 132 
6.5 Discussion....................................................................................................................... 140 
6.6 Conclusion ...................................................................................................................... 141 
Chapter 7: Device Testing ........................................................................................................ 142 
7.1 Introduction ................................................................................................................... 142 
7.2 Materials and Methods .................................................................................................. 143 
Use of NB-UVB devices in the HI-Light Vitiligo Trial .............................................................. 143 
Devices and test equipment .................................................................................................. 143 
7.3 Study 1: Photometric characterisation of the NB-UVB devices prior to their use in the trial
 ....................................................................................................................................... 145 
7.4 Study 2: Quality assurance of devices prior to distribution to trial participants ............... 146 
7.5 Results ............................................................................................................................ 147 
Study 1 – Characterisation of Devices ................................................................................... 147 
Study 2 – Results of devices prior to issue to participants .................................................... 149 
7.6 Discussion....................................................................................................................... 149 
Chapter 8: Discussion and conclusion ...................................................................................... 152 
8.1 Main Findings ................................................................................................................. 152 
Relevance to the wider literature .......................................................................................... 153 
Strengths and Limitations ...................................................................................................... 155 
 
 
8 
 
Generalisability ...................................................................................................................... 156 
8.2 Conclusions .................................................................................................................... 157 
Implications for healthcare .................................................................................................... 157 
Implications for research ....................................................................................................... 158 
Chapter 9: Acknowledgements ................................................................................................ 161 
9.1 Contribution of authors .................................................................................................. 164 
9.2 Publications .................................................................................................................... 167 
9.3 Data Sharing ................................................................................................................... 167 
References .................................................................................................................................. 168 
Appendix 1 Addendum to HI-Light Statistical Analysis Plan (SAP) Final Version 1.0 dated 15 October 
2018 174 
Appendix 2 Participant reported VNS treatment success at all assessed patches at 3 and 6 months
 ............................................................................................................................................................ 175 
Appendix 3 Participant assessed onset of treatment response ......................................................... 175 
Appendix 4 Target patch % repigmentation assessed by nurse at 3, 6, and 9 months ...................... 176 
Appendix 5 Summary of related AEs by preferred term name in MEDDRA coding ........................... 177 
Appendix 6 Utility and QALYs for participants aged 11 and over (available case data, Secondary Cost 
utility analysis) .................................................................................................................................... 178 
Appendix 7 Survey of recruiting centre staff ...................................................................................... 179 
  
 
 
9 
 
List of figures 
Figure 1 HI-light trial flowchart ............................................................................................................. 29 
Figure 2 Consort Diagram ..................................................................................................................... 49 
Figure 3 Figure showing target lesions before (A, a) and after (B, b) treatment. ................................. 59 
Figure 4 Sensitivity analyses of primary outcome ................................................................................ 61 
Figure 5 Treatment success at all assessed patches at 9 months ......................................................... 65 
Figure 6 Investigator assessed onset of treatment response ............................................................... 67 
Figure 7 Percentage of participants reporting treatment success for target patch during the trial .... 71 
Figure 8 Cost effectiveness Acceptability curve for NB-UVB only versus TCS only .............................. 94 
Figure 9 Cost Effectiveness Acceptability Curve for combination treatment versus TCS only ............. 95 
Figure 10 Stakeholder contribution to the design, development and execution of the HI-Light trial 132 
Figure 11 Stills from the HI-Light trial training videos. ....................................................................... 138 
Figure 12 Elevation drawing of the measurement jig ......................................................................... 144 
Figure 13 Photos showing three differing views of the test jig .......................................................... 145 
Figure 14 Spectral irradiance for the first batch of 10 tubes .............................................................. 147 
Figure 15 Tube irradiance (normalised to the maximum irradiance) as a function of time ............... 148 
 
List of Boxes 
Box 1 Underpinning Programme Theory ............................................................................................ 111 
Box 2 James Lind Alliance Vitiligo Priority Setting Partnership Top Research Priorities .................... 160 
 
 
 
  
 
 
10 
 
List of tables 
Table 1 Summary of protocol amendments ......................................................................................... 29 
Table 2 Key questions regarding the use of NB-UVB for generalised vitiligo (adapted from 
Madigan et al ) ...................................................................................................................................... 35 
Table 3 Summary of Instructions for adjusting light therapy treatment schedule and dosing ............ 38 
Table 4 Baseline characteristics ............................................................................................................ 49 
Table 5 baseline characteristics by treatment group and availability of primary outcome at 9 months
 .............................................................................................................................................................. 51 
Table 6 Description of vitiligo patches at baseline ............................................................................... 53 
Table 7 Treatment adherence, burden and discontinuation ................................................................ 55 
Table 8 Unblinding of investigators and participants at 9 months ....................................................... 58 
Table 9 Primary outcome analysis – participant reported treatment success (VNS), intention-to-treat 
(ITT) ....................................................................................................................................................... 60 
Table 10 Summary of subgroup analysis for the primary outcome (target patch only) ...................... 62 
Table 11 Treatment success by blinded PPI assessors (VNS using digital images at baseline and 9 
months) ................................................................................................................................................. 64 
Table 12 Participant reported treatment success (VNS) by body region (including all assessed 
patches) ................................................................................................................................................. 66 
Table 13 Percentage repigmentation assessed by blinded dermatologist and investigators .............. 68 
Table 14 Loss of treatment response at target patch assessed by participant at 12, 15, 18 and 21 
months .................................................................................................................................................. 69 
Table 15 Loss of treatment response at target patch assessed by participant at 12, 15, 18 and 21 
months (only for those who achieved treatment success by 9 months) ............................................. 70 
Table 16 Summary of quality of life scores ........................................................................................... 72 
Table 17 Adverse events ....................................................................................................................... 73 
Table 18 Unit Costs Table (UK£ sterling, 2017) ..................................................................................... 83 
Table 19 Quality assurance process (time and costs) for NB-UVB devices .......................................... 86 
Table 20 NB-UVB compared to TCS: mean (Standard Deviation) resource use according to 
intervention arm over the 9-month treatment phase for all participants (based on available data) .. 87 
Table 21 NB-UVB compared to TCS: mean (Standard Deviation) costs and outcomes according to 
intervention arm over 9-month treatment phase (UK£Sterling, 2017) for all participants (based on 
available data) ....................................................................................................................................... 88 
Table 22 Combination treatment versus TCS: mean (Standard Deviation) resource use according to 
intervention arm over the 9 month treatment phase for all participants (based on available data) .. 90 
Table 23 Combination treatment versus TCS: mean (Standard Deviation) costs and outcomes 
according to intervention arm over 9-month treatment phase (UK£Sterling, Price Year) for 
participants (based on available data) .................................................................................................. 92 
Table 24 Summary of sensitivity analyses (adjusted results) ............................................................... 96 
Table 25 Distribution of responses over the levels of the different domains of the EQ-5D-5L............ 99 
 
 
11 
 
Table 26 Unadjusted Utility and QALYs for participants aged 11 and over (available case data, 
primary Cost utility analysis) ............................................................................................................... 101 
Table 27 Distribution of responses over the levels of the different domains of the CHU-9D (number 
(%) of participants) .............................................................................................................................. 103 
Table 28 U adjusted Utilit  a d QALY“ fo  u de  s a aila le ase data  ..................................... 105 
Table 29 trial participant interview characteristics ............................................................................ 113 
Table 30 Summary of core principles for PPI involvement in the HI-Light trial .................................. 129 
Table 31 The impact of stakeholder contributions to the trial. .......................................................... 133 
Table 32 Summary statistics for the characterisation of the irradiance ............................................. 148 
Table 33 Average irradiances following simulated treatment regimens for type VI skin.  ................. 149 
 
 
 
12 
 
Abbreviations 
 
Word Abbreviation 
AE Adverse Event 
CEBD Centre for Evidence Based Dermatology 
CHU-9D Child Health Utility 9D 
CI Confidence Interval 
CONSORT Consolidated Standards of Reporting Trials  
DVD Digital Versatile Disc 
(e)CRF (electronic) Case report form 
EAC Equivalent annual cost 
EQ-5D-5L 5-level EuroQol 5-dimensional questionnaire 
GP General practitioner 
GRIPP2 Guidance for Reporting Involvement of Patients and the Public 
HI-LIGHT Home Interventions and Light therapy for the treatment of vitiligo 
HTA Health Technology Assessments 
ICER Incremental cost-effectiveness ratio 
ITT Intention to treat 
JAK Janus Kinase 
MED Minimum Erythemal Dose 
MHRA Medicines and Healthcare products Regulatory Agency 
NB-UVB Narrow band ultraviolet B light 
NCTU Nottingham Clinical Trials Unit 
NHS National Health Service 
NICE National Institute for Clinical Excellence 
NIHR National Institute for Health Research 
NNT Number Needed to Treat 
NRES National Research Ethics Service 
PPI Patient and Public Involvement 
PROMs Patient Reported Outcome measures 
PSSRU Personal Social Services Research Unit.  
QALY Quality-adjusted life year  
QP Qualified Person 
 
 
13 
 
RCT Randomised Controlled Trial 
REC Research ethics committee 
SAE Serious Adverse Event 
SD Standard Deviation 
START Systematic Techniques for Assisting Recruitment to Trials 
TCS Topical corticosteroid 
TSC Trial Steering Committee 
UK DCTN UK Dermatology Clinical Trials Network 
VitiQOL Vitiligo Specific Health Related Quality of Life Instrument  
VNS Vitiligo Noticeability Scale 
  
 
 
14 
 
Scientific Summary  
Background 
Vitiligo is a skin condition that results in complete loss of pigment. It affects around 0.5-2% of the 
o ld s populatio  a d a  de elop at a  age. Vitiligo can be distressing for patients, especially 
when it occurs on exposed areas such as the face and hands.  
Current clinical guidelines for the management of vitiligo recommend topical corticosteroids (TCS), 
narrowband UVB (NB-UVB), topical tacrolimus, and combination treatments, but the evidence base 
for all treatment approaches is limited. 
The HI-Light Vitiligo Trial addresses two priority topics from a James Lind Alliance Priority Setting 
Partnership that were highlighted as being important to people with vitiligo and healthcare 
professionals: 
1. Which treatment is more effective for vitiligo: steroid creams/ointments or light therapy? 
2. How effective is UVB therapy when combined with creams or ointments in treating vitiligo? 
Objectives 
1. To evaluate the comparative effectiveness and safety of home-based interventions for the 
management of active, limited vitiligo in adults and children. Comparing:  
• Handheld NB-UVB light with potent TCS (mometasone furoate 0.1% ointment) 
• Combination of handheld NB-UVB light plus potent TCS with potent TCS alone.  
2. To assess whether treatment response (if any) is maintained once the interventions are stopped.  
3. To compare the cost-effectiveness of the interventions from an National Health Service (NHS) 
and separately a family perspective.  
4. To understand the barriers and facilitators to adoption of these interventions within the UK NHS.  
Methods 
Study Design 
A multicentre, three-arm, parallel group, pragmatic, placebo-controlled randomised controlled trial 
(RCT), with nested health economic analysis and process evaluation.  
Recruitment and Follow-up 
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Participants were recruited from 16 UK hospitals, with recruitment from primary care, secondary 
care and community advertising, and were trained to deliver the treatments in their homes. 
Treatment was for 9 months with a furthe   o ths  follo -up, participants attended hospital 
clinics on two consecutive days at baseline for recruitment and training, and then at 3, 6 and 9 
months to assess outcomes. Follow-up to 21 months was by 3-monthly questionnaires.  
Eligibility Criteria 
Participants were aged 5 years and over, with a diagnosis of non-segmental vitiligo, limited to 
approximately 10% or less of body surface area, and at least one vitiligo patch that had been active 
in the last 12 months (self-reported). Participants had to be willing to stop other vitiligo therapies; 
be able to follow the treatment instructions and comply with safety precautions at home; and be 
willing and able to give informed (or parental/carer) consent.  
People were excluded if they had segmental or universal vitiligo; vitiligo limited solely to areas 
contra-indicated for treatment with potent TCS; history of skin cancer, radiotherapy use or 
photosensitivity (based on Minimum Erythemal Dose (MED) test); allergy or contra-indication to 
mometasone furoate; were pregnant women, breastfeeding or likely to become pregnant during the 
trial; those on immunosuppressive drugs; involved in another clinical trial; or 
the investigator thought were unable to use the treatments safely. 
Interventions 
Participants received a handheld NB-UVB light unit (active or dummy) and either TCS (mometasone 
furoate 0.1% ointment (Elocon®, Merck, Sharp and Dohme) or placebo ointment (vehicle). 
Treatments were used for up to 9 months. Participants received face-to-face training, online training 
and a written handbook of instructions. 
At baseline, participants selected a target patch that had been active in the last 12 months and in 
which they most wanted to see improvement. Participants could select up to two further study 
patches for treatment, with a maximum of one on each of three anatomical regions (head and neck, 
hands and feet, and rest of body). Participants could treat additional patches if they wished, but 
these were not assessed in the study. 
Handheld NB-UVB (Dermfix 1000 MX, Dermfix Limited, UK) was used on alternate days. The 
treatment schedule had a starting dose of 0.05 J/cm2, and increased incrementally. Participants 
recorded treatment times and side effects in a participant s diary.  
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TCS or placebo ointment was applied once daily on alternate weeks (1 week on, 1 week off).  
Outcomes 
Primary outcome 
Participant-reported treatment success at the target patch of vitiligo after 9 months of 
treatment, measured using the Vitiligo Noticeability Scale (VNS). Treatment success was defined as 
itiligo ei g a lot less oti ea le  o  o lo ge  oti ea le  compared with before treatment.  
Secondary outcomes  
a) Blinded assessment of treatment success (using VNS) at the target patch by a panel of three 
blinded assessors with vitiligo using digital images at baseline and 9 months;  
b) Participant-reported treatment success for each of the three body regions using the 
VNS, assessed at 9 months (all assessed patches);  
c) Onset of treatment response at the target patch: assessed by investigators using the 
question Co pa ed to the sta t of the stud , has the e ee  a ha ge i  the itiligo pat h?   
O set of t eat e t espo se as defi ed as sta ed the sa e (I.e. not worsened)  o  i p o ed  as 
all target patches were active patches at baseline;  
d) Percentage repigmentation: for the target patch at 9 months, using digital images assessed by a 
li i ia  u a a e of t eat e t allo atio  t eat e t su ess  % epig e tatio , plus li ded 
assessment by investigators at 3, 6 and 9 months;  
e) vitiligo-specific and generic quality of life: assessed at end of treatment (9 months) and end of 
follow-up (21 months);  
f) Maintenance of treatment response: assessed by participants for the target patch of vitiligo at 12, 
1 ,  a d  o ths, usi g the uestio  Co pa ed to si e ou stopped usi g the stud  
t eat e ts, has the e ee  a ha ge i  the itiligo pat h? . Loss of t eat e t espo se as defi ed 
as a espo se of o se  at any time-point;  
g) Burden of treatment: time per session for active light treatment and participant-reported 
treatment burden for TCS and light treatments at 3, 6 or 9 months.  
Safety outcomes 
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Adverse reactions during the treatment phase were recorded. Events of interest were pre-defined as 
grade 3 or 4 erythema and skin thinning. All serious adverse events were also recorded. 
 Sample size 
The target sample size was 440 participants (assuming 15% of participants allocated TCS alone would 
achieve treatment success, and to detect a clinically significant absolute difference between groups 
of 20%, with 2.5% two-sided alpha, 90% power and 15% loss to follow-up). A planned sample size 
review by the Data Monitoring Committee after 18 months of recruitment recommended extending 
recruitment to 516 participants. 
Randomisation and blinding 
Participants were randomised to active TCS plus dummy NB-UVB (TCS only group); active NB-UVB 
plus placebo ointment (NB-UVB only group); or active TCS ointment plus active NB-UVB 
(combination group). Randomisation was minimised by recruiting centre, body region of target patch 
(head and neck, hands and feet or rest of the body) and age (5–16 years or >16 years). 
Randomisation was via a secure web server created and maintained by the Nottingham Clinical Trials 
Unit (NCTU) to ensure allocation concealment. A central pharmacy distributed the interventions 
directly to parti ipa ts  ho es.  
Participants, research nurses, principal investigators, members of trial management group and data 
analysts were blinded to treatment allocation. Due to the unblinding risk from skin erythema after 
NB-UVB treatment, additional outcome assessments were performed by a panel of three patient 
assessors (for the primary analysis) and a blinded clinician for the secondary outcome of % 
repigmentation, using digital images taken at baseline and at 9 months. 
Statistical methods 
For all analyses, two pre-specified between-group comparisons were made: NB-UVB light versus TCS, 
and NB-UVB light plus TCS versus TCS. 
Primary analysis was by intention-to-treat, and with multiple imputation of missing data. The 
number and percentage of participants achieving t eat e t su ess  as epo ted. Randomised 
groups were compared using a mixed effects model for binary outcomes, adjusted by recruitment 
centre, body region of target patch, and age at randomisation. The primary estimate of effect was 
the difference in the percentage of participants achieving treatment success at 9 months, with 95% 
CI and p values. We also reported relative differences using risk ratios. Sensitivity analyses were 
conducted to (i) adjust for any variables with imbalance at baseline, (ii) repeat primary analysis 
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based on participants with primary outcome data and (iii) investigate the impact of treatment 
adherence. Planned subgroup analyses were (i) children versus adults); (ii) body region of the target 
vitiligo patch; (iii) hypomelanotic* patch (an indicator of disease activity): definitely or maybe versus 
no; (iv) >= 4 years duration of vitiligo versus <4 years. These analyses were conducted by inclusion of 
appropriate interaction terms in the regression model and were considered as exploratory. An 
additional post-hoc subgroup analysis explored the impact of skin type (types I to III versus types IV 
to VI).  
Secondary outcomes were analysed by a similar approach, using appropriate regression modelling 
depending on outcome type.  
*It is thought that patches which are hypomelanotic, with poorly defined borders, are more likely to 
be active patches, and therefore more responsive to treatment. Patches were assessed at the point 
of a do isatio  usi g a Wood s la p, and designated as hypomelanotic with poorly defined 
borders (or h po ela oti  fo  sho t  o  a ela oti  ith sha pl  defi ed o de s. 
Health economics  
A nested health economic analysis explored cost-effectiveness of the interventions from an NHS 
perspective (primary) and a family perspective (secondary). Assessed using participant self-report of 
healthcare appointments (number, which professional, and relevance to vitiligo), prescriptions for 
vitiligo treatments and personal expenses. The base case analysis estimates an incremental cost per 
additional successful treatment with incremental cost per QALY presented in secondary analyses.  
Process evaluation 
A mixed-methods process evaluation study was conducted to inform interpretation of trial results 
and to explore barriers and facilitators to adoption of the interventions within the UK NHS. 
Twenty-five trial participants (adults, young people or parents) and 10 commissioners were 
interviewed (9 interviews); twenty-four recruiting site staff completed an online survey; and, 
thirteen site staff participated in study-review focus groups.  
Interviews and focus group data were analysed thematically using an inductive approach; descriptive 
statistics were generated for online survey responses. Interview prompts and analysis were 
informed by an initial programme theory, which proposed how combination treatment might ideally 
work within the NHS. Data were organised to address three key questions:  
• Is home-based treatment manageable for people with vitiligo;  
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• Should combination treatment be made more widely available;  
• Could combination treatment be made more widely available in the NHS?  
Results 
Between May 2016 and September 2017, 517 participants were randomised (398 adults, 119 
children). Primary outcome data were available for 370 (72%) participants. Baseline characteristics 
were well balanced. 
The median percentage of NB-UVB treatment days was 81% for TCS, 77% for NB-UVB and 74% for 
combination groups, and for ointment 79% for TCS, 83% for NB-UVB and 77% for combination. Just 
under half of participants used the treatments for over 75% of the expected duration.  
Investigators thought that they had become unblinded for 21%, 28% and 27% of participants in the 
TCS, NB-UVB and combination groups respectively. The percentages of participants who thought 
that they had become unblinded were 39%, 55% and 44% respectively. Unblinding guesses for NB-
UVB were correct approximately 80% of the time, but for TCS the guesses were correct less than half 
of the time. 
For the primary outcome, treatment success using the VNS at 9 months was reported by 20/119 
(17%) of those allocated TCS, 27/123 (22%) allocated NB-UVB and 34/128 (27%) allocated 
combination treatment. The adjusted risk difference between combination treatment and TCS was 
10.9% (95% CI 1.0% to 20.9%; p= 0.03), and for NB-UVB compared to TCS 5.2% (95% CI -4.4% to 
14.9%; p= 0.29).  Corresponding adjusted risk ratios were 1.93 (95% CI 1.02 to 3.68) for combination 
treatment compared to TCS and 1.44 (0.77 to 2.70) for NB-UVB compared to TCS. 
Pa ti ipa ts ho adhe ed fo  % of e pe ted t eat e ts e e o e likel  to a hie e t eat e t 
success in the combination group compared with TCS (adjusted odds ratio 2.73 (95% CI 1.24 to 
6.02)), but not for UVB compared with TCS (adjusted  odds ratio 1.52 (95% CI 0.56 to 4.11)).  
Secondary outcomes supported the primary analysis. Treatment success (VNS) based on assessment 
of digital images by patient reviewers showed similar results but were more likely to suggest benefit 
from NB-UVB, with evidence of differences in treatment success for both the NB-UVB and the 
combination groups, compared with TCS.  
Pe e tage epig e tatio  su ess ates % epig e tatio  usi g li ded assess e t of digital 
images, confirmed that combination treatment was better than TCS: 4/119 (3%) for the TCS group, 
9/123 (8%) for NB-UVB group and 18/128 (15%) for the combination group.  
 
 
20 
 
Quality of life was high at baseline for all groups and showed no between group differences at 9 or 
21 months 
Overall 94% of participants achieved onset of treatment response by 3-months for all groups 
(defined as the active target patch having improved or stayed the same (i.e. not worsened)). TCS 
(40% improved 57% stayed the same); NB-UVB (61% improved, 35% stayed the same) and 
combination (60% improved, 38% stayed the same). 
For participants using active light devices the median treatment time was 20 minutes per treatment 
session. Participants required just over an hour (mean 70 minutes) of face to face training prior to 
using the treatment at home.  
 Burden of treatment was identified as an issue by 42/142 (30%) in the TCS group, 38/140 (27%) in 
the NB-UVB group and 36/149 (24%) in the combination group, although interpretation is difficult as 
all three groups used both treatments throughout (either active or dummy/placebo). In general, NB-
UVB treatment was more burdensome than treatment with TCS.  
Grade 3 or 4 erythema occurred in 62 (12%) participants (3 using dummy), and transient skin 
thinning in 13 (2.5%) participants (2 using placebo), with no serious adverse treatment effects.  
In line with the clinical results, the primary cost effectiveness analysis showed that the unadjusted 
incremental cost per additional successful treatment was £2,328.56  (adjusted £1,932.35) for 
combination treatment compared to TCS alone and £4,801.92  (adjusted £3,335.74) for NB-UVB 
alone compared to TCS alone. Whether combination treatment is  considered to offer value for 
money to the NHS depends on the maximum willingness to pay of decision makers to gain an 
additional treatment success and there is currently no evidence as to what the level might be. 
Process evaluation findings 
Process evaluation findings suggest that stakeholders were positive about the role of combination 
treatment in the management of vitiligo.  
Despite being time consuming and (potentially) complex, both participants and healthcare 
professionals indicated that, with appropriate support, combination treatment could be managed at 
home. Appropriate training and on-going monitoring, particularly in the early stages of treatment 
are essential, especially given concerns about potential side-effects associated with the treatments. 
Trial participants and healthcare professionals both advocated the broader use of  combination 
treatment in the NHS, with some caveats about which patients might benefit most.  
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Both healthcare professionals and commissioners recognised that the need for a developed 
infrastructure (nursing support, medical physics service) might be a barrier to broader NHS 
provision. Regional clinics might be a possible solution, as might some form of mixed economy 
approach, where patients purchase light-therapy devices alongside NHS support and training.  
Conclusions 
Implications for healthcare 
Combination treatment with NB-UVB and potent TCS is superior to potent TCS alone, although the 
benefits are likely to be modest. Combination treatment was relatively safe, well tolerated and cost-
effective for people with limited vitiligo that had been active within the last 12 months.  
Home-based NB-UVB therapy requires quality control of devices, training and support from 
healthcare professionals with experience of delivering phototherapy services and is time intensive 
for patients, but appears to be a useful treatment option for people with localised active vitiligo and 
provides considerable advantages over hospital NB-UVB therapy, which requires hospital visits 2-3 
times per week.  
Use of mometasone furoate 0.1% (a potent corticosteroid) as first-line treatment for vitiligo is 
supported as it achieved treatment success in 1 in 6 individuals and was effective in stopping the 
spread of active vitiligo patches. It was also found to be safe in both adults and children when used 
daily on alternate weeks for 9 months. 
Treatment effects were lost once interventions were stopped, suggesting that intermittent 
maintenance therapy is likely to be needed. 
These findings require a broad dissemination strategy that includes general practice as well as 
dermatology services.  
Implications for research 
Research priorities include: 
1. Development and testing of new vitiligo treatments with a greater response and longer-
lasting effects. 
2. Investigation of treatments suitable for people with widespread vitiligo.  
3. Research into different strategies to maintain treatment response once treatments are 
stopped 
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4. Further development and validation of outcome instruments to be included in the vitiligo 
core outcome set, to facilitate combining of trial results in meta-analyses.  
Trial registration  
ISRCTN17160087 
Funding 
 NIHR HTA 12/24/02  
Plain English Summary  
The HI-Light vitiligo trial aimed to find out whether treating vitiligo at home with a particular type of 
ultraviolet light (NB-UVB), either by itself or with a steroid ointment, is better than treatment using a 
steroid ointment on its own. 
We enrolled 517 children and adults who had small, recently changing patches of vitiligo into the 
study. Participants received one of three possible treatment options: steroid ointment (plus dummy 
light), handheld NB-UVB light (plus placebo ointment) or both treatments used together.  
We asked participants to judge how noticeable their target vitiligo patch was after 9 months of 
t eat e t. We o side ed the t eat e t as su essful if the pa ti ipa ts  espo ses e e eithe  a 
lot less oti ea le  o  o lo ge  oti ea le .  
The results showed that using both treatments together was better than using steroids ointments on 
its own. Around a quarter of participants (27%) who used both treatments together said that their 
itiligo as eithe  o lo ge  oti ea le  o  a lot less oti ea le  afte   o ths of t eat e t. This 
compared to 17% of those using steroid ointment on its own and 22% of those using NB-UVB light 
on its own.  
All treatments were able to stop the vitiligo from spreading. Patches on the hand and feet were less 
likely to respond to treatment than patches on other parts of the body. 
The trial found that the vitiligo tended to return once treatments were stopped, so ongoing 
intermittent treatment may be needed to maintain treatment response. 
The treatments were found to be relatively safe and easy to use, but light treatment required a 
considerable time commitment (approximately 20 minutes per session, 2 to 3 times per week). 
This trial showed that using steroid ointment and NB-UVB light together is likely to be better than 
steroid ointment alone, for people with small patches of vitiligo. Steroid ointment alone can still be 
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effective for some people and remains a useful treatment that is able to stop vitiligo from spreading. 
The challenge is to make handheld NB-UVB light treatment available as normal care within the NHS 
for people with vitiligo.
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Chapter 1: Introduction 
1.1 Background 
Vitiligo is an acquired, chronic skin condition, which causes loss of skin pigmentation. This leads to 
milky white, well-demarcated non-scaly patches on the affected skin and/or mucosal surfaces. The 
depigmentation seen in vitiligo is caused by destruction of pigment cells (melanocytes), although the 
precise cause of this is still unclear. Vitiligo is considered to be a multi-factorial disease 1-6. In the 
light of recent genome-wide studies, there is growing evidence that vitiligo has, at least in part, an 
autoimmune basis, and this is a target for future treatments, although these are still in development 
7.  
Vitiligo affects around 0.5- % of the o ld s populatio . Vitiligo a  de elop at a  age ut ost 
commonly occurs between the age of 10 and 30 years 8-12. Whilst there is equal prevalence of vitiligo 
in adults and children of both sexes, females tend to seek treatment more often, possibly due to the 
greater social stigma experienced by women and girls with the condition 10, 13. 
Vitiligo may be segmental (affecting one specific area of skin) but is commonly non-segmental 
(affecting multiple, symmetrically-distributed areas). The most commonly affected sites are the face, 
neck and trunk 14. The cosmetic disfigurement of this seemingly inconsequential skin disease has a 
major impact on quality of life 15. It can be particularly distressing for people with darker skin types, 
especially if the vitiligo occurs on highly visible sites, such as the face and hands16. People with 
vitiligo can experience a number of psychological problems such as depression and anxiety, which 
may lead to low self-esteem and social isolation 15-18.  
Current clinical guidelines for the diagnosis and management of vitiligo recommend narrowband 
ultraviolet light B (NB-UVB), topical tacrolimus, topical corticosteroids (TCSs) and combination 
treatments 19, 20.  
1.2 Rationale for the HI-light Vitiligo trial 
Importance of the topic to patients and healthcare practitioners 
A James Lind Alliance Priority Setting Partnership identified priority topics for future vitiligo research, 
which were important to patients and healthcare practitioners 21. The HI-Light Vitiligo Trial has been 
designed to address two of the priority topics: 
1. Which treatment is more effective for vitiligo: steroid creams/ointments or light therapy? 
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2. How effective is UVB therapy when combined with creams or ointments in treating vitiligo? 
The Priority Setting Partnership also highlighted the importance of testing vitiligo treatments in 
children; so the HI-Light Vitiligo Trial recruited both children and adults.  
1.3 Existing Evidence 
A 2010 Cochrane systematic review looking at interventions for the treatment of vitiligo identified 
57 trials covering 68 different treatment options 22. The quality of the trials included in the review 
was generally poor, making it difficult to make firm recommendations. The use of NB-UVB light 
therapy was generally supported, and the combination of light treatment with other active 
interventions appeared to be more effective than monotherapies. However, due to heterogeneity of 
trial designs, optimal dosing and treatment regimen for NB-UVB could not be established 23. In 2016 
the Cochrane review was updated, and covered 96 trials, none of which provided evidence that was 
of sufficient quality to alter these overall conclusions. 
When the HI-Light Vitiligo trial was first proposed in 2010, the only randomised controlled trial (RCT) 
that had been conducted to assess the use of hand-held NB-UVB devices for the treatment of vitiligo 
was the pilot study to the main HI-Light Vitiligo Trial 24. This demonstrated that the devices were safe 
and well tolerated when used to treat children and adults at home, and that people with vitiligo 
were keen to take part in a trial of home-based NB-UVB. 
Following this pilot trial, other studies have suggested the efficacy of hand-held NB-UVB devices for 
vitiligo, including in children, but the studies have been small or retrospective 25, 26, making it difficult 
to draw firm conclusions. 
1.4 Importance of assessing the use of hand-held NB-UVB devices at home 
In the UK, NB-UVB treatment is delivered almost exclusively in secondary care, requiring regular 
hospital visits. NB-UVB is usually reserved for people with widespread vitiligo, because most 
dermatology services are only equipped with large, full-body NB-UVB units 19.  
There are various devices available for the administration of NB-UVB treatments at home, which 
avoids the need for hospital visits. Some dermatology departments in the UK now supply home NB-
UVB units (large machines that look like portable sunbeds for treating large areas of skin) for use by 
patients with eczema and psoriasis. Early reports suggest that these are well tolerated and 
effective27-30. 
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When treating vitiligo, the choice of the NB-UVB device is usually based on the extent and 
anatomical location of the vitiligo; limited areas of vitiligo can be treated with a small, hand-held NB-
UVB devices 31.  
There are several potential benefits of using hand-held NB-UVB devices for treating early, limited 
vitiligo: 
• reduction in attendance at hospital and associated time and travel costs for patients 
• only treating involved areas, thus sparing uninvolved skin 
• when more extensive whole-body phototherapy is not indicated, NB-UVB treatment of 
vitiligo can still be used 
• low cost of the devices relative to expensive, whole body units 
Should a hand-held device prove to be effective and safe for the treatment of vitiligo, this could be 
an important addition to the treatment options available to people with limited vitiligo in the early 
stages of the condition, or for those wishing to treat only specific patches. 
1.5 Importance of treating early vitiligo 
Clinical studies have suggested that treatment of vitiligo in its early stages is more likely to be 
beneficial than treatment of longstanding vitiligo 25, 32. 
For this reason, participants in the HI-Light Vitiligo Trial were required to have at least one patch of 
vitiligo that changed in the last 12 months (see further details in Section 2.4). 
1.6 Patient reported outcome measures 
A survey and systematic review of the outcome measures used in previous vitiligo trials, suggested 
that patie ts  a d li i ia s  a  ha e dispa ate ie s ega di g hi h out o es a e most 
important in evaluating treatment response for vitiligo 33.  
An international e-Delphi consensus exercise has established core outcome domains for future 
vitiligo trials.34 Outcomes that should be measured in all future vitiligo trials include: 
• Repigmentation 
• Cosmetic acceptability of treatment response 
• Maintenance of gained repigmentation 
• Cessation of spread 
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• Quality of Life 
• Burden of treatment 
• Safety 
The HI-Light trial will assess all of these core outcome domains. The core outcome domains include 
important patient reported outcome measures, including the cosmetic acceptability of treatment 
response. Prior to recruiting participants to the HI-Light Vitiligo Trial, we developed a new patient-
reported outcome measure to assess this domain: the Vitiligo Noticeability Scale (VNS). This 
instrument has been recommended for use within the core outcome set35, and has been used as the 
primary outcome measure for the trial. 
The VNS was co-produced with vitiligo patients, using surveys and focus group work to agree the 
construct of interest and to develop a preliminary version of the instrument. The VNS measures how 
oti ea le  the patie t thi ks thei  itiligo is afte  t eat e t, usi g a -point scale, with treatment 
su ess ep ese ted  espo se optio s  o   a lot less oti ea le  o  o lo ge  oti ea le . 
1.7 NIHR HTA funding call 
In view of the limited evidence for home-based NB-UVB for vitiligo, the UK National Institute for 
Health Research (NIHR) Health Technology Assessment (HTA) programme issued a funding call and 
subsequently commissioned the HI-Light Vitiligo Trial. The HI-Light Vitiligo Trial is the first large-scale 
multi-centre, pragmatic RCT to evaluate the use of TCS and NB-UVB at home. 
The trial includes a nested cost-effectiveness analysis and a mixed methods process evaluation to 
explore the views of patients and healthcare professionals on the trial treatments and the potential 
barriers and facilitators to safe and effective use of the trial treatments within the National Health 
Service (NHS). 
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Chapter 2: Methods 
The full trial protocol is available on the NIHR project page, and a summary protocol published36. 
CONSORT guidelines have been followed for the analysis and reporting.  
2.1 Trial Objectives 
1. To evaluate the comparative effectiveness and safety of home-based interventions for the 
management of active, limited vitiligo in adults and children. Comparing:  
• Handheld NB-UVB light with potent TCS (mometasone furoate 0.1% ointment) 
• Combination of handheld NB-UVB light plus potent TCS with potent TCS alone.  
2. To assess whether treatment response (if any) is maintained once the interventions are stopped.  
3. To compare the cost-effectiveness of the interventions from an National Health Service (NHS) 
and family perspective.  
4. To understand the barriers and facilitators to adoption of these interventions within the UK NHS.   
 
2.2 Trial Design 
The HI-Light trial was a multi-centre, three –arm, parallel group, pragmatic, placebo-controlled RCT. 
The t ial e uited adults  aged  ea s  a d hild e   to  ea s  ith ea l  o  li ited vitiligo 
(defined as a coverage of approximately 10% or less of the body surface area).  
Trial treatments were administered at home by the participant, with or without assistance from a 
relative/carer. Participants were initially followed-up in secondary care at 3 and 6 months, and 
finally at 9 months where the primary outcome was assessed. Long-term follow-up continued for a 
further 12 months, with online or postal questionnaires completed at 12, 15, 18 and 21 months (See 
Figure 1) 
 
 
29 
 
 
Figure 1 HI-light trial flowchart 
 
 
The trial included a mixed-methods process evaluation and a health economic analysis. 
The study was approved by Health Research Authority East Midlands – Derby Ethics Committee 
(reference number 14/EM/1173) and by the local research and development department for each 
participating site prior to recruitment commencing. The trial was registered on Current Controlled 
Trials prior to start of recruitment (ISRCTN17160087). Subsequent changes to the protocol are 
summarised (Table 1) 
Table 1 Summary of protocol amendments 
Protocol 
version 
Date Summary of changes 
2.0 11-Mar-
2015 
Added details of the MRC Systematic Techniques for Assisting Recruitment to 
Trials (START) sub-study 
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3.0 30-Sep-
2015 
Clarified inclusion and exclusion criteria; added more details about training 
participants to use trial treatments; procedures clarified for digital images 
outcome analyses; changes to adverse events (AE) handling for erythema 
(grade 1 and 2 are not AE, but expected reactions); amendment of pre-
specified subgroup analysis to remove a comparison of active and inactive 
patches (as by definition all target patches will be active); addition of a 
subgroup analysis evaluating response of target patch by region of the body. 
4.0 03-Mar-
2017 
Added details of the nested process evaluation; updates to the safety 
handling section; introduction of an online automated blind-break procedure; 
change to sample size following sample size review by the Data Monitoring 
Committee (DMC). 
 5.0 18-Jan-
2018 
Amendment to reflect the fact that, due to trial timelines, some participants 
would not receive the full 12 month follow-up but would receive quality of life 
questionnaires and study feedback questions; updates to statistical analyses 
section to reflect the statistical analysis plan; addition of output testing of NV-
UVB devices after end of treatment phase. 
 
2.3 Trial Setting  
Participants were identified when they attended secondary care dermatology clinics, or when they 
responded to mailshots sent out from general practices. Some participants self-referred, in response 
to community advertising and trial publicity. A number of patient information sheets were used in 
the trial, depending on the age of the potential participant. 
Recruitment took place at 16 UK sites, details of which are in the Acknowledgements section of this 
report. 
2.4 Participants 
Patients were considered for entry into the trial if the following criteria were met: 
• Age 5 years or over with a diagnosis of non-segmental vitiligo confirmed by a dermatologist. 
• Vitiligo limited to approximately 10% or less of body surface area, with at least one patch 
reported by the participant to have been active in the last 12 months. 
• No other active therapy for vitiligo (or willing to stop current treatment; no washout period 
required). 
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• Able to administer the interventions safely at home. 
• Able and willing to give informed consent (or parental/guardian consent in the case of 
children). 
In addition, patients were not entered into the trial if any of the following exclusions applied: 
• Other types of vitiligo (e.g. segmental or universal vitiligo). 
• Patients with vitiligo limited to areas of the body for which NB-UVB light treatment or potent 
TCS would be inappropriate (e.g. around the genitals). 
• History of skin cancer (ever). 
• History of radiotherapy use (ever). 
• Photosensitivity (e.g. lupus, polymorphic light eruption, solar urticaria, chronic actinic 
dermatitis, actinic prurigo, porphyria or other photosensitivity disorders). 
• Pregnant or breastfeeding women. 
• Current use of immunosuppressive or immune modifying drugs (e.g. ciclosporin, 
azathioprine, mycophenolate mofetil, methotrexate). 
• Allergy or contraindication to mometasone furoate or its components. 
• Current participation in another clinical trial or intervention study. 
• Marked evidence of Koebner phenomenon in the vitiligo (with the condition spreading 
extensively at the site of skin injury).  
Informed Consent 
Written informed consent was obtained from each participant (or parent/carer in the case of 
children) prior to any trial procedures being carried out. Children provided assent as well, if they 
wished to. Separate written consent was obtained for participation in the process evaluation, 
supported by a separate age-appropriate information sheet. 
2.5 Randomisation and blinding 
Randomisation was carried out via a secure web-based server created and maintained by 
Nottingham Clinical Trials Unit (NCTU). Randomisation was minimised by recruiting centre, body 
region of target patch (head and neck, hands and feet or rest of body) and age (5-16 years or >16 
years).  
Participants were randomised to one of three treatment groups in a ratio of 1:1:1 as follows: 
• TCS ointment plus dummy NB-UVB light (TCS only); 
• Placebo (vehicle) ointment plus NB-UVB light (NB-UVB only); 
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• TCS ointment plus NB-UVB light (combination treatment ). 
 
After completing training in the in use of the trial interventions, undergoing a Minimum Erythemal 
Dose (MED) test and having photographs taken of the patches of vitiligo to be assessed in the trial, 
participants were randomised by staff at the recruiting hospital via a secure web-based server 
created and maintained by NCTU.  
Participants, research nurses, principal investigators, members of trial management group and data 
analysts were blinded to treatment allocation. The Senior Data Manager at NCTU (who created the 
randomisation schedule), medical physics staff (responsible for the testing of NB-UVB devices prior 
to distribution) and NCTU Quality Assurance staff (responsible for the blinding of NB-UVB devices) 
were all aware of the dummy/active nature of each device or ointment. 
Whilst every effort was made to ensure that blinding of trial interventions was maintained, and 
interventions were identical, there was a risk of blinding being compromised due to the nature of 
the treatments and their known side effect profile (in particular, erythema from NB-UVB treatment). 
Given this risk of unblinding, the following measures were taken to limit the impact on trial results: 
I. Information provided to participants emphasised that all participants received at least one 
active treatment for their vitiligo, reducing the risk of detection bias due to lack of treatment 
response.  
II. Noticeability of vitiligo was assessed using the VNS by an independent panel of three people 
with vitiligo, all of whom were blinded, using images taken at baseline and at 9 months. 
These data are presented as a secondary outcome. 
At the end of the treatment phase (9 months), participants and investigators were asked if they 
believed that they had become unblinded, and if so, to what treatments they thought had been 
allocated. These data were used to support the interpretation of trial results. 
2.6 Interventions 
Topical Therapy 
Potent topical corticosteroid 
Mometasone furoate 0.1% w/w ointment (Elocon® 0.1% Ointment, Merck Sharp & Dohme, 
Hertford), a potent corticosteroid used once daily, has been recommended in the European Clinical 
Guidelines for the management of vitiligo 37. In order to minimise the risk of adverse reactions, the 
Guidelines recommend a discontinuous regimen involving periods of use followed by break periods. 
Possible adverse reactions to mometasone furoate 0.1%, as listed in the Summary of Product 
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Characteristics38, include: infection, folliculitis, paraesthesia, burning sensation, contact dermatitis, 
skin hypopigmentation, hypertrichosis, skin striae, acneiform dermatitis, skin atrophy, pruritus, 
application site pain and visual disturbance. Participants were advised to stop use of the ointment if 
they noticed any side effects and to contact the local research team for review and advice on when 
to restart treatment. 
Vehicle ointment 
The vehicle ointment was white soft paraffin (and inert ointment) present in the base of 
mometasone furoate. Expected side effects from this treatment were minimal. 
Treatment regimen 
To reduce the risk of side effects, topical therapy was applied as a thin layer to the affected patches 
of skin only on alternate weeks (1 week on, 1 week off), for a period of 9 months. In order to 
mitigate the risk of interaction between ointment and light therapy, participants were instructed to 
wait for at least 2 hours following light therapy before applying the ointment. 
Light Therapy 
NB-UVB Device 
Several brands of NB-UVB units are CE marked for use in treating vitiligo and other skin conditions 
and are suitable for use at home. Dermfix 1000 MX units were used in the HI-Light trial, as guided by 
initial feasibility work24.  
Known adverse reactions to NB-UVB light therapy include: erythema, blistering, burns, pruritus, 
perilesional hyperpigmentation, hypersensitivity reactions, cold sores and dry skin. Potential long-
term risks include skin ageing and increased risk of skin cancer (although the latter is thought to be 
very low)39, 40. Side effects can be reduced by appropriate use of the device. 
Dummy Device 
The dummy light therapy device was identical to the active device, with the exception that a 
specially designed spacer comb, identical to that found on the active device, was used to block the 
transmission of NB-UVB light to the skin. The spa e  o  fo  the dummy devices was designed by 
the device manufacturer to be identical in appearance to the standard spacer comb in the normal 
devices. These dummy spacer combs filtered out UVB without changing the spectrum of visible light 
emitted by the device, so that when the dummy devices were used, they would look and feel just 
like active devices. 
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A ti e a d du  de i es e e t a ked usi g a ufa tu e s se ial u e s. E pe ie e f o  ou  
pilot trial has shown that the use of a dummy device is acceptable to patients and is effective in 
blocking the NB-UVB radiation.24 
There are no known side effects of the dummy NB-UVB devices. 
Quality control prior to distribution 
All light therapy devices (both active and dummy) were tested for safety and UV output by the 
Medical Physics Department at Nottingham University Hospitals NHS Trust prior to distribution to 
participants (See Chapter 7: Device Testing). Any device found to have an output that was ±20% of 
the expected mean output, or a dummy device testing positive for any NB-UVB emission, was 
returned to the manufacturer. Any device that was damaged or ceased to function during the 
treatment phase was replaced with a new unit. 
Treatment Regimen 
Although NB-UVB (UV radiation wavelengths of 311–312 nanometres) is now the most common 
form of light therapy used to treat skin conditions, many gaps remain in knowledge about its use. In 
a 2016 paper23, Madigan et al published a list of 12 key questions regarding the use of NB-UVB for 
generalised vitiligo. How each of these questions has been addressed within the context of the HI-
Light trial is presented in Table 2. 
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Table 2 Key questions regarding the use of NB-UVB for generalised vitiligo (adapted from Madigan et al ) 
 
Question Strategy tested in the HI-Light Vitiligo Trial 
1 What is the optimal weekly frequency of NB-UVB treatment? HI-Light Trial: every other day (3–4 times weekly). 
Rationale: this is the most commonly used treatment regimen in the UK. 
2 With regard to initial dosing, which strategy should ideally 
be employed? 
HI-Light Trial: all participants started on the same low dose, 0.05 J/cm2. 
Rationale: MED test was carried out before treatment, but only to identify any 
undiagnosed cases of photosensitivity. Starting at a fixed low dose, to minimise the 
risk of symptomatic erythema, was felt to be safer for home delivery of NB-UVB. 
3 At subsequent treatments, what increments should be used 
for dose escalation in the absence of perceptible erythema? 
HI-Light Trial: 10% dosing increase after each treatment not followed by erythema. 
Rationale: this reflects typical clinical practice in UK phototherapy services 
4 What is the maximum acceptable dose to be given in a single 
treatment? 
HI-Light Trial: maximum dose in the trial is 2.81 J/cm2. 
Rationale: this reflects typical clinical practice in UK phototherapy services. 
5 What is the ideal practice for dose adjustment following 
symptomatic erythema? 
HI-Light Trial: patient self-adjustment for grades 1 and 2 erythema (according to flow 
chart in patient handbook) and investigator adjusted dosing for grades 3 and 4. 
Rationale: the upwards and downwards dosing used in the trial reflects the clinical 
practice of most UK phototherapy services. 
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6 How should the protocol be adjusted for missed doses? HI-Light Trial: varies in function of number of missed treatments. 1 or 2 missed: go 
back one step on treatment schedule; 3 missed: go back two steps on treatment 
schedule; 4–6 missed: 50% of last dose; 6+ missed: restart treatment schedule from 
beginning. 
Rationale: this conservative approach ensured that participants who missed a lot of 
doses were not at risk of symptomatic erythema when they restarted treatment. 
7 Ho  should a ou se  of NB-UVB therapy be defined? (i.e. at 
what interval should further exposure be reassessed?) 
Not directly applicable within the scope of the trial. 
8 What is the maximum number of exposures allowable for 
patients with vitiligo, given the potential risk of 
carcinogenesis with NB-UVB? 
Not directly applicable within the scope of the trial. 
Participants in the trial only treated limited areas of skin and the total number of 
treatments was less than the current maximum recommended number of 
treatments. 
9 Should dosing strategies differ when treating children with 
vitiligo? 
HI-Light Trial: children were treated in the same way as adults. Parents were given 
the choice of what patches they were comfortable treating, and could opt out of 
treating sensitive areas if they wished to do so. 
Rationale: the home-based treatment is more flexible than hospital-based full-body 
treatment, so it is possible for children to be treated in the same way as adults. 
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10 Should shielding of sensitive structures (eyelids, areolas and 
genitals) be a universal requirement, or is it safe to expose 
these areas if affected by vitiligo? 
HI-Light Trial: the trial excluded treatment of vitiligo in the genital region. Other 
sensitive areas could be treated if they were affected by vitiligo, but would not 
otherwise be exposed to NB-UVB due to the localised nature of treatment using a 
hand-held device. If treating the eyes, patients were advised to seek assistance from 
someone else so that they could keep their eyes closed during treatment, thus 
reducing the risk of accidental exposure during treatment. 
11 What is the most accurate definition of treatment 
unresponsiveness? 
HI-Light Trial: responsiveness to treatment was defined by patient report using the 
uestio , Co pa ed ith the sta t of the stud , has the e ee  a ha ge i  the 
vitiligo patch?'  
12 How frequently should patients with vitiligo undergo 
surveillance following completion of a NB-UVB treatment 
protocol for both signs of relapse and adverse events? Is 
there a role for phototherapy in maintenance following 
repigmentation? 
HI-Light Trial: long-term treatment response was assessed 3-monthly for 1 year 
following completion of NB-UVB treatment. The trial was not designed to evaluate 
the use of intermittent treatment for maintenance of response. Long-term adverse 
events were not specifically collected in the trial. 
Rationale: patients are particularly interested in how long treatment response might 
last and this is now a core outcome domain for vitiligo clinical trials. 
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Prior to randomisation, all participants received an MED test, to ensure eligibility for the trial. 
Results of the MED test were not used to determine starting dose of the light therapy, but instead to 
ensure that the participant did not have any undiagnosed photosensitivity disorder. All participants 
follow a predefined treatment schedule for the light treatment, with a starting dose of 0.05 J/cm2 
(see Table 3). 
Table 3 Summary of Instructions for adjusting light therapy treatment schedule and dosing 
Situation What to Do 
No erythema or side effects after 
last treatment 
Increase dose by one step for the next treatment. 
Erythema or Overdose 
Grade 1 erythema after last 
treatment 
Go back one step on treatment schedule for next 
treatment 
Grade 2 erythema after last 
treatment 
Skip next scheduled treatment. Go back one step on 
treatment schedule for following treatment. 
Grade 3 erythema or 4 erythema 
after last treatment 
Apply thick layer of trial ointment and contact local 
research team or local on-call dermatologist. Treatment to 
resume only on advice of local research team.  
Light Overdose (used for 20% 
longer or more than intended 
treatment time) 
Apply thick layer of trial ointment and seek medical 
attention (prescription for clobetasol propionate 0.05% 
twice a day for 2-3 days required). Treatment to resume 
only on advice of local research team. 
Missed Treatments 
One or two missed treatments At next session, go back one step on treatment schedule. 
Three missed treatments At next session, go back two steps on treatment schedule. 
Four or more missed treatments Contact local research team for advice on new starting 
dose. 
Side Effects 
Itchy or dry skin Apply moisturiser 3-4 times a day, but not within 2 hours 
before light treatment. Continue treatments as normal. 
Tan around edges This is normal. Continue treatments as normal. 
Rash Stop treatment immediately and seek medical advice. 
Treatment to resume only on advice of local research 
team. 
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Cold sore Stop light treatment until the cold sore has healed. Adjust 
next treatment time according to missed treatment advice. 
 
Storage and distribution of trial treatments 
Following quality control assessments (light devices) or Qualified Person (QP) release (ointment), 
blinded light devices and ointment tubes were dispatched to a central distribution centre 
(Mawdsleys, Doncaster, UK) for storage. On randomisation of a participant by the trial 
investigator/nurse, the distribution centre was notified of the container numbers of ointment and 
the device to be allocated to that participant via a web-based system. Trial treatments were then 
se t di e tl  to the pa ti ipa t s ho e follo i g he k a d fu the  QP elease. 
Training in use of interventions – train the trainer  
As a part of the trial Site Initiation training, trial investigators/nurses were given in-depth training in 
the administering of trial interventions.  
Before randomisation, all participants were trained by the site investigator/nurse in how to apply 
the ointment, including guidance on avoiding application to the eyelids (if less than 1cm away from 
the eyelid margin) and sensitive body sites such as the genital area. In addition, participants received 
training in the correct use of the light therapy devices. Training also covered how to record 
treatment sessions using the trial handbook, how to follow the trial treatment schedule and how to 
manage adverse reactions. Participants were given either a DVD or electronic link allowing them to 
access a specifically designed training video at home, if they wished to revisit the training at any 
time. Written instructions were also included in the trial handbook. Any potential participant 
considered unable to follow the treatment regimen safely was excluded from the trial. 
Participants received a telephone call from the research nurse 2 weeks post-randomisation to check 
how they were getting on with the trial interventions and to confirm their understanding of 
treatment usage and completion of the treatment diaries. Additional training on use of either 
treatment was provided to the participants at this time point (over the telephone or face-to-face), if 
deemed necessary. 
Choice of vitiligo patch for treatment 
During the baseline clinic appointment, participants were asked to select up to three patches of their 
vitiligo to be assessed as a part of the trial, one from each of three anatomical regions (head and 
neck, hands and feet and rest of body), although they were permitted to treat as many patches as 
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they liked throughout the treatment phase. As an aide-mémoire for future appointments, 
i estigato s/ u ses e e e ou aged to d a  the pat hes hose  fo  assess e t o  a iki  
d a i gs  ithi  the C‘F o k ook. Of the three patches selected for assessment, participants 
chose one patch that they would most like to see an improvement in to be used as the target patch 
for the trial. 
The target patch had to be one that the participant thought had been active in the past 12 months. 
Previous studies had suggested that patches which are hypomelanotic, with poorly defined borders, 
are more likely to be active patches, and therefore more responsive to treatment.41 Patches were 
assessed at the poi t of a do isatio  usi g a Wood s la p, a d desig ated as h po ela oti  ith 
poo l  defi ed o de s o  h po ela oti  fo  sho t  o  a ela oti  ith sha pl  defi ed o de s 
(Table 5). 
Vitiligo is known to respond differently at different body sites, with the face and neck being more 
likely to respond to treatment than the hands and feet42. Training material provided to recruitment 
centres advised investigators / nurses to inform participants that patches on the hands and feet may 
be more difficult to treat so they may wish to choose a target patch from one of the other body 
regions. 
Adherence 
Participants used a treatment diary as an aide-mémoire throughout the treatment phase of the trial. 
Participants were encouraged to record each treatment session (both for ointment and for light 
therapy) in the treatment diary, along with any additional comments (such as experienced adverse 
reactions). Treatment diaries were reviewed by investigators/nurses at clinic appointments at 3 and 
6 months in order to assess the participants  understanding of the treatment regimen, to encourage 
adherence and to identify adverse events and any potential additional training requirements.  
Summary data obtained from the treatment diaries was used to assess adherence to the treatment 
regime.  
Adherence will be expressed as a percentage, calculated by dividing the total number of treatment 
sessions reported by the participant by the total number of expected sessions from randomisation to 
9 month follow up. The calculation will account for additional factors: 1) non-treatment session 
expected due to erythema; 2) discontinued treatment due to full repigmentation (adherence should 
be considered as 100% from the point where they achieved full repigmentation); 3) discontinued 
treatment for any other reasons (adherence will be 0% from the point of reported discontinuation. 
Reported use up to this point will be used for calculation). 
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Concomitant medications 
The risk of photosensitivity reaction from NB-UVB light in patients on medications is low, and no 
change to existing medications was required at the onset of the trial. Participants were advised at 
the start of the trial that such reactions can sometimes occur, and that they should contact a 
member of the research team if they developed a persistent rash during the treatment period. Any 
new medications that were started during the trial were documented on the Case Report Form and 
also i  the pa ti ipa t s edi al ecords at each visit (3, 6 and 9 months), and any medications 
known to cause photosensitivity were assessed alongside reported adverse reactions as a part of the 
safety profile of the trial.  
Since NB-UVB light is a form of radiation, participants were advised to avoid exposure to other forms 
of UV exposure during the treatment phase of the trial, including excessive exposure to sunlight. 
Patients were only eligible to take part in the trial if they were not using, or were willing to stop 
using, active therapy for vitiligo. Participants were asked to refrain from using any active treatments 
for their vitiligo throughout the treatment and long-term follow-up phase, to allow the duration of 
any treatment effect to be evaluated. 
Treatment modifications following adverse events 
Having been trained in recognising adverse events, participants were instructed to record any events 
in their treatment diaries and to contact their recruiting centre if they experienced events of 
concern, or a serious adverse event (whether they felt it was related to trial treatment or not). For 
treatment-related side effects, or drug-induced photosensitivity, the site research team provided 
telephone advice or arranged for a dermatology consultation, as necessary. If required, the research 
nurse or dermatologist suggested treatment modification, including reduction or suspension 
(temporary or permanent) of either TCS or light therapy. An appointment was scheduled for a 
dermatologist to review side effects if deemed necessary, in particular for reported episodes of skin 
thinning or for more severe episodes of erythema.  
In case of a medical emergency where an active treatment of the ointment or the device would need 
to be stopped, investigators and research nurses were advised to assume that both interventions 
e e a ti e. If k o ledge of a pa ti ipa t s allo atio  as e essa , the lo al i estigato  as a le 
to access a 24-hour online blind-break system held by NCTU. 
2.7 Outcomes 
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Primary Outcome 
Participant-reported treatment success at 9 months. 
Assessed for each participant at 9 months (end of treatment phase) at the target patch. Treatment 
su ess as defi ed as the pa ti ipa t epo ti g that thei  itiligo as eithe  a lot less oti ea le  o  
o lo ge  oti ea le  i  espo se to the uestio  Co pa ed ith the sta t of the stud , ho  
noticeable is the vitiligo now?', using the previously validated VNS 43. 
Secondary Outcomes 
1. VNS treatment success by blinded review of digital images at 9 months  
Assessed at 9 months at the target patch by three independent patient reviewers using digital 
images from trial participants and using the same question for the primary outcome. Treatment 
success was derived from the score given by the majority of the 3 blinded reviewers.  
 
2. Participant-reported treatment success by body region:  
Assessed at 9 months, measured using the VNS and analysed by body region (A, B and C). Each 
participant assessed up to 3 assessed patches from 3 different body regions, including the one 
chosen as the target patch. During the no-treatment follow-up phase, the same question was used 
at 12, 15, 18 and 21 months, to assess long-term patient reported noticeability for each body region.  
 
3. Onset of treatment response:  
Investigator-assessed onset of treatment response (including cessation of spread) for the target 
patch. To be assessed at ,  a d  o ths usi g the follo i g uestio : Co pa ed to the sta t of 
the stud , has the e ee  a ha ge i  the itiligo pat h?   
• Stayed the same (not worsened) 
• Improved  
• Got worse  
A treatment response was considered to have occurred if the response given was sta ed the sa e  
o  i p o ed . A al ses fo  this se o da  out o e used investigator-assessed responses because 
they were more likely to remain unblinded than the participants.  
 
4. Maintenance of treatment response:  
Participant-assessed maintenance of treatment response (including cessation of spread) for the 
target patch. This was assessed at 12, 15, 18 and 21 months, to assess long-term patient reported 
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oti ea ilit  usi g the follo i g uestio : Co pa ed to si e ou stopped usi g the study 
t eat e ts, has the e ee  a ha ge i  the itiligo pat h?   
• Improved 
• Stayed the same  
• Got worse  
Loss of maintenance of treatment response was defi ed as got o se .  
 
5. Percentage repigmentation at 9 months:  
Percentage repigmentation was assessed at 9 months by a blinded independent dermatologist using 
digital images taken at baseline and at 9 months for the target patch. Investigator assessment of 
percentage repigmentation was also conducted at 3. 6 and 9 months.  
 
6. Quality of life at end of treatment (9 months) and end of follow-up (21 months).  
• VitiQOL44 for adults, aged 18 and above 
• Skindex 2945 for adults, aged 18 and above. 
• EQ-5D-5L for aged 11 years plus adults.46, 47 
• CHU-9D48 for children up to and including 17 years of age 
 
7. Time burden of treatment: time per session for active light treatment and participant-
reported treatment burden for TCS and light treatments during treatment phase.  
Safety Outcomes 
The safety endpoints are the number of adverse reactions during the treatment phase.  
Participants were asked to record any adverse events in their treatment diary and were also asked at 
3, 6 and 9-month clinic visits about any adverse events they had experienced. Any adverse events 
deemed related to trial treatments (adverse reactions) were reported in the CRF. Erythema 
(redness) of grade 1 or 2 was not considered an adverse event, as this is an expected treatment 
response from use of NB-UVB. All serious adverse events (SAEs) were reported directly to the trial 
coordinating centre and assessed for seriousness, expectedness and causality by the Chief 
Investigator, or delegated medical monitor. SAEs were recorded and reported to the Medicines 
Health Regulatory Authority (MHRA) and Research Ethics Committee (REC) as part of the annual 
reports. 
Cost-effectiveness analysis 
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The within-trial economic evaluation estimates the incremental cost effectiveness from an NHS 
perspective of: 
I. NB-UVB light therapy (plus placebo ointment) compared to topical corticosteroid (plus 
dummy light)  
II. Combination of NB-UVB light therapy and TCS compared to TCS (plus dummy light).  
 
The economic analysis uses individual participant level data from the trial. The base case analysis 
undertakes a cost-effectiveness analysis from an NHS perspective for all participants. Secondary 
analyses consider the cost-utility of the comparators of interest for those with EQ-5D-5L data 
available (participants aged 11 years and over) and separately for those with CHU-9D data available 
(participants aged 5 to <18 years). Full details of the methods can be found in chapter 4, beginning 
on page 77. 
 
Data collection 
Trial data were entered into a web-based electronic Case Record Form (eCRF) (MACRO 4.2.1 version 
3800, Elsevier, London, UK). Staff at research sites had access to data from their site only, with 
access controlled through person-specific login credentials. Access to the trial database and 
database maintenance was managed by NCTU.  
 
In order to facilitate the data collection process, site staff members were provided with CRF 
workbooks that mirrored the data required for the electronic CRF. Investigators were asked to 
transcribe the data into the electronic CRF within 7 days of the data being collected where possible.  
 
Participants used a Trial Handbook, which included a detailed treatment diary, adverse event record, 
the use of any healthcare resources and any prescribed medicines. Site staff reviewed these 
handbooks at 3, 6 and 9-month clinic visits and entered summary data into the electronic CRF.  
 
The primary outcome was collected at the 9-month clinic visit. For those who did not attend this visit 
and who had not withdrawn from the trial, primary outcome data was obtained via telephone, post 
or text message where possible.  
 
After the treatment period (9 months), follow-up continued for a further 12 months, with 
participant-completed questionnaires at 12, 15, 18 and 21 months. These questionnaires were sent 
either by post with the data entered and returned on paper, or via email using electronic 
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questionnaires designed by staff at NCTU. Reminders were sent (via email or post) if the 
questionnaire remained uncompleted after 2 weeks, and again after 3 weeks. Members of NCTU 
staff chased up outstanding questionnaires after 3 weeks via telephone. 
 
2.8 Sample Size 
The choice of minimum clinically important difference between the groups was informed by a survey 
of the clinical membership of the UK Dermatology Clinical Trials Network (UK DCTN). Standard care 
was assumed to be TCS o othe ap  a d so TCS plus du  light the ap  is the o pa ato  
group for all treatment comparisons. There are two comparisons of primary interest:  
 
I. NB-UVB light therapy (plus placebo ointment) compared to TCS (plus dummy light)  
II. Combination of NB-UVB light therapy and TCS compared to TCS (plus dummy light).  
 
Assuming that 15% of participants allocated to receive TCS (plus dummy light therapy) would 
achieve treatment success as defined by the primary outcome, 372 participants were required to 
detect an absolute difference of 20%, with 2.5% two-sided alpha and 90% power. Allowing for 15% 
non-collection of primary outcome data, an original sample size of 440 participants was set.  
 
As there were limited data available to inform the sample size calculation for the trial, the Data 
Monitoring Committee conducted a planned sample size review in December 2016. This review 
resulted in a recommendation to increase the sample size to 516 participants in order to maintain 
90% power to detect a risk difference of 20% between the TCS arm and the other two arms. The 
Trial Steering Committee and the funders approved this recommendation. 
 
2.9 Statistical Methods 
Analyses were pre-defined in a statistical analysis plan (SAP), which was signed off prior to database 
lock. Points of clarification to the SAP that were made after database lock are summarised 
(SeeAppendix 1) 
Primary Outcome 
The number and percentage of pa ti ipa ts a hie i g t eat e t su ess  defi ed as a espo se of 
eithe  A lot less oti ea le  o  No lo ge  oti ea le  i  espo se to the uestio  "Co pa ed to the 
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start of the study, how noticeable is the vitiligo now?") is reported for each treatment group at 9 
months from randomisation.  
The primary analysis was performed on the ITT analysis set, where multiple imputation was used to 
account for missing primary outcome data at 9 months. Prior to primary analysis, baseline 
characteristics were summarised further by treatment arms and the availability of primary outcome 
at 9 months, in order to check the missing at random assumption of multiple imputation.  
Randomised groups were compared using a mixed effects model for binary outcome adjusted by 
recruitment centre, body region of the target patch, and age at randomisation (continuous). The 
primary effectiveness parameter comparing NB-UVB light with TCS alone, and NB-UVB light plus TCS 
with TCS alone, was the risk difference (risk ratio will also be included) in the percentage of 
participants achieving treatment success at 9 months along with 95% confidence interval and exact 
p-value. By default, risk differences are reported, because these estimates are more clinically 
intuitive for binary outcomes. However, where models estimating risk difference do not converge, 
odds ratios will be reported instead of risk differences.  
Sensitivity analyses were conducted to (i) adjust for any variables with imbalance at baseline, (ii) 
repeat primary analysis based on participants whose primary outcome was available at 9 months 
and (iii) investigate the effects of treatment adherence.  
Planned subgroup analyses were (i) children versus adults); (ii) body region of the target vitiligo 
patch; (iii) hypomelanotic patch (an indicator of disease activity): definitely or maybe versus no; (iv) 
 4 years duration of vitiligo versus <4 years. These analyses were conducted by inclusion of 
appropriate interaction terms in the regression model and were considered as exploratory. An 
additional post-hoc subgroup analysis explored the impact of skin type (types I to III versus types IV 
to VI).  
Secondary Outcomes 
I. VNS treatment success by blinded review of digital images at 9 months 
Between-group comparisons were performed using mixed effect regression model for binary 
outcome, adjusting by recruitment centre, body region of target patch and age (continuous). The 
analysis was performed on a modified ITT set, where no imputation of missing data was required. 
II. Participant-reported treatment success by body region (at 9 months):  
VNS treatment success at 9 months for all assessed patches (up to 3) was analysed using a multi-
level mixed effects model, accounting for potential correlation between treatment effects at 
different body regions within the same person. This analysis was conducted with multiple 
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imputation of missing treatment success data. Patient-reported treatment success by body region at 
3 and 6 months is presented descriptively 
III. Onset of treatment response (during treatment phase):  
Summary data by all the 3 categories (stayed the same, improved, got worse) is presented by 
treatment group and by timeline (3, 6, 9 months). The cumulative percentage of participants who 
achieved a treatment response (stayed the same or improved) at target patch is presented. Analysis 
of treatment response at 9 months was analysed using a mixed effect regression model for binary 
outcome, adjusting by recruitment centre, body region of target patch and age (continuous).  
Participant reported onset of treatment response is summarised as for investigator-assessed 
treatment response.  
IV. Maintenance of treatment response (during follow up phase):  
Maintenance of treatment response is presented separately for those who achieved and those who 
did not achieve treatment response at the end of the treatment phase. The cumulative percentage 
of participants with loss of maintenance of treatment response is presented by treatment arm. Data 
is reported for the target patch only. 
V. Percentage repigmentation at 9 months (by blinded dermatologist and investigator):  
Analysis of blinded dermatologist assessed percentage repigmentation at 9 months was analysed 
using a mixed effect regression model for binary outcome, adjusting by recruitment centre, body 
region of target patch and age (continuous). Where available, data from investigator assessments at 
9 months were used for missing data based on blinded clinician assessment of digital images. 
Treatment success based on investigator-assessed percentage repigmentation at 9 months is 
reported descriptively.  
Assessments carried out by investigators at 3 and 6 and 9 months are presented descriptively.  
VI. Quality of life at end of treatment (9 months) and end of follow-up (21 months).  
Total scores for VITIQOL, Skindex 29, CHU-9D and EQ-5D questionnaires at 9 months and 21 months 
are summarised by treatment arm using appropriate summary statistics.  
VII. Time burden of treatment:  
For active light therapy, the average time per treatment session was estimated using data collected 
at 3, 6 and 9 months. Time burden of TCS application was assumed to be minimal. The percentage of 
those who reported difficulties with the interventions are summarised, along with a description of 
the difficulties experienced.   
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Chapter 3: Results: clinical findings 
 
3.1 Recruitment and participant characteristics 
Recruitment took place between May 2016 and September 2017, the database was closed for 
follow-up on 31st December 2018   
A total of 1832 reply slips were received, of which 1093 received telephone screening and 549 clinic 
screening. Five hundred and seventeen participants (173 TCS only, 169 NB-UVB only and 175 
combination) were randomised.  
Primary outcome data at 9 months were available for 370 (72%) participants (See Figure 2).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total reply slips received
(n=1832)
Received telephone 
screening (n=1093)
Attended clinic screening
(n=549)
Randomised 
(n=517)
UVB
(n=169)
UVB+TCS 
(n=175)
TCS
(n=173)
Followed up at 3 months
(n=136 (80%))
Followed up at 6 months
(n=113 (67%))
Primary outcome 
collected at 9 months
(n=123 (73%))
Data included in analysis
(n=169)
Followed up at 3 months
(n=136 (79%))
Followed up at 6 months
(n=115 (66%))
Primary outcome 
collected at 9 months 
(n=119 (69%))
Data included in analysis 
(n=173)
Followed up at 3 months
(n=143 (82%))
Followed up at 6 months
(n=126 (72%))
Primary outcome 
collected at 9 months
(n=128 (73%))
Data included in analysis
(n=175)
Followed up at 12 
months (n=95 (55%))
Followed up at 15 
months (n=90 (52%))
Followed up at 18 
months (n=74 (43%))
Followed up at 21 
months (n=71 (41%))
Followed up at 12 
months (n=100 (59%))
Followed up at 15 
months (n=91 (54%))
Followed up at 18 
months (n=84 (50%))
Followed up at 21 
months (n=72 (43%))
Followed up at 12 
months (n=95 (54%))
Followed up at 15 
months (n=87 (50%))
Followed up at 18 
months (n=85 (49%))
Followed up at 21 
months (n=81 (46%))
Tr
ea
tm
en
t P
er
io
d
Fo
llo
w
-u
p
 p
er
io
d
Reasons for telephone exclusion
>10% body coverage (n=103)
No active patch (n=75)
Unwilling to stop other vitiligo treatment (n=39)
Unable/unwilling to consent (n=32)
Medical history unsuitable for interventions (n=76)
In another trial (n=54)
Reasons for clinic exclusion
Body site inappropriate (n=2)
>10% body coverage (n=9)
No active patch (n=2)
No diagnosis of non-segmental vitiligo (n=11)
Unsuitable for trial intervention (n=16)
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Figure 2 Consort Diagram 
*Note reasons for non-collection of primary outcome at 9 months were: not assessed in clinic (n=4), withdrew consent (n=60), 
discontinued due to AE (n=3), lost to follow up (n=75) and other (n=5). These reasons were similarly distributed within each treatment 
arm.  Of those withdrew consent, 11 stated that this was due to lack of treatment response and 33 due to time burden. Of those lost to 
follow up, 1 stated that this was due to lack of treatment response and 2 due to time burden.  
Baseline characteristics and sources of recruitment are summarised in Table 4.  
Participants were recruited from primary care (118/517, 23%), secondary care (213/517, 41%) and 
through self-referral from community advertising (186/517, 36%).  
Baseline characteristics were well balanced across treatment groups. Almost a quarter of the 
participants were children (119 /517, 23%). There was an equal balance of genders (268 /517, 52% 
male) and the majority were white (330/517, 64%). Participants of all skin types were enrolled, the 
most common being skin type III (195/517, 38%). Baseline characteristics for participants providing 
primary outcome data and those not providing primary outcome data are summarised (
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Table 5) 
Table 4 Baseline characteristics 
Characteristic  TCS  NB-UVB  Combination  Total  
  (n = 173)  (n = 169)  (n = 175)  (n=517)  
Age at randomisation 
(years)  
        
Mean(sd)  38.6[20.0]  36.9[18.9]  37.0[19.1]  37.5[19.3]  
Age of adults at 
randomisation (years)  
        
Mean(sd)  46.7[15.2]  44.7[14.0]  44.8[14.2]  45.4[14.5]  
N  133  130  135  398  
Age of children at 
randomisation (years)  
        
Mean(sd)  11.7[3.7]  10.8[3.5]  10.6[3.3]  11.1[3.5]  
N  40  39  40  119  
Gender          
Male  75(43%)  88(52%)  105(60%)  268(52%)  
Ethnicity          
White  112(65%)  114(67%)  104(59%)  330(64%)  
Indian  13(8%)  13(8%)  10(6%)  36(7%)  
Pakistani  12(7%)  15(9%)  27(15%)  54(10%)  
Bangladeshi  4(2%)  4(2%)  4(2%)  12(2%)  
Black  5(3%)  3(2%)  7(4%)  15(2%)  
Chinese  2(1%)  1(1%)  1(1%)  4(1%)  
Other Asian (Non-
Chinese)  
5(3%)  6(4%)  6(3%)  17(3%)  
Mixed Race  9(5%)  6(4%)  6(3%)  21(4%)  
Other  10(6%)  7(4%)  9(5%)  26(5%)  
Missing   1(1%)  0  1(1%)  2(<0.5%)  
Source of recruitment          
Primary care  35(20%)  36(21%)  47(27%)  118(23%)  
Secondary care  74(43%)  67(40%)  72(41%)  213(41%)  
Self-referral  64(37%)  66(39%)  56(32%)  186(36%)  
Skin photo type           
Type I  2(1%)  2(1%)  5(3%)  9(2%)  
Type II  31(18%)  32(19%)  29(17%)  92(18%)  
Type III  70(40%)  66(39%)  59(34%)  195(38%)  
Type IV  29(17%)  34(20%)  33(19%)  96(19%)  
Type V  35(20%)  25(15%)  44(25%)  104(20%)  
Type VI  6(3%)  10(6%)  5(3%)  21(4%)  
Medical history          
Type I diabetes  5(3%)  3(2%)  4(2%)  12(2%)  
Hyperthyroidism  4(2%)  2(1%)  6(3%)  12(2%)  
Hypothyroidism  21(12%)  18(11%)  10(6%)  49(9%)  
Addiso s disease  2(1%)  0  3(2%)  5(1%)  
Pernicious anaemia  5(3%)  3(2%)  6(3%)  14(3%)  
Alopecia areata   3(2%)  7(4%)  3(2%)  14(3%)  
Duration of vitiligo 
(years)  
        
Mean(sd)  11.5[12.0]  9.9[11.1]  11.3[10.5]  10.9[11.2]  
Median (25th, 75th 
centile)  
7[3,6]  5[3,11]  7[4,15]  7[3,15]  
Min, max  1,60  1,60  1,45  1,60  
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Previous treatments 
used for vitiligo  
        
Light therapy  28(16%)  26(15%)  37(21%)  91(18%)  
Corticosteroid 
cream/ointment  
80(46%)  75(44%)  80(46%)  235(45%)  
Calcineurin inhibitor  51(29%)  39(23%)  56(32%)  146(28%)  
Cosmetic camouflage  45(26%)  44(26%)  40(23%)  129(25%)  
Other  20(12%)  15(9%)  17(10%)  52(10%)  
 All data are N (%) unless otherwise indicated. 
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Table 5 Baseline characteristics by treatment group and availability of primary outcome at 9 months 
Characteristic 
TCS  
(n = 173) 
NB-UVB  
(n = 169) 
Combination 
(n = 175) 
With primary 
outcome (n=119) 
Without primary 
outcome (n=54) 
With primary 
outcome (n=123) 
Without primary 
outcome (n=46) 
With primary 
outcome (n=128) 
Without primary 
outcome (n=47) 
Age at randomisation (years) 
Mean(sd)  
Median (25th Q, 75th Q) 
Min, max 
Age of adults at randomisation 
(years) 
Mean(sd)  
Median (25th Q, 75th Q) 
Min, max 
Age of children at 
randomisation (years) 
Mean(sd)  
Median (25th Q, 75th Q) 
Min, max 
 
39.9[21.2] 
43.6[17.5,58.7
] 
6.1,84.5 
 
 
49.8[14.9] 
50.4[38.9,60.8
] 
20,84.5 
 
 
11.7[3.7] 
12[7.9,14.9] 
6.1,17.8 
 
 
35.8[16.9] 
32.4[22.4,49
] 
6.6,65.1 
 
 
40.6[14.2] 
39.5[28.6,51
.8] 
20.9,65.1 
 
 
11.9[3.7] 
10.3[10.2,14
.1] 
6.6,17.6 
37.5[20.2] 
39.5[15.8,52.8] 
5.2,76.2 
 
 
47.1[13.9] 
44.7[38.1,58.7] 
18.4,76.2 
 
 
10.2[3.4] 
9.7[7.3,13.2] 
5.2,16 
 
 
35.2[14.9] 
34.4[25.5,43.6] 
10,68.7 
 
 
39.1[12.8] 
37.1[29.6,45.9] 
18.1,68.7 
 
 
13.8[2.0] 
14.6[12.3,15] 
10,15.8 
 
36.5[200.2] 
36.4[15.5,51.2] 
5.4,78.1 
 
 
46.6[14.3] 
46.5[35.9,55.9] 
19.2,78.1 
 
 
10.9[3.1] 
10.2[8.9,12.4] 
5.4,17.8 
 
38.3[15.7] 
39[26.7,46.5
] 
5.7,72.7 
 
 
41.0[13.4] 
40.3[30.8,47
.3] 
18.4,72.7 
 
 
8.6[4.9] 
6.5[5.9,11.3] 
5.7,15.9 
Gender 
Male 
Female 
43(36%) 
76(64%) 
 
32(59%) 
22(41%) 
67(54%) 
56(46%) 
 
21(46%) 
25(54%) 
 
75(59%) 
53(41%) 
 
30(64%) 
17(36%) 
Ethnicity  
White 
Indian  
Pakistani 
Bangladeshi  
Black  
Chinese  
Other Asian (Non-Chinese) 
Mixed Race 
Other 
Missing   
74(62%) 
11(9%) 
9(8%) 
3(3%) 
3(3%) 
1(1%) 
4(3%) 
7(6%) 
7(6%) 
0 
 
38(70%) 
2(4%) 
3(6%) 
1(2%) 
2(4%) 
1(2%) 
1(2%) 
2(4%) 
3(6%) 
1(2%) 
85(69%) 
8(7%) 
10(8%) 
3(2%) 
2(2%) 
1(1%) 
4(3%) 
4(3%) 
6(5%) 
0 
 
29(63%) 
5(11%) 
5(11%) 
1(2%) 
1(2%) 
0 
2(4%) 
2(4%) 
1(2%) 
0 
 
77(60%) 
9(7%) 
21(16%) 
3(2%) 
4(4%) 
1(1%) 
4(3%) 
3(2%) 
5(4%) 
1(1%) 
 
27(57%) 
1(2%) 
6(13%) 
1(2%) 
3(6%) 
0 
2(4%) 
3(6%) 
4(9%) 
0 
Source of recruitment  
Primary care  
Secondary care  
Self-referral 
25(21%) 
51(43%) 
43(36%) 
 
10(19%) 
23(43%) 
21(39%) 
28(23%) 
49(40%) 
46(37%) 
 
8(17%) 
18(39%) 
20(43%) 
 
36(28%) 
59(46%) 
33(26%) 
 
11(23%) 
13(28%) 
23(49%) 
Medical history  
Type I diabetes 
Hyperthyroidism  
Hypothyroidism  
 
4(3%) 
3(3%) 
15(13%) 
 
1(2%) 
1(2%) 
6(11%) 
 
2(2%) 
3(3%) 
15(12%) 
 
1(2%) 
0 
3(7%) 
 
1(1%) 
3(3%) 
7(5%) 
 
3(6%) 
3(6%) 
3(6%) 
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Characteristic 
TCS  
(n = 173) 
NB-UVB  
(n = 169) 
Combination 
(n = 175) 
With primary 
outcome (n=119) 
Without primary 
outcome (n=54) 
With primary 
outcome (n=123) 
Without primary 
outcome (n=46) 
With primary 
outcome (n=128) 
Without primary 
outcome (n=47) 
Addiso s disease  
Pernicious anaemia  
Alopecia areata 
0 
3(3%) 
1(1%) 
2(4%) 
2(4%) 
2(4%) 
0 
2(2%) 
5(4%) 
0 
1(2%) 
2(4%) 
2(2%) 
2(2%) 
2(2%) 
1(2%) 
4(9%) 
2(4%) 
Skin photo type  
Type I 
Type II  
Type III  
Type IV  
Type V 
Type VI 
1(1%) 
24(20%) 
41(34%) 
23(19%) 
28(24%) 
2(2%) 
 
1(2%) 
7(13%) 
29(54%) 
6(11%) 
7(13%) 
4(7%) 
2(2%) 
23(19%) 
51(41%) 
21(17%) 
20(16%) 
6(5%) 
 
0 
9(20%) 
15(33%) 
13(28%) 
5(11%) 
4(9%) 
 
4(3%) 
21(16%) 
43(34%) 
22(17%) 
37(29%) 
1(1%) 
 
1(2%) 
8(17%) 
16(34%) 
11(23%) 
7(15%) 
4(9%) 
 
 
Duration of vitiligo (years) 
Mean(sd)  
Median (25th Q, 75th Q) 
Min, max 
11.8[12.9] 
7[3,15.5] 
1,60 
 
 
 
10.7[9.9] 
7[3,20] 
1,41 
 
 
9.7[11.2] 
5[2,10] 
1,60 
 
 
 
10.6[10.9] 
7.5[4,12.5] 
1,57 
 
 
 
10.8[10.3] 
7[3,15] 
1,45 
 
 
 
12.8[10.9] 
8[5,20] 
1,42 
Previous treatments used for 
vitiligo  
Light therapy  
Corticosteroid cream/ointment 
Calcineruin inhibitor  
Costimetic camouflage  
Other  
18(15%) 
55(46%) 
41(34%) 
34(29%) 
17(14%) 
 
 
10(19%) 
25(46%) 
10(19%) 
11(20%) 
3(6%) 
18(15%) 
54(44%) 
27(22%) 
34(28%) 
10(8%) 
 
 
8(17%) 
21(46%) 
12(26%) 
10(22%) 
5(11%) 
 
 
29(23%) 
62(48%) 
46(36%) 
32(25%) 
10(8%) 
 
 
8(17%) 
18(38%) 
10(21%) 
8(17%) 
7(15%) 
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All data are N (%) unless otherwise indicated. 
 
The active target patches were located on the head and neck for 31% (161/517) participants, hands 
and feet for 32% (164/517), and the rest of the body for 37% (192/517). Not all participants chose to 
treat and assess three patches of vitiligo: 31% (162/517) chose one patch; 43% (224/517) chose two 
patches and 25% (131/517) chose three patches for assessment. Over half of the participants chose 
to treat patches in addition to the three being formally assessed in the trial, with 29% (148/517) of 
participants electing to treat six of more patches (See Table 6). 
Table 6 Description of vitiligo patches at baseline 
Target patch location  TCS  NB-UVB  Combination  Total  
 (n = 173)  (n = 169)  (n = 175)  (n=517)  
Head and neck  53(31%)  52(31%)  56(32%)  161(31%)  
Hands and feet  56(32%)  53(31%)  55(31%)  164(32%)  
Rest of the body  64(37%)  64(38%)  64(37%)  192(37%)  
Total number of 
assessed patches 
included in study  
        
1  50(29%)  50(30%)  62(35%)  162(31%)  
2  74(43%)  77(46%)  73(42%)  224(43%)  
3  49(28%)  42(25%)  40(23%)  131(25%)  
Total number of 
patches the participant 
would like to treat  
        
1  13(8%)  12(7%)  14(8%)  39(8%)  
2 or 3  61(35%)  62(37%)  67(38%)  190(37%)  
4 or 5  52(30%)  49(29%)  39(22%)  140(27%)  
6 or more  47(27%)  46(27%)  35(31%)  148(29%)  
Activity of target patch          
Hypomelanotic with 
poorly defined border 
        
Definitely  52(30%)  46(27%)  52(30%)  150(29%)  
Maybe  14(8%)  20(12%)  18(10%)  52(10%)  
No  107(62%)  103(61%)  105(60%)  315(61%)  
Amelanotic with 
sharply defined border 
        
Definitely  97(56%)  101(60%)  99(57%)  297(57%)  
Maybe  10(12%)  19(11%)  19(11%)  58(11%)  
No  56(32%)  49(29%)  56(32%)  161(31%)  
All data are N (%) unless otherwise indicated. 
 
3.2 Adherence to trial treatment and treatment burden 
Adherence is reported in Table 7. The median percentage of NB-UVB treatment days, as a 
percentage of expected days of treatment, was 81%, 77% and 74% for the three groups respectively, 
and for ointment 79%, 83% and 77%. Just u de  half of the pa ti ipa ts used the t eat e t fo  % 
of the expected number of occasions, which was used as an indicator of good adherence in the 
sensitivity analyses of the primary outcome accounting for treatment adherence. Just over a quarter 
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of participants in all group discontinued one or more of the treatments before the end of the 9-
month treatment phase. 
For participants using active light devices the median time taken to administer the treatment was 
approximately 20 minutes, including time for set-up, administering the light, and documenting 
timings and side-effects in the treatment diary. In addition to written and online video training, 
participants required just over an hour (mean 70 minutes) of face to face training with a trained 
healthcare professional (usually a nurse) prior to using the treatment at home.  
Difficulties in using the treatments are summarised (Table 7). Burden of treatment was identified as 
an issue by 42/142 (30%) in the TCS group, 38/140 (27%) in the NB-UVB group and 36/149 (24%) in 
the combination group, although interpretation is difficult as all three groups used both treatments 
throughout (either active or dummy/placebo). Not surprisingly, NB-UVB treatment was more 
burdensome than treatment with TCS. Burden of treatment and side-effects were the most 
commonly cited difficulties for both groups and were common reasons for discontinuation of 
treatment, along with lack of treatment response. 
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Table 7 Treatment adherence, burden and discontinuation 
 TCS  
(n = 173) 
NB-UVB  
(n = 169) 
Combination 
(n = 175) 
Use of light treatment: reported number of treatment 
sessions as percentage of expected 
 Mean[SD]  
Median[IQR] 
 
 
68%[31%] 
81%[43%,95%] 
 
 
68%[28%] 
77%[51%,90%] 
 
 
 67%[27%] 
74%[48%,89%] 
Distribution of light adherence  
<25%  
25-49% 
50-74%  
>=75% 
Data not available  
 
19(11%) 
21(12%) 
23(13%) 
82(47%) 
   28(16%) 
 
16(9%) 
18(11%) 
31(18%) 
72(43%) 
   32(19%) 
 
14(8%) 
26(15%) 
35(20%) 
74(42%) 
26(15%) 
Use of ointment treatment: reported number of treatment 
sessions as percentage of expected 
 Mean[SD]  
Median[IQR] 
 
 
68%[29%] 
79%[47%,93%] 
 
 
73%[27%] 
83%[57%,95%] 
 
 
68%[28%] 
  77%[45%,92%] 
Distribution of ointment adherence  
<25%  
25-49% 
50-74%  
>=75% 
Data not available 
 
16(9%) 
22(13%) 
30(17%) 
74(43%) 
31(18%) 
 
12(7%) 
16(9%) 
27(16%) 
81(48%) 
33(20%) 
 
13(7%) 
28(16%) 
30(17%) 
77(44%) 
27(15%) 
Participant reported average duration (median[IQR] 
minutes, N) per light treatment session at  
3 months  
6 months  
9 months  
 
 
 
20[10,30], N=135 
22.5[12,42.5], 
N=120 
20[13,40], N=101 
 
 
15[10,30], N=142 
20[15,35], N=124 
20[12,30], N=111 
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 TCS  
(n = 173) 
NB-UVB  
(n = 169) 
Combination 
(n = 175) 
Burden of treatment: 
NB-UVB burden reported  
 
TCS burden reported 
 
Any burden reported (from either treatment)  
 
36/142(25%) 
 
18/142(13%) 
 
42/142(30%) 
 
35/140(25%) 
 
14/140(10%) 
 
38/140(27%) 
 
32/149(21%) 
 
14/149(9%) 
 
36/149(24%) 
Participants experienced difficulty using active light during the 9-month 
treatment period  
 
Difficulties experienced * 
Uncertainty of using light  
Treatment burden  
Side effect  
Other  
 
 
 
76/140 (54%) 
 
 
 
 
7 
35 
37 
9 
 
 
 
81/149(54%) 
 
 
 
18 
32 
43 
4 
Participants experienced difficulty using active TCS treatment during the 9-
month treatment period  
 
Difficulties experienced * 
Uncertainty of using TCS  
Treatment burden 
Side effect  
Other 
 
35/142(25%) 
 
 
 
 
5 
18 
12 
4 
 
 
 
31/149(21%) 
 
 
 
 
6 
14 
15 
0 
Participants discontinued NB-UVB  
 
Number discontinued within first 3 months  
Reasons for NB-UVB discontinuation*  
All assessment patches repigmented 
Time burden associated with treatment 
Side effects  
Lack of treatment response 
Other  
50(29%) 
 
17(10%) 
 
1 
23 
4 
9 
13 
47(28%) 
 
22(13%) 
 
1 
20 
9 
3 
14 
43(25%) 
 
10(6%) 
 
3 
17 
4 
7 
12 
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 TCS  
(n = 173) 
NB-UVB  
(n = 169) 
Combination 
(n = 175) 
Participants discontinued TCS  
 
Number discontinued within first 3 months  
Reasons for TCS discontinuation*  
All assessment patches repigmented 
Time burden associated with treatment 
Side effects  
Lack of treatment response 
Other  
48(28%) 
 
17(10%) 
 
1 
20 
3 
9 
15 
41(24%) 
 
19(11%) 
 
1 
17 
1 
5 
17 
43(25%) 
 
10(6%) 
3 
15 
5 
7 
13 
*Not mutually exclusive as participant can have multiple difficulties 
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3.3 Blinding 
At the 9-month clinic visit, investigators reported that they thought they had become unblinded for 
21% (31/145), 28% (43/153) and 27% (41/153) of participants in the TCS, NB-UVB and combination 
groups respectively. Participants were more likely to report that they thought they had become 
unblinded; 39% (45/116), 55% (66/120) and 44% (55/125) for the TCS, NB-UVB and combination 
groups respectively.  Of the 115 investigators who thought they had been unblinded, 78% (90/115) 
thought it was due to either presence or absence of erythema.  
Of those who indicated possible unblinding and were having NB-UVB, 83% (96/115) of investigators 
and 80% (132/166) of participants were correct. Of those who indicated possible unblinding and 
were having TCS, 32% (37/115) of investigators and 39% (64/166) of participants were correct. 
(Table 8).  
 
Table 8 Unblinding of investigators and participants at 9 months 
 
TCS  
 
NB-UVB  
 
Combination 
 
Number of investigators 
Number unblinded  
 
Of those who indicated unblinding:  
Investigator guess of light treatment received  
Correct  
incorrect 
Investigator guess of TCS treatment received  
Correct  
Incorrect  
 
145 
31(21%) 
 
 
 
27(87%) 
4(13%) 
 
21(68%) 
10(32%) 
 
153 
43(28%) 
 
 
 
35(81%) 
8(19%) 
 
4(9%) 
39(91%) 
 
153 
41(27%) 
 
 
 
34(83%) 
7(17%) 
 
12(29%) 
29(71%) 
Number of participants  
Number unblinded  
 
Of those who indicated unblinding:  
Participant guess of light treatment received  
Correct  
incorrect  
Participant guess of TCS treatment received  
Correct  
incorrect  
116 
45(39%) 
 
 
 
25(56%) 
20(44%) 
 
23(51%) 
22(49%) 
120 
66(55%) 
 
 
 
59(89%) 
7(11%) 
 
23(35%) 
43(65%) 
125 
55(44%) 
 
 
 
48(87%) 
7(13%) 
 
18(33%) 
37(67%) 
 
 
3.4 Primary Outcome 
The percentage of participants who reported a treatment success (VNS) at 9 months was 17% 
(20/119) for the TCS only group, 22% (27/123) for NB-UVB only group and 27% (34/128) for the 
combination group. For participants where primary outcome was obtained, 96% (355/370) were 
obtained face-to-face at the 9-month clinic visit, 2% (9/370) via post, 1% (3/370) via telephone and 
1% (3/370) via text message. Primary analysis was performed using multiple imputation. Adjusted 
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risk difference was 5.2% (95% CI -4.4% to 14.9%; p= 0.29) for NB-UVB only compared with TCS only, 
and 10.9% (95% CI 1.1% to 20.9%; p= 0.03) for combination compared with TCS only (Table 9). The 
number needed to treat (NNT) for NB-NB-UVB compared to TCS was 19 and for combination 
compared to TCS was 10.  
A  additio al . % /  pa ti ipa ts a hie ed a pa tial t eat e t espo se  slightl  less 
noticeable on the VNS): 24% (28/119) in the TCS group, 29% (36/123) in the NB-UVB group and 35% 
(45/128) in the combination group (Table 9). 
The percentage of participants with a treatment success at 3 and 6 months is shown in Table 9. 
Images demonstrating examples of good and poor treatment responses are shown in Figure 3. 
 
 
Figure 3 Figure showing target lesions before (A, a) and after (B, b) treatment. 
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Table 9 Primary outcome analysis – participant reported treatment success (VNS), intention-to-treat (ITT) 
 TCS 
(n = 173) 
NB-UVB 
(n = 169) 
Combination 
(n = 175) 
 
 
 
 
 
 
 
 
 
Between-group comparisons (ITT) 
Patient response to VNS scale at 3 
months  
More noticeable  
As noticeable  
Slightly less noticeable  
A lot less noticeable  
No longer noticeable  
Patient response to VNS scale at 6 
months  
More noticeable  
As noticeable  
Slightly less noticeable  
A lot less noticeable  
No longer noticeable  
 
 
 
16(12%) 
70(52%) 
34(25%) 
13(10%) 
2(1%) 
 
 
11(10%) 
51(44%) 
37(32%) 
14(12%) 
2(2%) 
 
 
26(19%) 
57(42%) 
34(25%) 
19(14%) 
0 
 
 
23(20%) 
37(33%) 
33(29%) 
18(16%) 
2(2%) 
 
 
15(10%) 
62(43%) 
47(33%) 
17(12%) 
2(1%) 
 
 
10(8%) 
36(29%) 
45(36%) 
28(22%) 
7(6%) 
Participants with primary outcome 
data at 9 months  
119(69%) 123(73%) 128(73%) NB-UVB vs TCS Combination vs TCS 
Adjusted^ risk 
difference (95% 
CI) 
Adjusted risk 
ratio 
(95% CI) 
Adjusted risk 
difference 
(95% CI) 
Adjusted risk 
ratio 
(95% CI) 
Patient response to VNS scale at 9 
months  
More noticeable  
As noticeable  
Slightly less noticeable  
A lot less noticeable  
No longer noticeable  
 
Patient reported treatment success* 
using VNS scale at 9 months  
 
 
18(15%) 
53(45%) 
28(24%) 
15(13%) 
5(4%) 
 
20(17%) 
 
 
27(22%) 
33(27%) 
36(29%) 
25(20%) 
2(2%) 
 
27(22%) 
 
 
17(13%) 
32(25%) 
45(35%) 
27(21%) 
7(5%) 
 
34(27%) 
 
 
 
 
5.2%  
(-4.4%,14.9%) 
 
 
 
 
 
1.44(0.77,2.70) 
 
 
 
 
10.9% 
(1.1%,20.9%) 
 
 
 
 
 
1.93(1.02,3.68) 
All data are N (%) unless otherwise indicated. 
*Treatment success will be defined as answer to either A lot less noticeable or No longer noticeable.  
^Adjusted by centre, body region of target patch and age of participant with vitiligo.  
Based on multiple imputation. 
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Sensitivity analyses were performed: 1) with further adjustment of baseline data; 2) only on 
participant with primary outcome data at 9 months; 3) accounting for adherence to trial treatment. 
Results from sensitivity analyses were consistent with the primary analysis. Participants who 
adhe ed to t eat e t i te e tio s  % of e pe ted t eat e ts e e o e likel  to a hie e a 
treatment success. Adjusted odds ratio 1.91 (95% CI 0.87, 4.19) for NB-UVB compared with TCS, and 
2.67 (95% CI 1.19, 5.99) for combination compared with TCS (Figure 4). 
 
 
 
Figure 4 Sensitivity analyses of primary outcome 
Further adjustment of baseline was for gender.  
Complete case analysis was based on available data without imputation. 
CACE analyses were performed to account for the impact of treatment adherence.  
 
Subgroup analyses of the primary outcome were performed according to: 1) body region of the 
target patch (head & neck, hands & feet, rest of the body); 2) age (adults, children); 3) 
hypomelanotic patch with poorly defined borders (definitely/maybe, no); 4) duration of vitiligo (<4 
ea s,   ea s ; a d  post hoc analysis by skin type (I to III, skin type IV to VI).  
No differences were found between the groups for any of the planned and post-hoc sub-groups, 
with the exception of body region of the target patch, where analyses based on patches on the rest 
of the body appeared to favour combination treatment compared to TCS  (Table 10). 
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Table 10 Summary of subgroup analysis for the primary outcome (target patch only) 
 VNS treatment success rate  NB-UVB  
Vs TCS  
Odds ratio^  
(95% CI) 
Combination  
Vs TCS  
Odds ratio  
(95% CI) 
TCS 
 
NB-
UVB 
 
Combination 
By body region of target patch  
Adjusted* Odds Ratio (95% CI) 
Head and neck (N=161) 
  
Hands and feet (N=164) 
  
Rest of body (N=192)  
 
 
10(29%) 
 
2(5%) 
 
8(17%) 
 
15(42%) 
 
4(12%) 
 
8(15%) 
 
11(26%) 
 
4(13%) 
 
19(36%) 
 
1.78(0.70,4.52) 
 
1.93 (0.35,10.78) 
 
1.01(0.38,2.68) 
 
1.15(0.43,3.09) 
 
2.56(0.45,14.77) 
 
2.88(1.06,7.80) 
By age 
Adjusted Odds Ratio (95% CI) 
Adults (N=398)  
 
Children (N=119)  
 
 
13(15%) 
 
7(23%) 
 
20(22%) 
 
7(22%) 
 
22(24%) 
 
12(33%) 
 
1.64(0.76,3.55) 
 
1.03(0.26,4.04) 
 
2.03(0.93,4.43) 
 
1.80(0.60,5.37) 
By hypomelanotic and poorly defined border 
Adjusted Odds Ratio (95% CI) 
Definitely or Maybe (N=202) 
  
No (N=315)  
 
 
10(22%) 
 
10(14%) 
 
11(20%) 
 
16(23%) 
 
16(30%) 
 
18(24%) 
 
1.05(0.41,2.67) 
 
1.78(0.83,3.82) 
 
1.72(0.64,4.66) 
 
2.08(0.92,4.68) 
By duration of vitiligo  
Adjusted Odds Ratio (95% CI) 
  ea s N=  
  
< 4 years (N=150)  
 
 
11(14%) 
 
8(22%) 
 
14(21%) 
 
10(20%) 
 
18(20%) 
 
16(47%) 
 
1.68(0.73,3.82) 
 
0.99(0.29,3.49) 
 
1.72(0.76,3.87) 
 
3.28(0.91,11.92) 
By skin type  
Adjusted Odds Ratio (95% CI) 
Skin type I to III (N=296) 
  
Skin type IV to VI (N=221)  
 
 
10(15%) 
 
10(19%) 
 
14(18%) 
 
13(28%) 
 
14(21%) 
 
20(33%) 
 
1.18(0.54, 2.59) 
 
1.64(0.57, 4.78) 
 
1.38(0.64, 2.96) 
 
2.56(0.63, 10.37) 
All data are N (%) unless otherwise indicated. 
*Adjusted by centre, body region of target patch and age of participant with vitiligo. Analysis with multiple imputation  
^Due to model convergence only odds ratios were possible to be obtained for between group comparisons.  
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3.5 Secondary Outcomes 
VNS treatment success from blinded PPI reviewers 
Treatment success from blinded image assessment by patient reviewers were broadly consistent 
with the primary analysis but were more likely to suggest benefit from NB-UVB, with evidence of 
significant differences in treatment success for both the NB-UVB and the combination groups, 
compared with TCS (Table 11).  
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Table 11 Treatment success by blinded PPI assessors (VNS using digital images at baseline and 9 months) 
 TCS  
 
NB-UVB  
 
Combination 
 
Between-group comparisons 
TREATMENT PHASE    NB-UVB  
vs TCS  
Combination 
vs TCS  
Adjusted^ risk 
difference (95% 
CI)  
Adjusted risk ratio  
(95% CI) 
Adjusted risk 
difference (95% 
CI)  
Adjusted risk ratio  
(95% CI) 
Treatment success by blinded PPI 
assessors at 9 months (target patch) 
 
11%(12/112) 
 
20%(22/108) 
 
28%(32/116) 
 
9.7% (1.2%, 
18.2%) 
 
2.22(1.14, 4.31) 
 
 
16.3% (7.0%, 
25.6%) 
 
3.52(1.80, 6.89) 
All data are N (%) unless otherwise indicated.  
^Analyses adjusted by centre, body region of target patch and age of participant with vitiligo
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Participant reported VNS treatment success by region of the body (including all assessed patches) 
 
Patches on the hands and feet were less likely to respond to treatment than other parts of the body, 
regardless of the treatments being used. However, the between group comparisons given in Table 
12 indicate that there was no evidence of a differential treatment effect according to the location of 
assessed patches. (Table 12 and Figure 5). Participant-reported VNS at 3 and 6 months by body 
region is summarised (See Appendix 2). 
 
Figure 5 Treatment success at all assessed patches at 9 months  
 
 
 
67 
 
Table 12 Participant reported treatment success (VNS) by body region (including all assessed patches)  
 TCS  
 
NB-UVB  
 
Combination 
 
Between-group comparisons 
TREATMENT PHASE    NB-UVB  
vs TCS  
Combination 
vs TCS  
Participant reported treatment success at 
9 months by body regions (maximum 3 
patches per person) 
Head and neck 
Hands and feet 
Rest of body 
 
 
 
23%(14/61) 
10%(8/83) 
15%(14/94) 
 
 
 
32%(20/63) 
11%(7/79) 
17%(16/92) 
 
 
 
33%(23/69) 
18%(13/74) 
34%(30/89) 
Adjusted* Odds Ratio^ for 
interactions (95% CI)  
Adjusted Odds Ratio for interactions 
(95% CI) 
Hands and Feet 
vs Head and 
Neck 
 
0.89(0.22,3.54) 
Hands and Feet vs 
Head and Neck 
 
1.30(0.31,5.52) 
Rest of body vs 
Head and Neck 
 
1.06(0.30,3.74) 
Rest of body vs 
Head and Neck 
 
2.42(0.67,8.76) 
All data are N (%) unless otherwise indicated.  
*Analyses adjusted by centre, body region of target patch and age of participant with vitiligo 
^Due to model convergence only odds ratios were possible to be obtained for between group comparisons.  
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Overall 94% of participants had achieved onset of treatment response by 3-months for all groups 
(defined as the active target patch having improved or stayed the same (not worsened) as assessed 
by investigators) (Figure 6). TCS (40% improved 57% stayed the same); NB-UVB (61% improved, 35% 
stayed the same) and combination (60% improved, 38% stayed the same). 
Participant reported onset of treatment response is summarised (Appendix 3). 
 
 
Figure 6 Investigator assessed onset of treatment response 
 
Treatment success - percentage repigmentation 
 
Percentage repigmentation was assessed by a dermatologist using digital images taken at baseline 
and 9 months. Results were supportive of the primary outcome, although the rates of treatment 
success were lower: 3% (4/115) for the TCS group, 8% (9/116) for the NB-UVB group and 15% 
(18/120) for the combination group. Adjusted odds ratio 2.22 (95% CI 0.66, 7.51) for NB-UVB 
compared with TCS, and 4.62 (95% CI 1.50, 14.24) for combination compared with TCS (Table 9 
Percentage repigmentation assessed by blinded dermatologist and investigators). Review by blinded 
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investigators during clinic visits were also supportive of the primary outcome (Table 13). Full details of repigmentation rates at all time points are 
summarised ( Appendix 4). 
Table 13 Percentage repigmentation assessed by blinded dermatologist and investigators 
 TCS  
 
NB-UVB  
 
Combination 
 
Between-group comparisons 
TREATMENT PHASE    NB-UVB  
vs TCS  
Combination 
vs TCS  
% repigmentation - treatment success at 9 
months assessed by blinded dermatologist 
(using digital images of target patch) 
3%(4/115) 8%(9/116) 15%(18/120) Adjusted* Odds Ratio^ (95% CI)  
2.22(0.66, 7.51) 
Adjusted Odds Ratio (95% CI)  
4.62(1.50, 14.24) 
 
% repigmentation - treatment success 
assessed by investigators (target patch) at  
3 months  
6 months  
9 months  
 
 
3%(4/134) 
7%(8/115) 
9%(10/134) 
 
 
4%(6/136) 
5%(6/113) 
10%(11/136) 
 
 
4%(6/143) 
11%(14/125) 
18%(21/143) 
  
All data are N (%) unless otherwise indicated.  
*Analyses adjusted by centre, body region of target patch and age of participant with vitiligo 
^Due to model convergence only odds ratios were possible to be obtained for between group comparisons.  
Long-term follow-up (post-intervention) 
Long term follow-up rates at 12,15,18 and 21 months were 56%, 52%, 47% and 43%, and so results are presented descriptively.  
By 21 months (12 months after stopping treatment), just over 40% (149/338) of participants reported that repigmentation had been lost (Table 14). These 
percentages e e si ila  fo  those ho a hie ed t eat e t su ess  at  o ths Table 15).  
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Table 14 Loss of treatment response at target patch assessed by participant at 12, 15, 18 and 21 months   
 TCS  
 
NB-UVB  
 
Combination 
 
LONG-TERM FOLLOW-UP 
PHASE 
   
Loss of treatment response at target 
patch assessed by participant at  
12 months  
15 months  
18 months  
21 months  
 
 
19%(18/95) 
30%(31/105) 
37%(39/107) 
46%(50/108) 
 
 
23%(23/100) 
35%(39/111) 
40%946/116) 
43%(50/116) 
 
 
19%(18/95) 
30%(32/107) 
37%(41/112) 
43%(49/114) 
 All data are N (%) unless otherwise indicated.  
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Table 15 Loss of treatment response at target patch assessed by participant at 12, 15, 18 and 21 months (only for those who achieved treatment success 
by 9 months)   
 TCS  
(n = 173) 
NB-UVB  
(n = 169) 
Combination 
(n = 175) 
LONG-TERM FOLLOW-UP 
PHASE 
   
Loss of treatment response at target 
patch assessed by participant at  
12 months  
15 months  
18 months  
21 months  
 
 
6%(1/17) 
28%(5/18) 
33%(6/33) 
33%(6/18) 
 
 
13%(3/23) 
36%(9/25) 
38%(10/26) 
38%(10/26) 
 
 
28%(7/25) 
36%(10/28) 
38%(11/29) 
47%(14/30) 
 All data are N (%) unless otherwise indicated.  
 
Participant reported VNS throughout the trial (treatment and follow-up) 
 
VNS scores throughout the study treatment period (0 to 9 months) and follow-up period (12 to 21 months) are shown (Figure 7). The number included at 
each timepoint varies according to follow-up completion rates, but shows treatment success to be achieved by 6 months in the combination group and 
maintained for approximately 3 months, before loss of gained pigmentation in the longer term. 
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Figure 7 Percentage of participants reporting treatment success for target patch during the trial 
 
Quality of life 
There was no difference between the groups in any of the generic or vitiligo-specific quality of life instruments at any timepoint (Table 16)  
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Table 16 Summary of quality of life scores 
 
TCS  
(n = 173) 
NB-UVB  
(n = 169) 
Combination 
(n = 175) 
Between-group comparisons 
NB-UVB  
vs TCS  
Combination 
vs TCS  
At baseline  
VitiQOL score (adults) 
Mean(sd)  
N 
Skindex 29 score (adults) 
Mean(sd)  
N 
EQ-5D utility score (all)  
Mean(sd) 
N  
CHU-9D utility score (children)  
Mean(sd)  
N 
34.7[21.8] 
133 
 
22.8[15.7] 
132 
 
0.9[0.1] 
151 
 
1[0.1] 
40 
33.3[23.8] 
129 
 
21.4[18.6] 
130 
 
0.9[0.2] 
140 
 
0.9[0.1] 
35 
 
 
35.6[23.3] 
135 
 
23.8[18.7] 
133 
 
0.9[0.2] 
147 
 
0.9[0.1] 
39 
  
At 9 months     
VitiQOL score (adults) 
Mean(sd) 
N  
32.7[21.2] 
85 
27.9[22.0] 
85 
 
31.7[21.5] 
85 
Adjusted difference in means (95% CI) 
-5.5(-11.8, 0.8) 
Adjusted difference in means (95% CI) 
-2.0(-8.3, 4.4) 
Skindex 29 score (adults) 
Mean(sd) 
N 
 
19.2[14.9] 
82 
17.5[16.6] 
83 
 
20.3[15.6] 
84 
Adjusted difference in means (95% CI) 
-2.2(-6.8, 2.4) 
Adjusted difference in means (95% CI) 
0.3(-4.3, 4.9) 
EQ-5D utility score (all)  
Mean(sd) 
N 
0.9[0.2] 
97 
0.9[0.1] 
89 
0.9[0.1]98 Adjusted difference in means (95% CI) 
0.045(0.003,0.087) 
Adjusted difference in means (95% CI) 
0.031(-0.010,0.073) 
CHU-9D utility score (children)  
Mean(sd) 
N 
1[0.1] 
31 
1[0] 
28 
 
0.9[0.1] 
35 
Adjusted difference in means (95% CI) 
0(-0.028,0.027) 
Adjusted difference in means (95% CI) 
-0.023(-0.048,0.002) 
 
At 21 months  
  
VitiQOL score (adults) 
Mean(sd)  
N 
36.1[21.1] 
56 
31.1[22.8] 
57 
 
38.4[23.6] 
63 
  
Skindex 29 score (adults) 
Mean(sd) 
N 
 
22.5[16.5] 
57 
 
19.1[16.6] 
52 
 
25.9[17.5] 
60 
  
Lower score means better outcome for VitiQOL, Skindex. Higher score means better outcome for EQ-5D and CHU-9D 
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Adverse and serious adverse events 
 
Safety 
A total of 124 (25%) participants reported 206 related-adverse events, 33 events from 24 
participants (14%) in the TCS group, 69 events from 48 participants (28%) in the NB-UVB group and 
104 from 52 participants (30%) in the combination group. A full listing of related-adverse events are 
provided in Appendix 5. There were five serious adverse events reported from five participants, but 
none were related to trial interventions (See Table 17) 
Details of grades 3 or 4 erythema and skin thinning are shown (See Table 17). In general, fewer 
adverse events were reported in children than adults. 
There were five reported Serious Adverse Events, but none was related to trial treatments. These 
were asthma, fracture, pancreatitis, pneumonia and syncope.  
Table 17 Adverse events 
 TCS  
(n = 173) 
NB-UVB  
(n = 169) 
Combination 
(n = 175) 
Total number of participants reported any related AEs 
 
Total number of related AEs  
AEs by severity  
Mild  
Moderate  
Severe  
AEs by outcome  
Recovered  
Resolved with sequelae  
Ongoing  
Unknown  
24(14%) 
 
33 
 
30 
3 
0 
 
20 
3 
7 
3 
48(28%) 
 
69 
 
32 
24 
13 
 
53 
6 
5 
5 
52(30%) 
 
104 
 
58 
40 
6 
 
92 
3 
6 
3 
Number of erythema events in adults  
Grade 3 erythema  
Grade 4 erythema  
Number of erythema events in children  
Grade 3 erythema 
Grade 4 erythema 
 
Erythema events by outcome  
2(2) 
0 
2 
1(1) 
1 
0 
 
3 
22(20) 
8 
14 
7(6) 
6 
1 
 
29 
37(26) 
33 
4 
8(7) 
8 
0 
 
45 
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Recovered  
Resolved with sequelae  
Ongoing  
Unknown 
3 
0 
0 
0 
25 
1 
0 
3 
44 
0 
1 
0 
Number of skin thinning* event in adults  
Number of skin thinning events in children  
Skin thinning events by outcome  
Recovered  
Resolved with sequelae  
Ongoing  
Unknown 
5(5) 
1(1) 
6 
3 
0 
2 
1 
2(2) 
0 
2 
1 
1 
0 
0 
5(5) 
0 
5 
2 
2 
1 
0 
*Skin thinning was defined as any events classified as skin atrophy, skin striae, telangiectasia or spider vein.  
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Chapter 4: Health Economic Evaluation 
4.1 Introduction 
A systematic review in 2018 showed that the economic evidence base for vitiligo treatment and care 
is virtually non-existent49. One of the two studies identified in this review estimated the annual 
direct cost of treating vitiligo in the USA to be $15,000,000 for the price year 200450. The other study 
demonstrated that 32.5% of people with vitiligo would be willing to make a one-off payment of 
€  fo  a u e  p i e ea 51, allowing an estimate of the maximum potential for benefit 
should a cure be found. These papers indicate the cost both to the person affected and the health 
care system but do not provide evidence to inform resource allocation decisions. No papers were 
identified that undertook full economic evaluations of vitiligo treatments either alongside clinical 
trials or as economic modelling. Mcmanus et al.49, identified a need for full economic evaluations of 
currently prescribed vitiligo treatments. This chapter reports what we believe to be the first full 
economic evaluation of vitiligo treatment, both of a current standard treatment (TCS) and new 
treatment (home based NB-UVB light therapy) alone and in combination with TCS. In this chapter 
the methods, results and discussion pertaining to the economic evaluation undertaken alongside the 
trial are reported. 
4.2 Methods 
The primary objective of the health economic evaluation was to estimate the within-trial cost-
effectiveness of i) active hand-held NB-UVB light compared to TCS only (standard care) and ii) active 
hand-held NB-UVB plus TCS compared to TCS only (standard care) in terms of cost per treatment 
success at the end of the treatment period (9 months) in the treatment of vitiligo, using individual 
level data collected within the trial. These were deemed the appropriate economic questions as 
each compares to current standard care. 
The secondary objective was to undertake two separate cost utility analyses at the end of the trial 
intervention period (9 months) for those with (i) EQ-5D-5L utility values available (participants aged 
11 and over years) and (ii) CHU-9D utility values available (participants aged 5 to <18 years). 
Including the EQ-5D-5L values of those aged 11-17 in (i) deviates slightly from what was proposed in 
the protocol in recognition that lower than expected response rates to the utility instruments, 
particularly at follow-up, means it makes more sense to use all the data available regardless of age. 
The evaluation was undertaken in line with published guidelines for the economic evaluation of 
health care interventions as appropriate52-56. 
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The trial was conducted in the UK, which has a national health service (the NHS), providing publicly 
funded healthcare that is largely free of charge at the point of use. Therefore the analysis was 
primarily undertaken from an NHS perspective, in keeping with the NICE reference case.56 Out of 
pocket costs incurred by participants and where applicable their parents/guardians arepresented 
separately reflecting a personal perspective.  
The primary economic analysis compares the costs and outcomes over the 9-month intervention 
period from randomisation and therefore costs and benefits are not  discounted. 
4.3 Resources use and costs 
Identification of resources 
In keeping with the chosen perspective, the base case captured the intervention costs (including any 
side-effe t osts  to the NH“ a d the pa ti ipa t s ide  use of the NH“ i ludi g health a e isits 
and prescriptio s  as a esult of itiligo. Pa ti ipa ts  pe so al out of po ket e pe ses i u ed as a 
result of their vitiligo were also captured in a separate analysis taking a broader perspective. The 
time spent by patients administering the interventions is presented descriptively elsewhere in this 
report, but participant time burden administering treatment was not costed.  
Measurement of resource use data 
Resource use for the intervention phase was collected at 3, 6 and 9 months, using information 
recorded by participants in daily diaries and in case report forms collected at follow-up visits. In the 
follow-up period, resource use was collected via online participant questionnaires at 12, 15, 18 and 
21 months (or via paper copies if preferred).  
 
Valuation of resource use data 
The cost of the intervention was estimated at the individual level as follows. 
NB-UVB Device: 
In costing the intervention, the cost of the hand-held de i e as esti ated usi g the a ufa tu e s 
purchase price divided by an annuity factor (interest rate 3.5%, 5 years) to give an equivalent annual 
cost (EAC). EAC was divided by 12 months and multiplied by 9 to give an equivalent cost of the 9-
month timeframe. The purchase price of personal protective equipment (such as goggles and 
glasses) were included at full cost since it is not believed these would have the same durability as the 
device itself. We did not include in the analysis any costs for repairs or replacement devices required 
due to malfunction or damage, because if participants reported a faulty device during the trial, a 
replacement device was issued instead of repairing the existing device; in practice, repairs would be 
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more likely. We do, however, report in Table 19 the mean number of NB-UVB devices used over the 
9 month treatment period to show that malfunction of the devices was low. The price of the device 
was varied in sensitivity analysis and thus the uncertainty surrounding the cost of the device 
(including any replacement or repairs) that would change the conclusions of the study was explored. 
The number of devices received per participant over the course of the trial was recorded and 
reported descriptively to indicate the level of faults experienced in the trial.  
Participants received training in how to use the device correctly, through practical demonstration, 
written instructions and a video. The time spent by investigators delivering this training was 
captured in the CRF. 
As these devices are not routinely prescribed currently in the NHS, it is unclear how they would be 
rolled out if they were to be adopted. In the analysis we assume the devices are given to patients at 
hospital appointments within the dermatology department and once returned at 9 months given to 
a new patient. 
Topical Corticosteroid 
Participants receiving the TCS intervention were supplied with two 90g tubes of mometasone 
furoate 0.1% ointment (Elocon® 0.1% Ointment, Merck Sharp & Dohme, Hertford). The cost of the 
TCS was sourced from the Prescription Cost Analysis for 201757 and had the National Average 
Discount Percentage of 7.37% (https://www.nhsbsa.nhs.uk/prescription-data/understanding-our-
data/financial-forecasting) deducted and the professional pharmacist fee of £1.29 added, assuming 
in practice that a single tube would be prescribed at any one time. 
Where participants requested additional ointment, this was recorded and costed at the individual 
participant level.  
Whichever intervention group participants were in, it was assumed that in practice all participants 
would see a dermatologist at 0, 3, 6, and 9 months and these were costed even though they will 
essentially cancel each other out between treatment arms. 
Side effects requiring medical attention from either the NB-UVB device or TCS were recorded in the 
CRF. These unscheduled contacts were costed using published unit costs. 
 
Unit costs 
All resource use relevant to the NHS perspective, including wider NHS usage due to vitiligo, was 
valued using UK unit costs (in £Sterling) for the 2017 price year (the most recent price year available 
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at the start of the analysis). Unit costs were identified from published sources, such as Unit Costs of 
Health and Social Care58, Prescription Cost Analysis57 and NHS Reference Costs (Department of 
Health, 2017). A table of unit costs, together with their sources, is presented in the Results section.  
Personal costs incurred by participants as out of pockets costs due to their vitiligo were valued using 
patient reported estimates. These were not adjusted to reflect the year in which they were incurred 
since timing is likely to have had a negligible effect on price for the types of items reported (for 
instance, the majority of items were sun creams, emollients or camouflage products that are (or 
similar to products) also available on prescription and the NIC per item in the Prescription cost 
analysis barely changed between 2016 and 2017 – from £8.34 in 2016 to £8.29 in 2017)5659. 
 
Total costs 
The cost of all reported resource use (relevant to an NHS perspective) was calculated for each 
participant. These figures were then summed for each participant, giving a total cost over the 9-
month treatment period in the primary analysis. For each of the different intervention arms, a mean 
cost per participant was estimated.  
4.4 Identification of outcome(s) 
Vitiligo Noticeability Scale 
The primary clinical outcome measure in the HI-LIGHT trial is participant reported treatment success, 
measured at 9 months, using the VNS43. Treatment success, a binary outcome, is defined by whether 
the pa ti ipa t espo ds that thei  ta get itiligo pat h is a lot less oti ea le  o  o lo ge  
oti ea le  i  espo se to the uestio : "Co pa ed to the sta t of the stud , ho  oti ea le is the 
vitiligo now?". No previous studies have compared the treatments being compared in this study, 
hence the use of single study-based estimates of effectiveness. 
Quality of Life 
Quality Adjusted Life Years (QALYs) were estimated in secondary analyses using utility scores 
obtained from the EQ-5D-5L instrument for participants aged 11 years and over and the CHU-9D in 
the analysis focussed on children under the age of 18 years.60, 61 For participants aged 5-6 years old, 
the CHU-9D was completed by parental proxy, but for all other ages these instruments were self-
completed.  
The decision to use the EQ-5D-5L was based on the EUROQOL EQ-5D-Y user guide 
(https://euroqol.org/wp-content/uploads/2016/09/EQ-5D-Y_User_Guide_v1.0_2014.pdf) available 
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at the time of study design, which stated that although the EQ-5D-Y is ge e all  e o e ded  the 
adult version might be possible. We chose to use just the one version of the EQ-5D in the study for 
consistency and because the EQ-5D-Y does not currently have a UK valuation set. The CHU-9D was 
chosen over the EQ-5D-Y because a UK valuation set exists for it. 
Neither generic utility instrument had been used in this disease area before. Therefore their 
inclusion was somewhat experimental, seeking to start to build up some evidence as to their 
potential for use in vitiligo. 
Measurement of outcome(s) 
Utility measurements were collected in person at clinic visits at baseline and 9 months and via 
online/postal questionnaire at 21 months.  
4.5 Valuation of outcome(s) 
In the cost utility analysis, the responses received on the quality of life instruments was converted to 
utility scores using the EQ-5D-5L Crosswalk62 UK preference weights in the base case analysis; this is 
in line with current recommendations63, 64. The CHU-9D was valued using the UK value set58. 
Following this, the utility values were used to calculate the number of quality adjusted life years 
(QALYs) generated over the trial treatment period of 9 months and for sensitivity analyses over the 
treatment and follow-up period of 21 months, using both linear interpolation and area under the 
curve analysis with and without baseline adjustment65. Separate cost-utility analyses report the 
incremental cost per QALY based on the EQ-5D-5L responses (for participants aged 11 years and 
over) and the CHU-9D responses (for participants aged 5-17) from an NHS perspective. The impact of 
using different preference weights for the EQ-5D-5L was explored in sensitivity analyses. 
4.6 Economic analysis 
All analyses were conducted in Stata MP4 version 15. The economic base-case analysis was 
performed on the full analysis set, where, in line with that undertaken for the primary statistical 
analysis, multiple imputation was used to account for missing primary outcome data and cost data at 
9 months. The final analysis was a within-trial analysis, taking a 9-month time horizon in the base 
case analysis. As the time horizon being evaluated is 9 months in the base case costs and benefits 
were not discounted.  
The main base case analysis was a cost effectiveness analysis, meaning decision makers will need to 
make a value judgement about the acceptable value of the cost per treatment success. The cost 
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effectiveness analysis was chosen as the primary analysis because it enabled the whole sample to be 
analysed together, irrespective of the pa ti ipa t s age. There was also some concern that available 
generic utility instruments may not be able to fully capture the health-related quality of life aspects 
of people living with vitiligo. Further details for this choice are discussed in section 4.15. 
The secondary objective to assess cost utility analysis, combined estimated mean costs and QALYs 
for each intervention option for the two comparisons of interest with a feasible range of values for 
decision makers willingness to pay (ʎ), to obtain a distribution of net benefits for different levels of 
ʎ. In secondary analyses, the reported economic analysis used a cost-effectiveness threshold of 
£20,000 per QALY.  
Mean (SD) resource use per participant was estimated for each randomised group. Mean difference 
(95% CI) in mean resource use between arms (NB-UVB only to TCS only; and combination treatment 
compared with TCS only) is presented. Mean (SD) cost per participant is estimated for each 
randomised group. Mean difference (95% CI) in mean cost between arms (NB-UVB only to TCS only; 
and combination treatment compared with TCS only) is estimated unadjusted.  
The primary outcome for the economic evaluation is cost per treatment success. 
The secondary outcome for the economic evaluation is quality-adjusted life years (QALYs) of 
participants over 9 months in the base case. Mean (SD) utility and mean (SD) QALYs per participant 
per randomised group is presented, and mean difference (95% CI) in utility and QALYs between arms 
(NB-UVB only to TCS only; and combination treatment compared with TCS only) is estimated 
unadjusted and adjusted.  
Base case analyses took account of missing data and are presented unadjusted and adjusted for age 
and target patch. The primary economic analysis, using the clinical outcome, used the imputation 
model and output of the primary clinical analysis presented in chapter 3. Other analyses employed 
multiple imputation with chained equations using MI impute in STATA generating 60 (m=60) 
datasets using predictive mean matching and separately by treatment allocation, the approach 
reported in Faria et al66.  Costs were adjusted for age and location of target patch as were QALYs in 
addition to adjusting for baseline utility using seemingly unrelated regression (SUR)67. 
 
 
4.7 Sampling uncertainty 
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Since costs and outcomes were skewed, non-parametric bootstrapping was used to determine the 
level of sampling uncertainty surrounding the mean ICERs by generating 10,000 estimates of 
incremental costs and benefits. These estimates were plotted on a cost-effectiveness plane. In 
addition, Cost-Effectiveness Acceptability Curves were produced, which show the probability each 
intervention arm is cost effective at different values of willingness to pay.  
4.8 Subgroup analysis/Analysis of heterogeneity 
Other than doing separate pre-planned secondary analysis based on the different utility instruments 
used (EQ-5D-5L and CHU-9D), no subgroup analyses were undertaken. 
4.9 Sensitivity analyses 
Sensitivity analyses were undertaken to explore key uncertainties around important parameters in 
the economic evaluation.  
1. Impact of missing data was explored by comparing base case results using multiple 
imputation to a complete case analysis. 
2.   Cost of the NB-UVB device: the cost effectiveness of the interventions is likely to be significantly 
driven by the cost of the NB-UVB device. There is uncertainty about how the device would be 
prescribed and used, if it were found to be effective and adopted by the NHS. The base case analysis 
annuitised the device cost assuming that the device would be used for a period of 5 years but there 
is uncertainty surrounding this period of use and in practice the devices may not be returned by 
patients at the end of treatment. We estimate the device price at which a decision would switch 
from being cost effective to cost ineffective. 
3. Wider cost perspective: As part of the trial participants were asked about the costs (if any) 
incurred by themselves or their families in terms of out of pocket costs as a result of their vitiligo. 
These costs will be added to the base case results to see if they would change the conclusions 
reached when considering only NHS costs. 
4. Impact of adherence: Given any  clinical effectiveness  found and low adherence  (defined as 
less than 75% adherent), the economic analysis wasl  repeated including only the adherent sample, 
where adherence was estimated as total sessions used divided by total expected sessions. 
5. Longer-term analysis: If either comparison was found clinically effective at 9 months, then 
the cost effectiveness and cost utility analyses would be repeated at the 21 months follow-up point 
should the completion rate of follow-up data facilitate this. Though interventions will have stopped 
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post 9 months, it might be useful to explore the longer-term cost effectiveness of the comparators 
of interest beyond this point to see if value for money (if found at 9 months) is sustained. In any 
sensitivity analyses taking a 21-month time horizon, costs and benefits in months 13 to 21 would be 
discounted using the recommended rate of 3.5% for both costs and benefits.56 It is expected that the 
majority of costs and benefits would be captured in this period, and therefore it is not considered 
necessary to develop a decision-analytic model. 
This chapter has been written in line with CHEERS reporting quality guidelines. Any deviations from 
the Health Economics Analysis Plan (HEAP) are described and justified in the results section below. 
 
4.10 Results 
Table 18 presents the unit costs (UK£2017), their source and any assumptions used throughout the 
economic analysis. 
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Table 18 Unit Costs Table (UK£ sterling, 2017) 
Resource Item Unit Cost (£2017) Source (notes) 
Intervention resources 
Annuity factor  4.515 based on 
r = 3.5% and n = 5 
Drummond et al.52 
Purchase price 149.00 Dermfix Ltd website 
Annuitised 9-month purchase pricea 24.75 (Purchase price divided by annuity factor to give equivalent 
annual cost (EAC). EAC divided by 12 months and multiplied by 
9.) 
Annuitised 9-month quality assurance (£17.83 multiplied by 
annuity factor)  
2.96  
 
Quality assurance: Medical Physics, Nottingham University 
Hospitals 
Glasses (per set) 15.00 Dermfix Ltd website 
Goggles (per set) 7.00 Dermfix Ltd website 
TCS (per 90g tube of mometasone furoate 0.1%)  12.13 Health and Social Care Information Centre Prescription Cost 
Analysis57 
Investigator face to face and telephone support (per minute, 
assumed band 7 £54 per hour) 
0.90 PSSRU 2017 58 
Dermatologist Face to face first appointment consultant-led 159.00 NHS Schedule of Reference Costs 68 
Dermatologist Face to face follow-up appointment consultant-
led 
129.00 NHS Schedule of Reference Costs 68 
Dermatologist telephone appointment consultant-led 100.00 NHS Schedule of Reference Costs 68 
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Primary Care resources (per visit) 
GP  37.00  PSSRU 2017 58 
Practice Nurse  10.85  PSSRU 2017 58 
Pharmacist (assumed to be a community pharmacist)  11.11  PSSRU 2017 58 
Hospital Doctor  53.33  PSSRU 2017 58 
Hospital Nurse  15.00 PSSRU 2017 58 
Therapist  27.00  PSSRU 2017 58 
Other (reported by participants) Range from 15.00 
to 86.00 
 PSSRU 2017 58 and NHS Schedule of Reference Costs 68 
Other Resources 
Medication (Various, NIC per item less NADP plus professional 
fee) 
Range from 3.37 to 
36.92 
 PCA 201757 
Participant and family out of pocket costs Various Estimates reported by participants 
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4.11 Intervention costs 
The intervention costs consisted of the device plus consumables costs, drug costs, dermatologist 
appointments, training and unscheduled visit/telephone costs. We did not include the costs of 
training the nurses to deliver the training session with participants or of developing the video as 
these were assumed to be sunk costs. 
Glasses and goggles were given out for eye protection when using the NB-UVB device. These were 
costed for the actual number given out to participants (See Table 20 and Table 22 for mean number 
used by group): some requested more than one set if their vitiligo patch was in a difficult to reach 
place or if they needed help because they were a child.  
Quality assurance – the process of setting up and checking the quality of devices before they were 
issued to patients was estimated using expert opinion from staff at the Nottingham University 
Hospitals medical physics department. The quality assurance process involved device in and device 
out processes. Before devices were issued to participants they were tested for electrical safety and 
output, spectral characterisation was undertaken, and some data administration was involved. 
When devices were returned, they again had their output tested and some data administration was 
involved. Table 19 shows the time and cost for each aspect. Staff time was assumed to be a mid-
point band 5 on Agenda for Change and the batch size was assumed to be 10 devices at once. 
Quality assurance costs were also multiplied by the annuity factor to gain the cost over the study 
period. In reality, quality assurance might be undertaken more frequently than every 5 years or may 
be provided using a different service model (e.g. specialist versus local sites undertaking the activity) 
which may affect cost but the impact of this assumption is tested in the sensitivity analysis section, 
where price is varied to see the impact on cost per treatment success. 
It was assumed that devices would be given to patients at an appointment with the dermatologist. It 
was assumed they would have four visits with a dermatologist over the 9-month treatment period 
whichever treatment group they were in. Those receiving the NB-UVB would also have had an 
appointment with a nurse in the dermatology department and a training session with the nurse. 
Table 20 and Table 22 show that training time was a mean of 73.08 minutes in the NB-UVB only 
group and 69.17 minutes in the combination treatment group. In addition to routine visits to the 
dermatologist and nurse at set intervals, unscheduled contacts were also recorded. Such visits could 
either be face to face or over the telephone and occurred due to side-effects or concerns over the 
use of treatments. The number of such contacts were low in all groups, although the combination 
treatment group had the most (See Table 20 and Table 22). 
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Table 19 Quality assurance process (time and costs) for NB-UVB devices 
Device out 
Set-up time 
per batch 
(mins) 
Cost of set-
up per 
device (£) 
Time per 
device (mins) 
Cost per 
device (£) 
Total 
cost 
Electrical safety 
testing 10 0.52 5 2.58 3.10 
Output testing 20 1.03 8 4.13 5.17 
Spectral 
characterisation 30 1.55 10 5.17 6.72 
Data administration 5 0.26 5 2.58 2.84 
        
Device in 
Set-up time 
(mins) 
Cost of set-
up (£) 
Time per 
device (mins) 
Cost per 
device (£) 
Total 
cost 
Output testing 20 1.03 8 4.13 5.17 
Data administration     5 2.58 2.58 
 
Those participants receiving active TCS received two 90g tubes of mometasone furoate 0.1% 
ointment at the outset of the study and any requests for further tubes were recorded and costed 
accordingly and similar amounts were requested in the TCS only and combination treatment (See 
Table 20, Table 21 and Table 22) 
4.12 Resource use, costs and primary clinical outcome  
Use of resources for the intervention and wider health care resource use related to vitiligo are 
shown in Table 20 and Table 22 using available case data. These show that wider health care 
resource use (primary care, secondary care and medicines) used for vitiligo but beyond those 
required for the intervention were not significantly different between groups. Vitiligo patients can 
be seen to be low users of NHS health care, perhaps because there is a lack of treatments currently 
available for this condition, or because the trial was offering the best treatment for the condition 
and so they had little need for further care. Table 21  and Table 23 display the mean resource use 
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per participant by treatment group using available case data. It can be seen that the overall mean 
cost per participant in the NB-UVB only group was £774.64 (SD 83.71) compared to £599.98 (SD 
96.18) in the TCS only group, giving an unadjusted mean difference in cost of £174.66 (95% CI 152.75 
to 196.66). The combination treatment group had overall mean costs per participant of £813.38 (SD 
111.39); compared to the TCS only group this gave an unadjusted mean difference of £213.40 (95% 
CI 188.33 to 238.46) per participant. These figures suggest that the costs of the interventions are not 
offset by reductions in wider health care resource use related to vitiligo, and that if the interventions 
are to be considered cost-effective, the additional cost of the interventions needs to be justified in 
terms of additional benefit attained. 
Table 20 NB-UVB compared to TCS: mean (Standard Deviation) resource use according to 
intervention arm over the 9-month treatment phase for all participants (based on available data) 
 NB-UVB only (n=169) TCS only (n=173) Mean difference 
(95% CI) 
 Mean Std dev (n) Mean Std dev (n)  
  
Intervention  
NB-UVB 
intervention* 
1.08  0.30 (169) 0.00 0.00 (173) 1.083 
(1.04 to 1.13) 
Glasses 1.41 0.58 (169) 0.00 0.00 (173) 1.41 
(1.33 to 1.50) 
Goggles 0.46 0.60 (169) 0.00 0.00 (173) 0.46 
(0.37 to 0.54) 
TCS 0.00 0.00 (169) 2.15 0.55 (173) -2.15 
(-2.23 to -2.07) 
Training time 
(mins) 
73.08 40.47 (169) 0.00 0.00 (173) 73.08  
(67.03 to 79.13) 
Dermatologist 
time (clinic + 
telephone) 
4.00 0.00 (169) 4.00 0.00 (173) 0.00 
(0.00 to 0.00) 
Nurse time 
(clinic + 
telephone) 
2.00 0.00 (169) 0.00 0.00 (173) 2.00 
(2.00 to 2.00) 
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Unscheduled 
clinic with 
Nurse 
0.03 0.20 (169) 0.01 0.11 (173) 0.02   
(-0.02 to 0.05) 
Unscheduled 
telephone with 
Nurse 
0.46  0.95 (169) 0.39 0.87 (173) 0.07   
(-0.13 to 0.26) 
Unscheduled 
clinic with 
dermatologist 
0.04  0.20 (169) 0.02  0.13 (173) 0.02 
(-0.01 to 0.06) 
Unscheduled 
telephone with 
dermatologist 
0.03 0.20 (169) 0.02 0.17 (173) 0.01 
(-0.03 to 0.05) 
Primary Care and Community  
Number 0.17 0.64 (132) 0.12 0.44 (136) 0.06  
(-0.07 to 0.19) 
Secondary Care  
Number 0.20 0.61 (132) 0.48  4.47 (136)  -0.28 
(-1.05 to 0.49) 
Other  
Medication 0.08 0.35 (133) 0.12 0.50 (138) -0.04 
(-0.14 to 0.06) 
Out of pocket 
purchases 
0.28 0.88 (137) 0.40 1.44 (141) -0.12 
(-0.40 to 0.16) 
* Includes number of NB-UVB devices only. 
Table 21 NB-UVB compared to TCS: mean (Standard Deviation) costs and outcomes according to 
intervention arm over 9-month treatment phase (UK£Sterling, 2017) for all participants (based on 
available data) 
 NB-UVB only (n=169) TCS only (n=173) Mean difference 
(95% CI) 
 Mean Std dev (n) Mean Std dev (n)  
Intervention  
NB-UVB Device 24.75 0.00 (169) 0.00  0.00 (173) 24.75 
(24.75 to 24.75) 
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Quality 
assurance for 
device 
2.96  0.00 (169) 0.00  0.00 (173) 2.96 
(2.96 to 2.96) 
Glasses 21.21 8.74 (169) 0.00  0.00 (173) 21.21 
(19.91 to 22.52) 
Goggles 3.19 4.18 (169) 0.00  0.00 (173) 3.19 
(2.56 to 3.81) 
TCS 0.00 0.00 (169) 26.08 6.67 (173) -26.08 
(-27.09 to -25.07) 
Training time 65.77 36.42 (169) 0.00  0.00 (173) 65.77 
(60.32 to 71.22) 
Dermatologist 
(clinic + 
telephone) 
546.00  0.00 (169) 546.00 0.00 (173) 0.00 
(0.00 to 0.00) 
Nurse (clinic + 
telephone) 
72.00 0.00 (169) 0.00  0.00 (173) 72.00  
(72.00 to 72.00) 
Unscheduled 
clinic with 
Nurse 
0.53 3.64 (169) 0.21  1.93 (173) 0.32 
(-0.29 to 0.94) 
Unscheduled 
telephone with 
Nurse 
8.34 17.53 (169) 7.16  16.30 (173) 1.19 
(-2.41 to4.79) 
Unscheduled 
clinic with 
dermatologist 
5.34 25.78 (169) 2.24 16.89 (173)  3.11 
(-1.52 to 7.73) 
Unscheduled 
telephone with 
dermatologist 
2.96 20.20 (169) 1.73 16.96 (173) 1.22   
(-2.74 to 5.19) 
Total cost of 
intervention 
753.06 59.16 (169) 583.42 29.59 (173) 169.64 
(159.73 to 179.56) 
Primary Care and Community  
Cost 5.90  22.20 (132) 3.90 15.21 (136) 2.00   
(-2.56 to 6.57) 
Secondary Care  
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Cost 9.30 30.05 (132) 11.05 77.14 (136) -1.74 
(-15.90 to 12.42) 
Other  
Medication 1.49 7.06 (133) 2.48 10.52 (138) -0.99 
(-3.14 to 1.16) 
Total mean 
cost per 
participant 
 774.64 83.71 (131) 599.98   96.18 (132) 174.66 
(152.75 to 196.56) 
Out of pocket 
costs 
4.94 20.09 (137) 14.44 96.78 (141)  -9.49  
(-26.11 to 7.12) 
Primary outcome 
VNS  27 
(21.95) 
 20 
(16.81) 
 7 (5.14) 
 
Table 22 Combination treatment versus TCS: mean (Standard Deviation) resource use according to 
intervention arm over the 9 month treatment phase for all participants (based on available data) 
 Combination treatment 
(n=175) 
TCS only (n=173) Mean difference 
(95% CI) 
 Mean Std dev (n) Mean Std dev (n)  
  
Intervention  
NB-UVB 
intervention* 
1.07 0.30 (175) 0.00 0.00 (173) 1.07 
(1.03 to 1.12) 
Glasses 1.50 0.56 (175) 0.00 0.00 (173) 1.50 
(1.41 to 1.58) 
Goggles 0.40  0.56 (175)  0.00 0.00 (173) 0.40 
(0.32 to 0.48) 
TCS 2.12   0.49 (175) 2.15 0.55 (173) -0.03   
(-0.14 to 0.08) 
Training time 
(mins) 
69.17 34.51  
(175) 
0.00 0.00 (173) 69.17 
(64.01 to 74.33) 
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Dermatologist 
time (clinic + 
telephone) 
4.00 0.00 (175) 4.00 0.00 (173) 4.00  
(4.00 to 4.00) 
Nurse time 
(clinic + 
telephone) 
2.00 0.00 (175) 0.00 0.00 (173) 2.00  
(2.00 to 2.00) 
Unscheduled 
clinic with 
Nurse 
0.13 0.51 (175) 0.01 0.11 (173) 0.12 
(0.04 to 0.20) 
Unscheduled 
telephone with 
Nurse 
0.66 1.29 (175) 0.39 0.87 (173) 0.28  
(0.04 to 0.51) 
Unscheduled 
clinic with 
dermatologist 
0.10 0.43 (175) 0.02  0.13 (173) 0.09 
(0.02 to 0.15) 
Unscheduled 
telephone with 
dermatologist 
0.05 0.27 (175) 0.02 0.17 (173) 0.03  
(-0.01 to 0.08) 
Primary Care and Community  
Number 0.12 0.55 (142) 0.12 0.44 (136) .002  
(-0.12 to 0.12) 
Secondary Care  
Number 0.20 0.63 (142) 0.48  4.47 (136)  -0.28  
(-1.03 to 0.46) 
Other  
Medication 0.09  0.34 (141) 0.12 0.50 (138) -0.03   
(-0.13 to 0.07) 
Out of pocket 
purchases 
0.31   1.27 (144) 0.40 1.44 (141) -0.09   
(-0.41 to 0.23) 
*Includes number of NB-UVB devices only. 
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Table 23 Combination treatment versus TCS: mean (Standard Deviation) costs and outcomes 
according to intervention arm over 9-month treatment phase (UK£Sterling, Price Year) for 
participants (based on available data) 
 Combination treatment 
(n=175) 
TCS only (n=173) Mean difference 
(95% CI) 
 Mean Std dev (n) Mean Std dev (n)  
  
Intervention  
NB-UVB Device 24.75 0.00 (175) 0.00  0.00 (173) 24.75 
(24.75 to 24.75) 
Quality 
assurance for 
device 
2.96 
 
0.00 (175) 0.00  0.00 (173) 2.96 
(2.96 to 2.96) 
Glasses 22.46  8.34 (175) 0.00  0.00 (173) 22.46 (21.21 to 
23.70) 
Goggles 2.80   3.90 (175) 0.00  0.00 (173) 2.80  
(2.22 to 3.38) 
TCS 25.71 5.99 (175) 26.08 6.67 (173) -0.37 
(-1.70 to 0.97) 
Training time 62.25 31.06 (175) 0.00  0.00 (173) 62.25 
(57.61 to 66.90) 
Dermatologist 
(clinic + 
telephone) 
546.00 0.00 (175) 546.00 0.00 (173) 546  
(546.00 to 546.00) 
Nurse (clinic + 
telephone) 
72.00 0.00 (175) 0.00  0.00 (173) 72.00 
(72.00 to 72.00) 
Unscheduled 
clinic with 
Nurse 
2.41 9.53 (175)   0.21  1.93 (173) 2.20 
(0.75 to 3.66) 
Unscheduled 
telephone with 
Nurse 
12.30 23.92 (175) 7.16  16.30 (173) 5.14 
(0.82 to 9.46) 
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Unscheduled 
clinic with 
dermatologist 
13.27 55.45 (175) 2.24 16.89 (173) 11.03 
(2.37 to 19.70) 
Unscheduled 
telephone with 
dermatologist 
5.14   26.84 (175) 1.73 16.96 (173) 3.41   
(-1.33 to 8.15) 
Total cost of 
intervention 
792.06   94.61 (175) 583.42 29.59 (173) 208.64 
(193.82 to 223.46) 
Primary Care and Community  
Cost 2.84 14.09 (142) 3.90 15.21 (136) -1.06   
(-4.52 to 2.40) 
Secondary Care  
Cost 8.52 26.87 (142) 11.05 77.14 (136) -2.53 
(-16.05 to 11.00) 
Other  
Medication 1.20  6.09 (140) 2.48 10.52 (138) -1.28   
(-3.30 to 0.75) 
Total mean 
cost per 
participant  
813.38 111.39 (136)   599.98   96.18 (132) 213.40 
(188.33 to 238.46) 
Out of pocket 
costs 
6.62 28.45 (144) 14.44 96.78 (141) -7.81 
(-24.37 to 8.75) 
Primary outcome 
VNS – No. 
successful (% 
successful) 
34 
(26.56) 
  20 
(16.81) 
 14 (9.75) 
 
4.13 Primary Economic Analysis 
Cost effectiveness analysis of NB-UVB only compared to TCS only 
The unadjusted risk difference for NB-UVB compared to TCS was 3.64% (adjusted 5.20%), this 
equates to a number needed to treat (NNT) of 27 (19 adjusted); in other words, 27 (19) participants 
would need to be treated for one of them gain treatment success. 
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The incremental difference in cost was £174.65 (95% CI 152.75 to 96.55) unadjusted or £173.44 
(95% CI 150.55 to 196.32) adjusted for age and body region of target patch. The unadjusted 
incremental cost was £4,801.92 (£3,335.74 adjusted) per additional successful treatment. Figure 9 
shows the probability that NB-UVB only is cost-effective at different possible levels of willingness to 
pay for an additional treatment success; probability increases as willingness to pay increases. It can 
be seen that there is a lot of uncertainty surrounding the decision as to whether NB-UVB alone, 
compared to TCS alone, represents value for money as there is always at least 40% probability of 
making the wrong decision if choosing to fund NV-UVB alone below a threshold value of willingness 
to pay of £10,000 per additional treatment success. 
 
 
Figure 8 Cost effectiveness Acceptability curve for NB-UVB only versus TCS only 
 
Cost effectiveness analysis of combination treatment compared to TCS only 
The unadjusted risk difference for combination treatment compared to TCS was 9.16% (adjusted 
10.94%). This equates to a number needed to treat (NNT) of 10 (9 adjusted) i.e. 10 (9) participants 
would need to be treated for one of them to gain a treatment success. 
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The incremental difference in cost was £213.40 (95% CI 190.02 to 236.78) unadjusted or £211.46 
(95% CI 188.10 to 234.81) adjusted for age and location of target patch. The unadjusted incremental 
cost was £2,328.56 (£1,932.35 adjusted) per additional successful treatment. 
Figure 2 shows the probability that combination treatment is cost-effective at different possible 
levels of willingness to pay for an additional treatment success. It shows that combination treatment 
is likely to be cost effective if the decision maker is willing to pay more than around £3,000 per 
additional treatment success. There is, however, currently no evidence to indicate how much a 
decision maker would be willing to pay for an additional treatment success as defined in this study. 
Should the decision makers willingness to pay per additional treatment success be low (i.e. less than 
£2,500) then it can be seen that uncertainty surrounding the decision to fund combination 
treatment is high. 
 
 
 
Figure 9 Cost Effectiveness Acceptability Curve for combination treatment versus TCS only 
 
Sensitivity Analysis 
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A number of sensitivity analyses were undertaken to explore key uncertainties around important 
parameters in the economic evaluation. The results of this are summarised in Table 24 with greater 
detail below for each analysis. 
Table 24 Summary of sensitivity analyses (adjusted results) 
 NB-UVB only versus TCS only Combination treatment versus TCS only 
Analysis Incremental 
costs 
Incremental 
effect (Risk 
difference)  
Incremental 
cost per 
treatment 
success 
Incremental 
costs  
Incremental 
effect (Risk 
difference)  
Incremental 
cost per 
treatment 
success 
Primary 
imputed  
£173.44  5.20% £3,335.74 £211.46 10.94% £1,932.35 
Complete 
case 
£172.61 4.88% £3,535.40 £212.59 9.96% £2,134.11 
Cost of 
device zero 
£121.79 5.20% £2,342.35 £158.54 10.94% £1,448.82 
Cost of 
device 
doubled 
£225.02 5.20% £4,327.78 £264.33 10.94% £2,415.55 
Wider cost 
perspective 
£163.90 5.20% £3,152.30 £200.95 10.94% £1,836.31 
Adherent 
patients 
only 
£193.34 13.87% £1,393.98 £230.83 20.06% £1,150.65 
 
Complete case analysis 
The base case assumed data to be missing at random and undertook imputation to allow for this66. 
Table 24 presents the results for a complete case analysis which only includes participants with 
complete resource use and outcome data in order to see if this changes the conclusions reached in 
the base case analysis. Three hundred and forty eight participants had complete data on both cost 
and outcome (success of treatment) – 113 in TCS only, 115 in NB-UVB only and 120 in combination 
treatment. 
The cost of the NB-UVB device 
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The cost effectiveness of the interventions is likely to be driven significantly by the cost of the NB-
UVB device. There is uncertainty about how the device would be prescribed and used within the 
NHS. If adopted as an effective treatment, patients may have to pay for the device themselves (with 
training, support and quality assurance paid for by the NHS), or the device might be adopted and 
provided free at point of use by the NHS for NHS patients. The base case analysis annuitised the 
device cost, assuming that the device would be used for a period of 5 years, but there is uncertainty 
surrounding this period of use and in practice it may be that the devices are not returned by patients 
at the end of treatment.  
We re-estimated the incremental cost per successful treatment assuming that patients paid for the 
device, quality assurance, glasses and goggles as one extreme and at the other we doubled the price 
of the device, quality assurance, goggles and glasses to provide an upper estimate. 
As expected (see Table 23), reducing the cost of devices to zero reduced the incremental cost per 
treatment success, thereby lowering the amount an NHS decision maker would have to be willing to 
pay for this treatment to be implemented in the NHS. Conversely, doubling the cost of the device 
increased the incremental cost per treatment success and meant that the NHS would have to value a 
treatment success more highly than the base case to be willing to adopt the treatments.  
Changes in the price of the device had less impact on the combination treatment comparison to TCS 
only, due to the greater treatment success observed in the combination group. As noted in the 
primary base case analysis, it is not clear how much a decision maker would be willing to pay to 
achieve one more additional treatment success as measured on the VNS. Therefore, these figures 
just provide a range around the likely cost per treatment success. 
Wider cost perspective 
As part of the trial, participants were asked about the out of pocket costs (if any) incurred by 
themselves or their families as a result of their vitiligo. These costs were added to the base case 
results (NHS perspective only) to see how they would impact on the incremental cost per treatment 
success. Forty-seven (11.1%) of participants reported incurring out of pocket costs during the 9-
month treatment period: 17 in TCS only, 17 in NB-UVB only and 13 in the combination group. The 
mean number of items and mean cost per participant by group can be seen in Table 20 to Table 22. 
The type of items included (from most to least purchased), camouflage / makeup, sun cream and 
sun care, clothes/scarves, face creams / moisturisers / emollients, fake tan / tanning products, travel 
for appointments, private appointment including multivitamins, and herbal remedies.  
 
 
99 
 
Taking into account the participant out of pocket costs in relation to vitiligo reduced the incremental 
cost per treatment success, as these costs were higher in the standard care arm (TCS only) (see Table 
23 for results). 
Impact of Adherence 
Since significant clinical effectiveness was found and a little under half of the participants used the 
treatment for over 75% of the expected duration, the primary economic analysis was repeated 
including only the adherent sample, where adherence was estimated as total sessions used divided 
by total expected sessions. 227 participants adhered to treatments >75% of the time; this sample 
was used as the adherent sample, minus 3 participants (1 of whom had the primary outcome missing 
and 2 whom had cost data missing). 
The intervention was more cost-effective for patients who adhered to treatment, as they were the 
ones most likely to achieve a successful outcome (see table 23 for estimates). 
Longer term analysis (12 to 21 months) 
In the health economic analysis plan we intended to explore the longer-term cost effectiveness of 
the comparators of interest beyond the 9 months treatment period (if either were found effective), 
to see if value for money was sustained. In the trial, only 30.4% of participants had complete data on 
NHS resource use in months 10-21, 44.5% of participants aged 11 or over completed the EQ-5D -5L 
at 21 months, and 43.3% of participants aged under 18 at beginning of the study had completed the 
CHU-9D at 21 months. Given the sparsity of data we have not performed an economic evaluation 
over the longer-term follow up as it would be too speculative. However, we report mean estimates 
of the pa ti ipa t s (all ages, n=517) wider NHS use over months 10 to 21 (the follow-up period) and 
utility at 21 months. Only 157 participants had complete resource use data for the whole 12 month 
follow-up period (which may have been for zero use), 64 had nine months of data available, 56 had 
six months of data available, 59 had three months worth of data available and 181 had no resource 
use data recorded for the follow-up period.   The mean quarterly NHS cost per participant over the 
12 month follow-up period was £21.26 (sd 46.32) for combination treatment (n=114), £25.89 (sd 
52.82) for NB-UVB alone (n=117), and £21.74 (sd 42.33) for TCS alone (n=105). The mean 
prescription cost per participant over the 12 month follow-up period was £14.82 (sd 45.22) for 
combination treatment (n=114), £13.78 (sd 45.63) for NB-UVB alone (n=117), and £13.20 (sd 51.44) 
for TCS alone (n=107). The mean out of pocket cost per participant over the 12 month follow-up 
period was £42.85 (sd 398.74) for combination treatment (n=114), £3.62 (sd 16.93) for NB-UVB 
alone (n=117), and £8.48 (sd 39.41) for TCS alone (n=107).  
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Mean utility (EQ-5D-5L) per participant aged 11 or over at 21 months was 0.856 (sd 0.230) for 
combination treatment (n=73), 0.865 (sd 0.231) for NB-UVB alone (n=61), and 0.833 (sd 0.274)for 
TCS alone (n=69). Mean utility (CHU-9D) per participant (aged under 18 years at the outset of the 
study) at 21 months was 0.938 (sd 0.054) for combination treatment (n=20), 0.941 (sd 0.056) for NB-
UVB alone (n=16), and 0.937 (sd 0.118)for TCS alone (n=16)). 
 
4.14 Secondary Economic Analysis 
Cost utility analysis for those aged 11 and over 
Of the 517 participants in the trial, 456 (88%) participants were aged 11 or over, 155 were 
randomised to TCS only, 148 were randomised to NB-UVB only and 153 were randomised to 
combination treatment. 
The cost utility analysis was planned as a secondary analysis due to the fact that, to our knowledge, 
no prior study had utilised the EQ-5D-5L, or CHU-9D for children, in patients with vitiligo. There were 
some concerns that such generic quality of life instruments might not be appropriate for this 
condition, as much of the effect may be visual or psychological rather than on physical quality of life. 
Such concerns seem to have be borne out in the study, Table 25 shows the domains on the EQ-5D 
selected by participants at baseline. 55% of participants reported having no problems on any of the 
five domains of the EQ-5D at baseline, suggesting that over half of the sample started the study in 
perfect health as defined by this instrument. This is a large ceiling effect that was also observed at 
subsequent follow-up (Table 25). No floor effect was observed at any time point.  
Table 25 Distribution of responses over the levels of the different domains of the EQ-5D-5L 
Levels Mobility 
No. (%) 
Self-
care 
No. 
(%) 
Usual 
activities 
No. (%) 
Pain/ 
Discomfort 
No. (%) 
Anxiety/ 
Depression No. 
(%) 
No. in 
health 
state 
11111 
(55555) 
Baseline       
1 (no 
problems) 416 (91.8) 
436 
(96.3) 
394 
(87.0) 376 (83.0) 292 (64.5) 
55.0% 
2 
22 (4.9) 
8 
(1.8) 41 (9.1) 44 (9.7) 108 (23.8) 
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3 
9 (2.0) 
4 
(0.9) 7 (1.6) 22 (4.9) 40 (8.8) 
 
4 
4 (0.9) 
1 
(0.2) 6 (1.3) 7 (1.6) 5 (1.1) 
 
5 (unable 
to/ extreme) 0 (0) 
1 
(0.2) 2 (0.4) 1 (0.2) 6 (1.3) 
(0%) 
Blank 
2 (0.4) 
3 
(0.7) 3 (0.7) 
3 (0.7) 
2 (0.4) 
 
9 months       
1 
271 (90.0) 
290 
(96.4) 
271 
(90.3) 249 (82.7) 215 (71.4) 
59.8% 
2 
19 (6.3) 
6 
(2.0) 16 (5.3) 29 (9.6) 55 (18.3) 
 
3 
9 (3.0) 
3 
(0.7) 9 (3.0) 18 (6.0) 22(7.3) 
 
4 
1 (0.3) 
1 
(0.3) 3 (1.0) 4 (1.3) 5 (1.6) 
 
5 0 (0) 0 (0) 1 (0.3) 1 (0.3) 4 (1.3) (0%) 
blank 
1 (0.2) 
1 
(0.3) 1 (0.3) 0 (0) 0 (0) 
 
Final assessment (19 or 21 months) 
1 
131 (64.5) 
180 
(88.7) 
192 
(94.6) 173 (85.2) 153 (75.4) 
50.3% 
2 
50 (24.6) 
14 
(6.9) 2 (1.0) 21 (10.3) 36 (17.7) 
 
3 
19 (9.4) 
3 
(1.5) 0 (0.0) 3 (1.5) 9 (4.4) 
 
4 
1 (0.5) 
1 
(0.5) 1 (0.5) 1 (0.5) 2 (1.0) 
 
5 
0 (0.0) 
1 
(0.5) 1 (0.5) 1 (0.5) 0 (0.0) 
0% 
blank 2 (1.0) 4 7 4 3 (1.5)  
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Table 26 Unadjusted Utility and QALYs for participants aged 11 and over (available case data, 
primary Cost utility analysis) 
 NB-UVB only (n=148) TCS only (n=155) Mean difference 
(95% CI) 
 Mean Std dev (n) Mean Std dev (n)  
Va  Hout et al  utilit  alue set k o  as the oss alk  
Secondary outcomes 
EQ-5D-5L 
Baseline 
0.8920 0.1866 (140) 0.9172 0.1145 (151) -0.0252   
(-0.0607 to 0.0102) 
EQ-5D-5L 
9 months 
0.9287 0.1422 (89) 0.8843 0.1666 (97) 0.0444 
(-0.0006 to 0.0894) 
QALYs at 9 
months 
0.6871 0.0913 (89) 0.6721 0.0983 (97) 0.0150 
(-0.0125 to 0.0425) 
 Combination treatment 
(n=153) 
TCS only (n=155) Mean difference 
(95% CI) 
 Mean Std dev (n) Mean Std dev (n)  
Secondary outcomes 
EQ-5D-5L 
Baseline 
0.8906   0.1719 (147) 0.9172 0.1145 
(151) 
-0.0266 
(-0.0599 to 0.0066) 
EQ-5D-5L 
9 months 
0.9182  0.1325 (98) 0.8843 0.1666 
(97) 
0.0339 
(-0.0086 to 0.0764) 
QALYs at 9 
months 
0.6843 0.0993 (96) 0.6721 0.0983 
(97) 
0.0122 
(-0.0159 to 0.0402) 
 
Cost utility analysis for participants aged 11 years and over for NB-UVB only compared to TCS only 
The unadjusted mean cost per participant in the NB-UVB only treatment group (n = 131) was 
£774.64 (SD 83.71, 95% CI 760.17 to 789.11) compared to £599.99 (SD 96.18, 95% CI 583.43 to 
616.55) for the TCS only group (n = 132) giving an unadjusted mean incremental cost per participant 
of £174.65 (95% CI 152.75 to 196.55). The imputed, adjusted, and bootstrapped mean incremental 
cost per participant was £169.58 (95% CI 165.50 to 173.65) more for the NB-UVB only treatment 
group than the TCS only group. 
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The imputed, adjusted, and bootstrapped mean incremental QALYs gained were 0.0204 (95% CI 
0.0180 to 0.0229) in favour of the NB-UVB only compared to TCS only (See Table 26). The adjusted 
incremental cost per QALY was £8,293.88. 
Cost utility analysis for participants aged 11 years and over for combination treatment compared 
to TCS only 
The unadjusted mean cost per participant in the combination treatment group (n = 136) was 
£813.38 (SD 111.39, 95% CI 794.49 to 832.27) compared to £599.99 (SD 96.18, 95% CI 583.43 to 
616.55) for the TCS only group (n = 132) giving an unadjusted mean incremental cost per participant 
of £213.40 (95% CI 188.33 to 238.46). The imputed, adjusted, and bootstrapped mean incremental 
cost per participant was £203.93 (95% CI 199.39 to 208.47) more for the combination treatment 
group than the TCS only group. 
The imputed, adjusted, and bootstrapped mean incremental QALYs gained were 0.0145 (95% CI 
0.0123 to 0.0167) in favour of the combination treatment compared to TCS only (See Table 26). The 
adjusted incremental cost per QALY was £14,081. 
Alternative utility value sets were tested to see if they had any impact on the results but because the 
size of QALY gains were so small in this study (Appendix 6) the choice of value set did not affect the 
results presented above in the cost utility analysis. 
Cost utility analysis for under 18’s 
One hundred and nineteen participants were aged under 18 years of age, 40 received TCS only, 39 
NB-UVB only and 40 combination treatment. Complete cost and outcome data were only available 
for 91 (75.8%) of these participants. The results presented here are based on a complete case 
analysis only, as an imputed, adjusted analysis was not possible due to the small sample size. Table 
27 shows the utility, as measured on the CHU-9D at baseline, 9 months, and QALYs for the 9 month 
treatment period. The incremental QALYs were non-significantly different from zero. 
The ceiling effect on this instrument was better than the EQ-5D-5L but still high; 30% of participants 
had no problems according to any of the nine dimensions on the CHU-9D (Table 27). The domains of 
worry, tiredness and sleeping were those in which problems were reported most often.  
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Table 27 Distribution of responses over the levels of the different domains of the CHU-9D (number (%) of participants) 
Level Worry Sad Pain Tired Annoyed Schoolwork Sleep Routine  Activities 
Baseline          
1 (no problems) 91 (75.8) 109 (90.8) 104 (86.7) 67 (55.8) 104 (86.7) 97(80.8) 90 (75.0) 110 (91.7) 106 (88.3) 
2 20 (16.7) 7 (5.8) 13 (10.8) 30 (25.0) 11 (9.2) 20 (16.7) 20 (16.7) 6 (5.0) 6 (5.0) 
3 5 (4.2) 2 (1.7) 2 (1.7) 10 2 (1.7) 0 (0.0) 6 (5.0) 3 (2.5) 3 (2.5) 
4 1 (0.8) 0 (0.0) 0 (0.0) 6 (5.0) 2 (1.7) 0 (0.0) 2 (1.7) 0 (0.0) 1 (0.8) 
5 (very problematic) 2 (1.7) 1 (0.8) 0 (0.0) 5 (4.2) 0 (0.0) 1 (0.8) 1 (0.8) 0 (0.0) 1 (0.8) 
Blank 1 (0.8) 1 (0.8) 1 (0.8) 2 (1.7) 1 (0.8) 2 (1.7) 1 (0.8) 1 (0.8) 3 (2.5) 
Number in health state 111111111 
(555555555) 
        30.0% 
(0.0%) 
9 months          
1 (no problems) 83 (88.3) 88 (93.6) 84 (89.4) 42 (44.7) 86 (91.5) 81 (86.2) 66 (70.2) 82 (87.2) 83 (88.3) 
2 8 (8.5) 4 (4.3) 9 (9.6) 25 (26.6) 5 (5.3) 10 (10.6) 17 (18.1) 7 (7.4) 3 (3.2) 
3 0 (0.0) 1 (1.1) 0 (0.0) 19 2 (2.1) 0 (0.0) 8 (8.5) 2 (2.1) 3 (3.2) 
4 1 (1.1) 0 (0.0) 0 (0.0) 4 (4.3) 0 (0.0) 2 (2.1) 1 (1.1) 2 (2.1) 2 (2.1) 
5 (very problematic) 1 (1.1) 0 (0.0) 0 (0.0) 3 (3.2) 0 (0.0) 0 (0.0) 1 (1.1) 0 (0.0) 2 (2.1) 
Blank 1 (1.1) 1 (1.1) 1 (1.1) 1 (1.1) 1 (1.1) 1 (1.1) 1 (1.1) 1 (1.1) 1 (1.1) 
Number in health state 111111111 
(555555555) 
        29.8% 
(0.0%) 
21 months          
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1 (no problems) 48 (92.3) 47 (90.4) 47 (90.4) 26 (50.0) 32 (61.5) 44 (84.6) 41 (78.8) 49 (94.2) 46 (88.5) 
2 2 (3.8) 3 (5.8) 4 (7.7) 18 (34.6) 8 (15.4) 6 (11.5) 7 (13.5) 2 (3.8) 4 (7.7) 
3 1 (1.9) 1 (1.9) 0 4 (7.7) 1 (1.9) 2 (3.8) 4 (7.7) 1 (1.9) 1 (1.9) 
4 0 (0.0) 0 (0.0) 0 (0.0) 2 (3.8) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.9) 
5 (very problematic) 1 (1.9) 1 (1.9) 1 (1.9) 2 (3.8) 2 (3.8) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Blank 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 9 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Number in health state 111111111 
(555555555)    
     36.5% 
(0.0%) 
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Table 28 Unadjusted Utility and QALYS for under 18’s availa le ase data  
 NB-UVB only (n=39) TCS only (n=40) Mean difference 
(95% CI) 
 Mean Std dev (n) Mean Std dev (n)  
Secondary outcomes 
CHU-9D 
Baseline 
0.9450 0.0635 
(35) 
0.9506 0.0528 
(40) 
-0.0056  
(-0.0324 to 0.0212) 
CHU-9D 
9 months 
0.9538 0.0416 
(28) 
0.9513 0.0523 
(31) 
0.0025 
(-0.0223 to 0.0273) 
QALYs at 9 
months 
0.7154 0.0312 
(28) 
0.7135   0.0392 
(31)  
0.0019  
(-0.0167 to 0.0205) 
 Combination treatment 
(n=40) 
TCS only (n=40) Mean difference 
(95% CI) 
 Mean Std dev (n) Mean Std dev (n)  
Secondary outcomes 
CHU-9D 
Baseline 
0.9326 0.0605 
(39) 
0.9506 0.0528 
(40) 
-0.0180  
(-0.043 to 0.0074) 
CHU-9D 
9 months 
0.9318 0.0590 
(35) 
0.9513 0.0523 
(31) 
-0.0195  
(-0.0471 to 0.0080) 
QALYs at 9 
months 
0.6988 0.0443 
(35) 
0.7135   0.0392 
(31)  
-0.0147 
(-0.0353 to 0.0060) 
 
NB-UVB compared to TCS: cost utility analysis for participants aged less than 18 years old (Table 
27)  
For those participants with complete cost and utility data, the unadjusted mean cost per participant 
in the NB-UVB only treatment group (n = 28) was £769.01 (SD 79.58, 95% CI 738.16 to 799.87) 
compared to £597.51 (SD 49.31, 95% CI 579.43 to 615.60) for the TCS only group (n = 31). The 
unadjusted mean incremental cost per participant of £171.50 (95% CI 137.35 to 205.65The 
unadjusted incremental cost per QALY was ££92,381.98. This figure is significantly higher than 
accepted threshold values and thus would not be considered cost-effective.  
Combination treatment compared to TCS: cost utility analysis for participants aged less than 18 
years old  
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For those participants with complete cost and utility data, the unadjusted mean cost per participant 
in the combination treatment group (n = 35 was £818.4723.94 (SD 91.20102.92, 95% CI 787.159.12 
to 849.8058.77)  compared to ££597.51 (SD 49.31, 95% CI 579.43 to 615.60) for the TCS only group 
(n = 31). The unadjusted mean incremental cost per participant of £220.965.27 (95% CI 184.23 to 
257.69). Since mean cost was higher for the combination treatment group and QALYs less (albeit by 
a very small amount), it is possible to say that for this group of participants standard care (TCS only) 
dominates – that is, it is both cheaper and more effective than combination treatment. However, 
one should note the small sample sizes. 
4.15 Discussion 
This chapter has presented the results for the first full economic evaluation of treatments for vitiligo, 
and uses standard care of TCS as the comparator. The additional cost of the combination treatment 
was not offset by NHS cost savings but did result in significant treatment success over the 9 month 
treatment period which could be gained if decision makers were willing to pay more than the 
unadjusted incremental cost of £2,328.56 (£1,932.35 adjusted) per additional successful treatment 
as defi ed i  this stud   a lot less oti ea le  o  o lo ge  oti ea le  o  the Vitiligo 
Noticeability Scale). NB-UVB alone was less costly than combination treatment but also less effective 
such that the incremental cost per successful treatment was higher than for combination treatment, 
suggesting that the NHS would get better value for money from combination treatment than light 
therapy alone. 
 
  
This study also suggests that patients with vitiligo do not use NHS services for their condition very 
much. This may be because the range of treatments available is limited and the condition is often 
viewed by some as being cosmetic, making people with vitiligo feel that there is not much help 
available. 
We undertook the cost effectiveness analysis as the primary analysis because it enabled us to 
analyse all participants together, irrespective of age. We also had a prior belief that available generic 
utility instruments may not be able to fully capture the health-related quality of life aspects people 
living with vitiligo experience. This seems to have been borne out with a high ceiling effect on the 
EQ-5D-5L, where 55% of participants were in the health state 11111 (perfect health) at the 
beginning of the study. Although there was less of a ceiling effect on the CHU-9D, with 30% of 
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participants in the best possible health state, in nearly a third of children there was no capacity to 
measure any gain using these instruments. Those with less than perfect health reported problems in 
terms of anxiety/depression, pain and discomfort; and with usual activities. Undertaking the cost 
utility analysis gave slightly contradictory results to the clinical and cost effectiveness results, in that 
NB-UVB only appeared more cost effective than combination treatment for those aged 11 and over, 
hilst eithe  t eat e t a  appea ed ost effe ti e fo  the u de  s sa ple usi g the CHU-9D 
(although this probably reflects the small sample size for this age group). The cost utility results are 
not that useful, and likely reflect a lot of uncertainty around the QALYs gained as the gain between 
groups was effectively very close to zero in both comparisons. Therefore, more weight should be 
attached to the clinical effectiveness results and further work to explore the measurement 
properties of the EQ-5D and CHU-9D in this patient group is warranted, given the high ceiling effect 
observed in this study. A number of sensitivity analyses were undertaken, and these suggest that 
perspective, cost of the NB-UVB light device, and method of dealing with missing data do not change 
the conclusions reached. Repeating the analysis including only adherent participants does not 
change the overall conclusions either, although in this case the results do suggest that if it were 
possible to predict which individuals were likely to be adherent to treatment, the cost per treatment 
success for this group would be lower than the base case as they have a higher probability of 
success. 
New treatments such as Janus Kinase (JAK) inhibitors are currently being developed as a novel 
treatment for vitiligo, especially for those with more extensive skin involvement. Although these 
treatments show some initial signs of promise, they are likely to be very costly when they become 
available within healthcare systems. The relatively lower costs of the interventions assessed in this 
trial may therefore be advantageous when resources are limited, and the trial has yielded useful 
cost-effectiveness data which can be used for comparison with these novel treatments. 
4.16 Conclusion 
Combination treatment has a lower incremental cost per successful treatment than NB-UVB only but 
whether this is considered cost-effective will depend on the judgement of healthcare decision 
makers regarding how much they are willing to pay to achieve a successful treatment. The fact that 
vitiligo has few treatment options available, and the likely high cost of newer treatments being 
developed, may be important to consider in this regard.  
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Chapter 5: Process evaluation 
5.1 Introduction 
The clinical effectiveness (or otherwise) of home-based interventions for vitiligo is only one factor in 
determining whether such interventions will eventually be implemented across the NHS. This 
chapter considers the health economic impact of home-based provision; here we explore the 
process of intervention delivery and the experience of managing treatment at home. Understanding 
how treatments are experienced, and unpicking the opinions of those involved in providing them (in 
the trial and potentially in future clinical services), will help us to navigate and interpret the HI-Light 
clinical and economic findings. It will also help us to generate better informed recommendations for 
future clinical practice; recommendations which are supported by the subjective experience and 
preferences of those affected by vitiligo. 
This focus has pertinence for home-based light treatment as neither dermatology nor primary care 
services currently routinely prescribe hand-held (home-based) NB-UVB for any dermatological 
condition. New services would need to be commissioned and designed. Should such provision be 
initiated it would necessarily involve the provision of relatively expensive equipment for long-term 
domestic use. Although TCSs are already being prescribed for vitiligo, potent TCSs are prescribed 
mainly in secondary care, whereas in primary care, lower-potency TCSs tend to be used, and for 
shorter time periods. Clinicians and patients recognise that both NB-UVB and potent TCSs may have 
potentially harmful side effects. Moreover, the complexity of treatments delivered in combination, 
side-effect monitoring and routine dose adjustment might all influence how well home-based 
treatment is accepted and integrated within personal and domestic circumstances. How this 
complexity is managed in the HI-Light trial might also inform the nature and scope of future clinical 
supervision and the support that is made available for future home-based treatment.  
At the outset, a programme theory (Box 1) was described, which outlines how home-based 
treatment for vitiligo might work in ideal circumstances. Although informed by prior development 
work and a pilot trial24, the programme theory, by its very nature, includes a number of speculative 
or idealistic assumptions. Home- ased t eat e t fo  itiligo is ia le he  clinicians and 
commissioners consider vitiligo to be a condition that warrants treatment  a d he  patie ts 
decide that the  ish to e ei e t eat e t fo  thei  itiligo . Clinicians and commissioners need to 
u de sta d thei  ole i  the path a  to aki g these t eat e ts a aila le to patie ts  and patients 
eed to e happ  to e ei e this t eat e t  (for both treatment options). That patients should not 
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e overburdened or confused by using both treatments concurrently  is i po ta t, a d patie ts 
should e able to access support from the medical professionals as required . P e ious esea h 
might suggest that achieving all these criteria can be challenging24.  
Aims and objectives 
The aim of this process evaluation is to generate insight from a range of stakeholders which will 
support the interpretation of HI-Light clinical and cost effectiveness data and inform the generation 
of recommendations for future clinical practice.  
Specific objectives include:  
• To contextualise clinical and cost effectiveness data with subjective reports of the 
experience of home-based therapy. 
• To consider whether stakeholders (patients, clinicians and commissioners) view home-based 
treatment for vitiligo to be acceptable and feasible. 
• To identify difficulties with the delivery and management of home-based treatment for 
vitiligo. 
• To consider implementation issues associated with the future delivery of home-based 
treatment for vitiligo.  
 
The process evaluation will use qualitative and quantitative data to test the programme theory and 
inform recommendations for the future delivery of home-based treatment for vitiligo.  
 
5.2 Methods 
Study Design 
This is a mixed methods process evaluation incorporating stakeholder interviews, interviews with 
NHS commissioners, an online survey of those who delivered home-based treatment in the trial and 
focus groups with those who delivered the trial. 
Ethical approval was obtained for the process evaluation on 10th April 2017 (Ethics reference 
14/EM/1173, SA04) from NRES Committee East Midlands – Derby. 
Participants 
(i) Trial participants were recruited from the main HI-Light Vitiligo trial.  
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Sampling was purposive, focussed initially on age, treatment allocation, recruiting site and treatment 
success (based on the primary outcome). Other factors, such as treatment adherence, early stopping 
of treatment, ethnicity/skin type, gender, extent of vitiligo, number of patches being treated, and 
whether the participant experienced problems with treatment, guided later stage recruitment of 
interviewees.  
Participants were approached at the 9-month time-point to minimise impact on treatment 
adherence.  
(ii) Commissioners were identified via online directories of Clinical Commissioning Groups (CCG) and 
via personal contact with members of the study team.  
(iii) Upon completion of the trial, site investigators (principle investigators and research nurses) at all 
recruiting centres were invited to take part in an online survey and/or a focus group to review the 
delivery of NB-UVB  
To avoid any impact on recruitment to the trial, all activities with recruiting site staff were conducted 
after recruitment had finished.  
 
HI-Light – Ho  Ho e- ased treat e t for itiligo ight fu tio  i  the NHS. 
[This document describes the ideal situation for a person with vitiligo who is seeking treatment within the NHS] 
Initial consultation in primary care 
A patient visits their GP because they are concerned about pale patches on their skin. The GP correctly diagnoses vitiligo. 
The GP is aware that vitiligo is treatable and is knowledgeable about all possible management options and recognises the 
importance of early treatment. After a discussion about the physical and psychological impact of their vitiligo and the 
possible management options, the patient decides they wish to receive treatment for their vitiligo. The GP is supportive 
and offers to prescribe a potent topical corticosteroid and manage within primary care if appropriate, and/or offers referral 
to a dermatologist. The GP also refers the patient for other relevant services such as camouflage and psychological support 
as required and provides advice on sun protection.  
Topical corticosteroids (TCS) 
The GP or dermatologist prescribes TCS on an intermittent regimen to avoid side-effects and the patient is happy to receive 
this treatment. A healthcare professional fully educates the patient on the use of TCS (including information on frequency 
of application, amount to be used, and sites to avoid e.g. the genital area) and prescribes the TCS for as long as is required 
to achieve the desired outcome. The patient feels empowered to use the TCS, is aware the treatments are slow acting but 
is prepared to stick to the recommended duration and frequency of application. The patient is willing and able to return for 
regular follow up visits for monitoring of side effects and efficacy. The patient experiences no side effects from the TCS. If 
after 3 months of TCS there is no beneficial effect, the treatment is stopped. If there is a beneficial effect, the TCS is 
continued for up to a year, with regular follow up. The TCS is stopped once the vitiligo is completely cleared.  
Hand-held narrow-band (NB) UVB light therapy 
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The dermatologist prescribes hand-held NB-UVB. The patient is happy to receive this treatment and is able to commit 
sufficient time to use the device. A phototherapy service is available and home phototherapy is supported. A medical 
professional with a full understanding of how to use hand-held NB-UVB for vitiligo fully educates the patient on the use of 
hand-held NB-UVB (including treatment regimen). The patient feels empowered to use the hand-held NB-UVB device. The 
patient is then given a hand-held NB-UVB device which has been checked for output and safety to take home. The patient 
is aware the treatments are slow acting but is prepared to stick to the recommended duration and frequency of application 
despite it taking a significant amount of time each day and is able to treat all patches of vitiligo without experiencing any 
problems with the regimen or the device. The patient is willing and able to access support from the medical professionals 
as required. The patient is willing and able to return for regular follow up visits for monitoring of side effects and efficacy. If 
after 3 months of NB-UVB there is no beneficial effect, the treatment will be stopped. If there is a beneficial effect, the NB-
UVB is continued for up to a year, with regular follow up. The NB-UVB is stopped once the vitiligo is completely cleared.   
Combination treatment of topical corticosteroids (TCS) and hand-held narrow-band (NB) UVB light 
therapy 
Combination treatment of TCS and hand-held NB-UVB is considered to be the most appropriate treatment option for this 
patient so a dermatologist prescribes these as above. The patient is not overburdened or confused by using both 
treatments concurrently.  
Service provision / clinician perspective 
Clinicians are able to diagnose vitiligo and recognise the importance of early treatment. Clinicians and commissioners 
consider vitiligo to be a condition that warrants treatment. They are willing to offer hand-held NB-UVB and/or TCS therapy 
for vitiligo to all suitable patients. Both clinicians and commissioners understand their role in the pathway to making these 
treatments available to patients. Clinicians have the knowledge, skills and resources required to prescribe these 
treatments, train patients in using them, and to ensure the hand-held NB-UVB devices are correctly maintained. Support 
services are available including medical physics, phototherapy and medical photography.  
Box 1 Underpinning Programme Theory 
Data collection 
(i) Semi-structured interviews were carried out with those trial participants who consented to this 
element of the study.  
Interviews lasted between 30 and 60 minutes in duration; they were conducted by telephone or 
video call. All data was recorded using digital audio recording equipment and interviews were 
transcribed in full by a professional transcription service.  
Interviews focused upon experiences of participating in the trial, perceptions of treatment, and 
views on whether treatments should be available to more people with vitiligo. Topic guides were 
used to structure the interviews, and participants were encouraged to focus upon (or introduce) any 
topic they felt important.  
Participants were offered a £20 gift voucher to compensate for their time if they participated in an 
interview. 
Participants provided consent were asked to sign an online consent form before the interview, 
however, if it was not possible to obtain consent in this way, verbal consent was obtained prior to 
the interview commencing in line with the ethical approval. 
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(ii) Interviews with commissioners were similarly guided by a semi-structured topic guide. Interviews 
with commissioners were shorter, approximately 20-30 minutes.  
They were also delivered via telephone or video call and recorded using digital recording equipment. 
Data was transcribed in full.  
(iii) An online survey (see Appendix 7) was delivered to all recruiting centre staff via the Survey 
Monkey online survey software. Questions considered the challenge of delivering NB-UVB and 
sought insight and recommendations about the nature and form of any future implementation of 
NB-UVB in the treatment of vitiligo.  
The survey was live between 25th March and 24th April 2019. 
Following the online survey, site investigators were invited to a one-da  esults  eeti g he e 
progress in the HI-Light trial was presented (29th May 2019). At this meeting participants took part in 
short focus group discussions (60 minutes) as well as whole group discussion of the trial findings. 
Discussions were guided by semi-structured topic guide (Appendix 15) with each focus group 
facilitated by experienced facilitator. 
All discussion at this meeting was audio recorded and transcribed in full  
Data analysis 
(i) Data was anonymised and handled using the NVivo software package (QSR International, 
Warrington, UK) for qualitative data analysis (version 12).  
Transcripts were coded following the conventions of framework analysis69, 70 using a framework 
initially derived from the underpinning programme theory and set out in 3 broad matrices: 
experience of treatment, need for treatment, and future implementation. The coding framework 
was developed and amended as data suggested new insight and topics. 
Coding and thematic development were checked by multiple members of the team to ensure valid 
and relevant interpretation.  
(ii) Data was anonymised and handled using the NVivo software package for qualitative data analysis 
(version 12). 
Data was charted to the analytic framework described above, although into separate matrices so as 
to distinguish commissioner data. Coding and thematic development were checked by multiple 
members of the team to ensure valid and relevant interpretation.  
(iii) Descriptive statistics were generated for the online survey responses. 
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Free text responses (in the online survey) and focus group discussions were anonymised and 
handled using the NVivo software package for qualitative data analysis (version 12).  
Again data was charted to matrices described above; site investigator data was charted to dedicated 
matrices to ensure that this data could be considered independently. Coding and thematic 
development were checked by multiple members of the team to ensure valid and relevant 
interpretation.  
Themes across matrices for (i), (ii) and (iii) were compared, contrasted and synthesised in order to 
address study objectives.  
5.3 Results 
Data overview 
(i) Twenty-five interviews with trial participants (or parents) were conducted between 13th July 2017 
and 20th July 2018 (See Table 29). 
Twelve out of the 16 recruiting sites were represented in the sample.  
Table 29 trial participant interview characteristics 
 Group Number in sample 
Age group of participants  5-11 years 10 
12-17 years 2 (+1) 
18+ years 13 
Treatment group A 10 
B 7 
C 8 
Treatment success (according to 
primary outcome)? 
Yes 9 
No 12 
No primary outcome data 4 
Adherence to treatment Completed treatment 19 
Stopped treatment early 3 
Did not attend 9-month visit  3 
Ethnicity / skin type I 0 
Ii 4 
Iii 10 
Iv 6 
V 5 
Gender M 12 
F 13 
Number of patches treated 1 2 
2 to 3 10 
4 to 5 6 
6+ 7 
Number unscheduled visits 0 16 
1 3 
2 3 
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3 3 
Reported issues with using light 
device 
Problems  10 
No problems 15 
 
(ii) Nine commissioner interviews, involving 10 individuals, were conducted between 5th June 2017 
and 10th October 2017.  
Participants included strategic and operational roles in commissioning process, and represented a 
geographic spread across England. Most were medically trained, and included GPs with a special 
interest in dermatology.  
(iii) Twenty-four recruiting site staff completed the online survey – seven doctors, 16 nurses and one 
other.  
Ten of these had prior experience of phototherapy services, for others Hi-Light had been their 
introduction to this treatment. To support anonymity we did not collect data about which site they 
represented. 
Thirteen site staff participated in the focus groups representing ten recruiting sites. Eleven nurses 
were split into two groups; two doctors formed the final focus group.  
Thematic analysis 
Thematic analysis is organised around three questions:  
1. Can home-based treatment for vitiligo be adequately managed by HI-Light trial participants, 
and supported by those clinical teams involved in the trial? 
2. Do stakeholders feel that home-based treatment should be made available as part of routine 
NHS provision? 
3. Do stakeholders feel that home-based treatment for vitiligo could be integrated within 
current NHS organisation and pathways? 
 
Is Home-based NB-UVB treatment and TCS for vitiligo manageable for participants? 
All bar two of the (healthcare professional) survey respondents agreed that home-based treatments 
a e eas  fo  pa ti ipa ts; dis ussio  g oup data ith site i estigato s  reinforced this, with 
healthcare professionals reporting that the phototherapy device is (superficially) simple to operate 
and most trial participants seemed to understand the instructions offered about light therapy and 
corticosteroid ointment. Trial participants offered a similar assessment indicating that they generally 
understood how to use the individual treatments, training and support offered by the research 
nurses and demonstration video had helped in this. 
Some practical difficulties with individual treatments were described (by both site investigators and 
trial participants) but nothing of a magnitude to prevent participants effectively managing their 
treatments. For light therapy: timers which failed, guard teeth which broke-off, difficulties reaching 
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parts of the body, and difficulties using (a flat device) on curved parts of the body. For TCS ointment: 
an unpleasant smell, a greasy feeling, and poorly absorbed. The time commitment required for light 
therapy was a common cause for comment: 
it felt like a  a ful a ou t of ti e, I a  p ett  us  a d to e e tuall  e spe di g i  e ess 
of th ee ua te s of a  hou  pe  t o da s just felt like a  i o di ate a ou t of ti e.  Adult 
participant 3 
Treating multiple patches could leave participants feeling overburdened: 
I sta ted ith o e tha  that e ause I as uite positi e, I as doi g diffe e t pa ts of  
od  like si  o  se e  o  so ethi g … The  I just did th ee, the th ee pat hes the  e e 
i te ested i  so I as just t eati g the , o o e.  Adult participant 4 
Time seemed to be more of an issue for parents treating a young child (i.e. keeping them still!), or if 
there were other children in the household that required attention. Participants described linking 
t eat e t to treat time  fo  hild e  su h as at hi g tele isio ; othe s des i ed uildi g 
routines that facilitated their time commitment:  
Yes it as al a s a ou d  o lo k afte   tea a d afte  I d ashed up a d hate e  ou 
k o , the  I did t ha e ti e to just sit a d do it the .  Adult participant 12 
Yeah, so I used to so t of do ea h eek i  ad a e so that I k e  hat I d got to do the e t 
eek a d ho  lo g ea h t eat e t as goi g to e, a d I d put  otes e t to it so I knew 
I d do e it, so o, I as uite o fo ta le ith that.  Parent of child participant 3 
Although time consuming, home-based phototherapy was considered less disruptive than regular 
hospital visits for phototherapy, and the potential for treatments at home was important to the 
majority of trial participants.  
Despite a generally positive assessment of each treatment, healthcare professionals and some 
participants flagged the complexity of treatments in combination. Site investigators reported that 
trial participants who they thought had a good understanding of treatments made errors with TCS 
and phototherapy dose, and suggested that some individuals had disregarded instructions and used 
the ointment/device excessively on multiple body-sites. One trial participant admitted as much: 
I just a ped it up p ett  u h st aight a a  a k to hat it as, ut agai  o ed ess 
hatsoe e  hi h o l  eall  se ed to o fi  it s a du .  Adult participant 11 
Some trial participants said that they found the combination treatment protocol complicated, 
particularly early on, and expressed caution when initially using the treatments:  
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Yeah I fou d it o fusi g fo  the fi st fe  eeks, it as like o e eek o  o e eek off [for 
TCS], a d e e  othe  da  fo  the light a d stuff  Parent of child participant 5 
Some trial participants acknowledged that they had made mistakes with treatment:  
I as o pletel  k a ke ed a d as [?] at the e d of the da , had do e the light t eat e t. 
So, I sat and did my chest which was one the areas being treated and part of, one of my, part 
of my left hand which is the other bit of the treatment and then started to do the second bit 
o  the left ha d a d fell asleep so I e ded up u i g self   Adult participant 3 
Stepping-up or down NB-UVB dose (as part of the treatment protocol or in response to erythema) 
was recognised to confuse and cause difficulties, with site investigators concerned that some 
participants never appeared to fully understand the process of incremental dose change. Trial 
participants indicated that their treatment diary was essential in guiding them: 
Yes, ithout that it ould e o he e, ithout the fo  that ou fill i  ith o es I ea  
and writing down the time you would be absolutely nowhere, there's no chance in a million 
that ou ould a tuall  keep to a thi g like the p oto ol  Adult participant 3 
A further area of complexity identified by trial participants was in assessing whether treatment was 
making any difference and the importance of the photographs in determining any change: 
ell I thought [things had improved] but when we got the photographs, you know we got 
the photog aphs o  the o pute ; it did t see  to e a  diffe e t to e ho est.  Adult 
participant 12 
o l  he  I e t a k a d sa  the diffe e e i  the photog aphs, so as I as t eati g it I 
couldn't really see any difference, when you saw the photographs versus my face in the 
i o  a tuall , the e as a diffe e e.  Adult participant 5 
Seasonal variation in skin tone might add to this complexity: 
e ause usuall  I do fi d I do get uite ta ed a d the efo e, et ee  the su e  a d 
i te  the e is a o t ast, so ithout looki g at the photog aphs I ould t tell hethe  
actually it was maki g a  diffe e e o  ot.  Adult participant 5 
Trial participants described nurses as having an important role in supporting them in assessing 
whether treatment was leading to improvement; nurses were also considered important in 
supporting the management of erythema (especially when it occurred for the first time). Overall, 
participants viewed nurse support positively:  
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they responded quickly, were helpful and friendly, they offered reassurance, and generally 
insured that participants were doing the right thing.  
In contrast, participants were sceptical of the potential for GP led support:  
I  all ho est  if I a g  GP up a d I had a  issue, the e useless a a , ou ha e to ait 
god k o s ho  lo g to get a  appoi t e t a d hate e  else  Parent of child participant 6 
Despite the acknowledged complexity of the combination treatment trial participants reported that 
they felt able to adhere to treatment regimen without any fundamental difficulty. Where they had 
not adhered to protocol this would more often be with light therapy and participants would point to 
legitimate (practical) reasons for this, such as other health conditions or holidays: 
like I sa  it as lite all  just he  e e t a a  o  holida , I just, I p o a l  ould 't ha e 
done it if I did take it to e ho est he  I  o  holida .  Adult participant 9 
Others had not adhered to light treatment protocol when they recognised no benefit from 
treatment, many associated this with receiving a dummy device.  
I thi k I o l  eall  fou d it onerous because I was just convinced it was a dummy, and I just 
felt as if I was, about 20 minutes I was really just wasting basically because I thought this 
as ot goi g to e a  good at all  Adult participant 11 
as soo  as I ealised that it as t e en tanning my skin I just, it was really hard to continue 
e ause it as eall  ti e o su i g  Adolescent participant 2 
These comments suggest the importance of expectations in shaping how treatments are managed – 
some individuals ceased treatment because expected improvement had not occurred. That noted it 
should be made explicit that most trial participants demonstrated generally realistic expectations, 
often borne out of previous treatment experience: 
I ea  it s ot like su u  o  a su ta  is it, where the skin sort of changes overnight 
p a ti all , if ou e got so ethi g happe i g i  the ell st u tu e a e that takes a u h 
lo ge  ti e e ause ou e aiti g fo  the ells to ege e ate  Adult participant 10 
 o ths I ould ha e e pe ted to ha e see  so ethi g.  Adult participant 2 
“o, it's just I did t ha e g eat e pe tatio s, possi l  e ause of p e ious t eat e ts a d 
stuff  Adult participant 13 
Expectations were, however, often tempered by an intuitive, emotional responses to the offer of a 
new treatment:  
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I as hopi g fo  the  to sh i k o  i g so e of the pig e tatio , like a a , get he  a k 
to he  o al olou .  Parent of child participant 5 
A tuall , I as e  pessi isti  a out the hole thi g ut I as, I did t eall  thi k that I 
as goi g to get a  e efit  Adult participant 13 
Should Home-based treatment be made more widely available? 
Although potentially complex (and confusing for some) there was a general sense that this type of 
combination treatment should be made available to more vitiligo patients; 18/24 HCP survey 
respondents agreed or strongly agreed with this. Focus groups with site investigators supported this 
by highlighting a clinical population that have few treatment options, and for whom the impact of 
vitiligo can be very distressing. 
We ha e al a s said that it is the est of a ad u h of t eat e ts, a d it p o a l  still is. 
The e is o fa tasti  t eat e t out the e fo  itiligo, the e does t see  to e, a d the t ial 
does t sho  that it s fa tasti . It s sho  that fo  patie ts its o th hile doi g e ause the 
quality of life is impaired for a lot of patients. They a e pi i g hopes o  it  Site Investigator 
9 – Research Nurse 
This is reflected in those reasons offered by trial participants for taking part in HI-Light. Some hoped 
that participation would bring them access to new treatments for themselves or their children, some 
subsequently hoped for complete remission, whilst others hoped that their disease would stop 
spreading. Fo  a i o it  of pa ti ipa ts the e as a se se of othi g to lose :  
had hoped it ould totall  e o e  the i e o ths o  ea lie  ou k ow, the sort of 
le ishes ould disappea  Adult participant 5 
I de ided to take pa t e ause h  ot, it ould e o ki g o   ski  o  ot ut I just 
de ided to take pa t to see hat happe ed  Adult participant 4 
I do t k o , p o a l  half a d half of me was hoping that yes, something would work and 
it ould help he , ut if it did t the  e as t eall  goi g to lose a thi g  Parent of child 
participant 7 
Others hoped that their involvement in HI-Light would benefit the broader vitiligo population by 
contributing to the development of a new treatment pathway. Given these assessments it is 
understandable that site investigators recognised the importance of new treatments for their 
patient population; even suggesting that (irrespective of clinical impact) new treatments offer 
vitiligo patients hope and the potential to engage with their condition.  
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As this desire for new treatments might suggest, commissioners confirmed that treatment pathways 
for vitiligo are often lacking, suggesting that dermatology, let alone vitiligo, is unlikely to be a priority 
in commissioning discussions. They also indicated that some commissioners perceive vitiligo to be a 
os eti  o ditio , hi h adds a fu the  a ie  to it ei g o side ed a p io it  a ea. Va iatio  i  
cosmetic impact (and associated concerns) was also manifest in comments made by trial 
participants, which suggests that willingness to pursue (complex) treatment might vary according to 
site or visibility of vitiligo: 
if I had, sa  if it as like o e i  a cosmetic important place I'm pretty sure I would be 
prepared to have a go at it long term, when saying long term, I mean over a period of years 
o  hate e  is e ui ed.  Adult participant 3 
I e e  felt that fo  a hap of  age, I ea  I  4, it s a it i ele a t e ause the e 
o se he  ou e got a it of a su ta  o iousl , ut it s ot like ei g pe haps a lad  ho 
os eti all  a  look a it odd  Adult participant 7 
These comments illustrate and support the assessment of site investigators that home-based 
therapy might not be appropriate for all vitiligo patients. In the online survey 12 site investigators 
indicated that home-based therapy would be appropriate for most people, 11 indicated that it would 
be appropriate for some, but none indicated that it would be appropriate for all people with vitiligo. 
Considerations for providing home-based treatment might be (i) clinical, (ii) practical, or related to 
(iii) personal circumstances: 
(i) Comments from consultant dermatologists (as part of the survey and site investigator discussions) 
speculated that combination treatment might be particularly beneficial for new patients as an early 
intervention.  
Trial findings point to variation in outcome according to body site of vitiligo patch (see chapter 3).  
Target patches were chosen by trial participants, and had to have been active in the preceding 12 
months, as reported by participants. Discussions with site investigators suggested that some 
participants may not have been able to judge this very well, with some investigators feeling potential 
participants may have exaggerated the activity of their vitiligo in order to obtain access to the 
treatments offered in the trial. 
(ii) The practical challenge of managing combination treatment (long-term use, dose fluctuation, 
potential side-effects, etc.) was recognised by both participants and site investigators. Participants 
suggested that not all people are sufficiently organised for these treatments; they thought that 
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individuals need to plan ahead, be committed to the treatments, and to be willing to incorporate 
them into their routine.  
If ou e a  o ga ised t pe of pe so  it e o es pa t of se o d atu e afte  a hile.  Adult 
participant 1 
In some cases, hospital based light therapy was considered more appropriate.  
Yes, to go to the a i et a d spe d fi e, te  i utes a d that is all e ause ou ill ha e 
t eated all ou  od  Adult participant 4 
The duration of home-based treatment was also a factor to be considered when considering 
individuals. 
I thi k doi g it fo  a  lo ge  [than nine months] probably would have been a bit 
challenging probably, because it became, it did start to become a bit more of a hassle to do it 
so egula l ,  Parent of child participant 2 
To a ds the e d, I ea  I eall  did fi d, it just felt like I as spe di g a lot of ti e  Adult 
participant 3 
Healthcare professionals felt that mental health issues, other health complaints, or significant caring 
espo si ilities e.g. ultiple hild e  ight all halle ge a  i di idual s a ilit  to ai tai  a 
complex treatment regimen over a long period of time. 
iii  Be o d p a ti al halle ges the e as o e  f o  health a e p ofessio als that a  i di idual s 
level of understanding about vitiligo and their expectations of treatment might also be important. 
Those with potential difficulties adhering to a long-term treatment programme may be unlikely to 
benefit home-based treatment, those with unrealistic expectations might find it difficult to adhere. 
Trial participants recognised that some individuals might exaggerate, or provide inaccurate 
information about patches, to gain access to a new treatment 
Establishing which individuals might benefit from home-based treatment was considered difficult by 
healthcare providers; fully sharing information about effectiveness, treatment burden and treatment 
duration may help support shared decision-making. Some site investigators even suggested that 
some kind of test, formal or informal, of whether or not a patient understands the treatment 
regimen might also be appropriate.  
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Could Home-based treatment be made more widely available outside the trial? 
A small number of site investigators indicated that they were already re-using devices from the trial 
and incorporating them into clinical practice for vitiligo. Indeed, some sites in the UK (e.g. Ninewells 
Hospital, Dundee) are already offering such devices for use at home, often to treat other skin 
conditions such as scalp psoriasis. 
Other site investigators pointed to the importance of situating new pathways within existing 
phototherapy provision for other skin conditions, with appropriate support from medical physics to 
monitor device output. That this would not be possible in all locations was recognised and some 
suggested that home-based treatment should be managed regionally by specialist centres.  
These perspe ti es i o  o issio e s  o e s that a  e  t eat e t ould eed to sit ithi  
(or at least not disrupt) existing service pathways. In contrast to site investigators, commissioners 
were, however, less aware of a need for new treatment pathways and perceived no explicit demand 
from patients, clinicians or healthcare providers. 
I'  ot getti g a  o plai ts fo  e a ple a out the se i es that e p o ide. Like GPs 
a e t o i g to e sa i g, e' e ot happ  ith this. As far as our GPs are concerned, 
the ' e getti g a good se i e e ause thei  patie ts a e t o plai i g to the . It s ot 
o i g up o  ou  o ito i g i  te s of pe fo a e  MC - Commissioner 
Should a new treatment pathway be considered, commissioners stressed that clinical and cost 
effectiveness would be key to any decision, they warned that significant changes to services would 
need to be supported by considerable evidence of clinical or cost improvement. 
I thi k the o l  issue ould e ti e … a ha ge i  se i e is so ethi g that can be time 
consuming. So the benefit has to be significant. So we're making an assessment how 
sig ifi a t the ha ge is.  JB -  Commissioner 
Investigators recognised that commissioners might be reluctant to commission new services and 
speculated upon different mechanisms for the provision of phototherapy devices.  
All investigators recognised that these devices can be easily purchased online and some reported 
that participants had indicated that they might buy one independently of NHS support. Similarly, 
several participants described considering purchasing a device, although for some the thought of 
goi g it alo e  dete ed the . 
I thi k the e a out £  a e t the , the e ot fa tasti all  e pe si e ut I did t the  
think I might go and buy one of those, la gel  e ause I as t su e ho  I ould use it ou 
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k o , it s e  se u e a d o fo ti g is t it to ha e that ki d of egi e a d do this, that a d 
the othe  e e  da , a d the  ou thi k ight oka  so I k o  he e I  up to  a d so o , so 
to suddenly be cut loose from that would be a little bit more you know, anxiety provoking, 
he  ou k o  that it s pote tiall  da ge ous  Adult participant 6 
Investigators recognised that the publication of (positive) trial findings might accelerate this type of 
independent use amongst a patient population desperate for treatment options. Most investigators 
were apprehensive about this – in the online survey only 2/24 felt NHS involvement was not 
important and 13 felt this essential or very important. Concerns for safety led some investigators to 
suggest that devices should be automatic (i.e. patients cannot adjust) or managed by a dermatology 
nurse. Some patients also suggested that devices could have safety features such as automatic cut-
outs to prevent overuse. Investigators also suggested that patient monitoring should be frequent 
and sooner than three months (as in the trial). Some participants recognised the value of an earlier 
monitoring visit, whereas others felt that this was not necessary: 
personally think it needs an interim visit, if only to compare the photograph, because I do 
thi k that ou fo get hat it as like a d ou do thi k oh it s ot aki g a  diffe e e , 
but then when you see the photograph and you see the shape changing  Parent of child 
participant 3 
The pote tial fo  so e fo  of i ed e o o  - where patients lease or purchase a phototherapy 
device within an NHS service – was considered by site investigators to be the most likely way that 
effective provision could be offered. However, this is not without its difficulties: both trial 
participants and site investigators were concerned about unequal access for those that cannot 
affo d to pu hase o  lease a de i e; so e health a e p ofessio als suggested that pu hasi g 
health a e  ight lead to u easo a le e pe tatio s a d/o  i o e t use if I  pa i g fo  it ill 
work!); and, the failure to return leased devices might make a service economically not viable (127 
light therapy devices were not returned during this trial).  
 
5.4 Discussion 
It is perhaps unsurprising that data generated from multiple sources (with contrasting clinical and 
patient perspectives) produces a complex, and at times contradictory, set of insights. 
• T eat e ts hi h a e eas , ut hi h a e o ple  i  combination. 
• Treatment which should be made available to more vitiligo patients, but where 
selection of patients might be essential. 
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• Treatment which might be purchased independently by patients, but which would 
need significant monitoring and support from the NHS. 
Through much of the process evaluation data (especially in participant and site investigator insights) 
there is a marked divergence between the recognised potential for home-based treatment and 
concerns for harm associated with its inappropriate or unsupervised use.  
Trial fidelity 
The process evaluation offers some insight to support the interpretation of the clinical and cost 
effectiveness data.  
Participant interviews demonstrated that adherence to the treatments was not hampered by a lack 
of knowledge about how to use the treatments, nor by a lack of support when using them. 
Intermittent non-adherence to treatment was acknowledged (and is perhaps unsurprising given the 
treatment burden associated with light therapy) but these were most often a pragmatic response to 
life circumstances and events. Trial adherence data (Table 7) shows that around two-thirds of 
participants used the treatments as specified in the treatment protocol whilst they were still using 
them. 
All of which suggests that trial procedures were adequate in supporting normal practice, and that 
clinical findings were neither inflated nor diminished by unrealistic or disastrous levels of treatment 
adherence. 
Where trial procedures were, however, less successful was in blinding participants to treatment 
allocation. Trial data demonstrates that a relatively high percentage of participants stopped 
treatment early, with only around half using treatments for at least three-quarters of the expected 
duration (Table 7). Whilst some participants stopped treatment because they had achieved 
complete remission, more commonly participants indicated that a lack of effect led them to cease 
treatment with some suggesting that they knew their light device to be a dummy. A lack of any 
redness in the skin or other indications such as warmth meant that around half correctly guessed 
they had the dummy device (89% of those using active light guessed correctly).  
With regard to trial outcomes, participants were largely able to judge the primary outcome (VNS). 
The use of photographs was crucial in this, due to the duration between visits, and/or because of 
difficulties in establishing whether minor changes had taken place. It is perhaps worth noting that 
participants indicated that seasonal variation in the noticeability of their vitiligo, more noticeable in 
summer, may have impacted upon their assessments. The consistency of other trial outcomes, 
however, suggests that this was not a major issue. 
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Population in need 
Site investigators recognised a clinical population with few treatment options, commissioners 
acknowledged that vitiligo is not a priority area, and trial participants expressed a desire to try new 
treatments which might work where normal clinical practice had failed. Health economic assessment 
suggests that many individuals with vitiligo manage with little or no NHS input. The culmination of 
these insights demonstrate that there is an unmet need for effective treatments for vitiligo.  
Participants were willing to go to great lengths to accommodate the time-consuming and complex 
treatment regimen; many were willing to continue treatment in the absence of any effect. 
Expectations were realistic - participants hoped for partial improvement or halting the spread of 
vitiligo (rather than complete re-pigmentation), few expected immediate results. These 
characteristics might suggest that the levels of treatment success observed in the trial, and ability of 
the interventions to stop the spread of vitiligo, offers sufficient potential for individuals with vitiligo 
to be willing to try (and persist with) home-based treatment in the future.  
Assuming that vitiligo does, however, have at least some degree of psychological impact in many 
people with the condition, it seems important that future recipients of vitiligo treatments should be 
fully informed about the likely success rate of home-based treatment, to ensure realistic 
expectations of treatment. 
Easy to do but complex to use 
Site investigators and trial participants recognised that treatments were relatively straightforward to 
use, with appropriate instruction and support.  
However, economic assessment points to the cost effectiveness of combination treatment (more so 
than treatments in isolation); a complex treatment protocol coupled with a considerable time 
burden (both each day and over a period of months) creates potential for incorrect use which can 
result in either increased side-effects or reduced effectiveness. Site investigators were particularly 
concerned about the potential for participants to harm themselves. Treatment diary planners and 
site staff were considered essential by trial participants in helping them to navigate this complexity. 
It is notable that some participants had considered purchasing a light therapy device, but had 
decided against this because of a lack ongoing NHS support. Site investigators stressed the 
importance of ongoing support and monitoring of patients in any future clinical service.  
The clinical data indicate a need for some form of intermittent maintenance therapy, as 
effectiveness diminished once treatments had been stopped. Many trial participants were relieved 
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to stop light therapy after nine months, suggesting that maintenance therapy with TCS is more likely 
to be a preferred approach over maintenance light therapy.  
 
Treatments may not be suitable for all 
Treatment burden means that home-based therapy is less appropriate for those wishing to treat a 
high number of patches. Lifestyle and personal circumstances may make adhering to a complex 
treatment regimen over an extended period difficult for some. It is also pertinent to remember that 
not everyone with vitiligo wants or is seeking treatment.  
Site investigators stressed the difficulty of predicting which participants were most likely to benefit 
from home-based treatment. Fully discussing the advantages and disadvantages, treatment burden 
and timescale of home-based treatments are essential in helping people with vitiligo reach informed 
decisions about treatment.  
Integrating within the NHS 
Site investigators were positive about the trial results (any improvement is worthwhile was a 
common sentiment), and participants were keen to see effective treatments for vitiligo become 
available. However, it is unclear whether sufficient improvement is manifest here to convince 
commissioners of the value of home-based phototherapy for the management of vitiligo. Home 
phototherapy services that support treatment of a broad range of skin conditions, as seen in existing 
specialist phototherapy units offering home phototherapy (e.g. Ninewells Hospital in Dundee), are 
likely to be more attractive.  
Both site investigators and trial participants recognised that light therapy devices might be privately 
purchased. Some site investigators were concerned about this, and some trial participants indicated 
interest in privately purchasing, whilst at the same time being concerned about a lack of clinical 
support if they did so. It is pertinent to stress here that training, treatment diaries, technical support 
and staff support were all considered essential by site investigators (and many trial participants) to 
the success and safety of home-based treatment. Medical physics is required to ensure that devices 
are appropriately calibrated and to ensure that bulb output is consistent; phototherapy services are 
required to support a complex treatment regimen, monitor effects, and support/temper patient 
expectations.  
The culmination of these two strands points to the potential for some form of mixed economy 
provision where light therapy devices are leased or privately purchased (independently or via the 
NHS) with treatment defined, supported and monitored by NHS services. The number of devices 
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(127) not returned after the end of treatment period in this trial might make NHS leasing of devices a 
less appealing prospect to commissioners. 
Site investigators recognised that not all settings are well placed to provide medical physics support, 
and commissioners suggested that new pathways are more attractive if they sit within existing 
provision (rather than requiring infrastructure development). This might point to a hub and spoke 
model of regional delivery whereby specialist sites with existing medical physics expertise could 
provide access to home phototherapy devices across a number of NHS Trusts, but clinical provision 
including training and monitoring of side-effects, could be delivered locally.  
It is perhaps appropriate to conclude by recognising that the challenge of any future home-based 
treatment for vitiligo will be in navigating the needs of patients and their enthusiasm for new 
treatment alongside the concerns of healthcare professionals about the potential side-effects 
associated with light therapy and long-term TCS use.  
Study strengths and limitations 
This process evaluation synthesises data from a range of relevant stakeholders to provide insight 
into the delivery and experience of home-based treatment for vitiligo. It complements the clinical 
and health economic data summarised elsewhere in this report. The subjective experiences which 
are reported here provide an important context to support interpretation of the clinical findings and 
provide situated detail to inform future service development and delivery.  
The evaluation is comprehensive in its coverage, in that those exposed to home-based treatment, 
those that delivered it, and those that might commission it in the future were all consulted. Insight 
might have been enhanced further with the inclusion of more teenagers in the process evaluation, 
but other than this it is positive that the views of adults, young people and parents of children with 
vitiligo were all incorporated into data collection. It is also positive that amongst those trial 
participants who engaged with the evaluation some had positive experience of treatment, others 
less so.  
As with all research of this kind we acknowledge that participants were to some extent self-
selecting, and it may be that those with particularly positive or strong views about home-based 
treatment were more likely to consent to involvement in the process evaluation. Site investigators 
could potentially have a vested interest in the future commissioning of home-based treatment for 
vitiligo and so might be inclined to give more positive views.  
As with all qualitative data, there is some degree of interpretation in our analysis of the interview 
and discussion group data. Whilst we have tried to ensure some rigour in this process (multiple 
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coders / group discussion about interpretations) there is always potential for us to misunderstand or 
misinterpret what we were told.   
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Chapter 6: Patient and Public Involvement 
 
6.1 Background 
The involvement of key stakeholders, such as patients and their carers, representatives from patient 
support groups, and health care professionals, is important when identifying clinical research 
priorities and when developing and designing clinical trials. This helps to ensure that the resulting 
research evidence is useful and relevant to clinical care, is delivered efficiently and recruitment 
targets are achieved with minimum unwarranted burden on participants. 
Many of the current treatments for vitiligo have been assessed through clinical trials, but variation in 
the design of these studies and a lack of standardised outcome measures makes it difficult to 
compare the effectiveness of these treatments71. Systematic reviews have also shown that there is 
wide variation in the choice of outcome measures used in vitiligo trials33.  
In addition to the lack of standardised outcome measures and limited use of patient reported 
outcome measures (PROMs) in vitiligo trials, until now there has been very limited stakeholder 
involvement in identifying the most important areas for future vitiligo research, or in designing new 
vitiligo trials. 
We sought to address these issues when we started to develop the HI-Light Vitiligo Trial, and here 
we report how we did so. 
6.2 Aims 
To evaluate the impact of stakeholder involvement in the design, delivery and dissemination of the 
HI-LIGHT Vitiligo Trial. 
6.3 Methods 
This work is reported using the Guidance for Reporting Involvement of Patients and Public (GRIPP2) 
guidelines72. It outlines the breadth of stakeholder activities that have contributed to the delivery of 
a multicentre RCT from 2009 to present, and the impact of this involvement on the design, delivery 
and dissemination of the HI-LIGHT Vitiligo Trial. For the purpose of this report, we use the term 
stakeholde  to i lude people ith itiligo a d thei  a e s, ep ese tati es f o  o ga isatio s 
representing people with vitiligo (e.g. patient support groups), and health care professionals who 
treat people with vitiligo and healthcare commissioners. 
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Data were collected and logged throughout the trial using the eight core principles of the Public 
Involvement Impact Assessment Framework (PiAFF) identified by Telford et al 73, outlined in Table 
30. 
Table 30 Summary of core principles for PPI involvement in the HI-Light trial 
Core principles Inclusion in the HI-Light trial 
Principle 1: the roles of the stakeholder 
are agreed between the researchers and 
the stakeholders involved in the 
research 
The role of the stakeholder representatives was 
documented in the funding application, protocol and 
final report 
Principle 2: researchers budget 
appropriately for the costs of the 
stakeholder involvement in research 
Stakeholder costs were included in the trial budget. 
Costs associated with stakeholder work throughout 
the trial (e.g. travel expenses, time commitments) 
were reimbursed. 
Principle 3: researchers respect the 
differing skills, knowledge and 
experience of stakeholders 
Different stakeholders (people with vitiligo and their 
carers, representatives from organisations 
representing people with vitiligo (e.g. patient support 
groups), and health care professionals) were involved 
in various aspects of the trial. Requests for 
involvement were tailored to each individual 
stakeholde  g oup s skills, k o ledge, e pe ie e a d 
stage of the trial. 
Principle 4: stakeholders are offered 
training and personal support to enable 
them to be involved in research 
Patient partners invited to join the Centre of Evidence 
Based Dermatolog s Patie t Pa el, hi h p o ides 
regular sharing of information, an annual face-to-face 
training day, and opportunities to attend relevant 
national training events and conferences. 
Principle 5: researchers ensure that they 
have the necessary skills to involve 
stakeholders in the research process 
Researchers involved in the HI-Light trial are 
experienced in the involvement of stakeholders in 
research and embedded within institutions that value 
the central role of patients and the public as partners 
in research.  
Principle 6: stakeholders are involved in 
decisions about how participants are 
Stakeholders were involved in the design and 
development of trial recruitment procedures and 
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both recruited and kept informed about 
the progress of the research 
documentation. Through The Vitiligo Society in 
particular, stakeholders were pivotal in the 
communication of trial developments to both 
participants and the wider vitiligo community and in 
giving advice about recruitment. 
Principle 7: stakeholder involvement is 
described in research reports 
Stakeholder contribution and analysis of its impact 
included in the final report and written up as a 
separate paper. 
Principle 8: research findings are 
available to stakeholders, in formats and 
in language that they can easily 
understand 
Stakeholders were invited to the HI-Light results 
meeting in order to discuss the findings of the 
research from a stakeholder perspective. Lay 
summaries of trial findings were developed with input 
from stakeholders. 
 
Details of stakeholder involvement and evidence of impact were collected on dedicated logs 
throughout the development and duration of the trial. 
6.4 Results 
Contextual factors relating to stakeholder involvement 
Funding body 
The HI-Light trial was funded by the National Institute for Health Research Health Technology 
Assessment (HTA) programme. This funding body is dedicated to the involvement of the public in the 
delivery of research, rather than through participation in clinical trials alone. The NIHR defines public 
invol e e t i  esea h as esea h ei g a ied out ith  o   e e s of the pu li  athe  
tha  to , a out  o  fo  the 74.  
Working in collaboration with the NIHR ensured committed funds for the involvement of the public 
throughout the delivery of the HI-Light trial, from the identification of the research question to the 
dissemination of trial results. 
Research Group 
Both the Centre of Evidence Based Dermatology (CEBD) and Nottingham Clinical Trials Unit (NCTU) 
have extensive experience in the involvement of the public in the delivery of clinical trials. The CEBD 
were able to utilise existing networks, including a well-established patient panel whose members 
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receive training and support through face-to-face workshops, newsletters and attendance at 
relevant training courses/conferences 
Sponsor organisation 
The University of Nottingham places strategic importance on the involvement of patients and the 
public in both teaching and research activities. A Public Engagement Lead is employed to support 
each faculty of the university, including the Faculty of Medicine and Health Sciences, to support 
researchers in developing PPI initiatives to engage effectively with PPI partners throughout project 
delivery. 
Patient support groups 
The research team had strong pre-existing links with UK based charity The Vitiligo Society. 
Stakeholders involved in the HI-Light trial  
Stakeholders (including people with vitiligo and healthcare professionals) were involved across all 
areas of trial design and delivery. They were involved in prioritising the initial research question; 
completing surveys to inform trial design; developing and testing the primary outcome; assisting in 
trial conduct, recruitment and oversight; and contributed to the analysis and interpretation of the 
trial results. The number and types of stakeholder involved at each stage in the trial life cycle are 
shown in Figure 10. 
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Establishing the research question
Development of primary outcome 
Validation of primary outcome
Research design & delivery
Supporting analysis
461
177
134
9
4
Stage of project Number of contributors Proportion of contributor type
Interpretation & dissemination of 
results
4
Vitiligo patients/carers Healthcare Professionals Other 
 
Figure 10 Stakeholder contribution to the design, development and execution of the HI-Light trial 
 
Stages of research and opportunities for stakeholder impact 
The impact of stakeholder contribution in the development and delivery of the HI-Light Trial are 
summarised in Table 31. 
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Table 31 The impact of stakeholder contributions to the trial. 
Stage of the research Methods used in the HI-Light trial Measures of impact 
Establishing the 
research question 
  
 In 2009, members of the HI-LIGHT Trial team led the 
Vitiligo Priority Setting Partnership in collaboration 
with the James Lind Alliance and The Vitiligo Society21. 
 
302 people with vitiligo, 142 healthcare professionals 
and 17 people from other sources contributed to the 
survey. 
 
 
The PSP identified the top priorities for future research as defined by people 
with vitiligo and healthcare professionals, whilst also highlighting the 
importance of assessing the suitability of vitiligo treatments for children. The 
National Institute for Health Research prioritised a commissioned research 
call to address two of the Top 10 research priority topics: 
(1) Which treatment is more effective for vitiligo: steroid creams/ointments 
or light therapy?  
(2) How effective is UVB therapy when combined with steroid creams or 
ointments in treating vitiligo?  
The HI-Light trial was designed to fit this call and recruited both children and 
adults to help in providing a much-needed evidence base for children with 
vitiligo.  
Development of 
primary outcome 
measure 
A systematic review was conducted to assess which 
outcomes are measured most frequently in vitiligo 
trials33. In parallel, a survey conducted between 
January and March 2009 asked people with vitiligo or 
Emphasised the inconsistencies across the reporting of outcome measures 
in vitiligo trials and the need for standardised outcome measures. 
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their carers (n=165) to suggest which outcomes 
should be used in future clinical trials. These two 
processes laid the foundation for work to identify a 
core set of outcomes measures, which should be 
captured in future vitiligo trials 
 
Three online discussion groups involving people with 
vitiligo (n=12) were held with an overall aim to further 
narrow down (i) the most important concepts when 
measuring treatment success and (ii) potential 
wording for questions to assess treatment success. As 
with the earlier PSP, participants for the focus groups 
were identified via the CEBD mailing list and through 
the VS. 
 
Helped to establish the most important outcome measures in vitiligo 
research, including cosmetic acceptability of treatment response. 
 
Survey work amongst people with vitiligo showed that the outcome domains 
that a e i po ta t to people ith itiligo i luded os eti all  a epta le 
epig e tatio  a d o al looki g ski 33 . 
 
Further work determined the most appropriate way of assessing cosmetic 
acceptability of treatment response contributed to the development of the 
VNS43. 
 
Validation of primary 
outcome measure 
 
Work was carried out to validate the primary outcome 
measure (VNS) through the scoring of baseline and 
after treatment images by health care professionals (n 
= 33) and people with vitiligo (n = 101).  
 
This work showed that (i) the VNS has good construct validity, acceptability 
and interpretability, supporting its inclusion as a patient-reported measure 
of the cosmetic acceptability of treatment response in vitiligo trials, (ii) the 
VNS is a better and more consistent indicator of global treatment success 
than percentage repigmentation, (iii) VNS scores of 4 or 5 can be interpreted 
as representing treatment success and (iv) further validation of the VNS is 
required43. 
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Research design and 
delivery 
  
Trial oversight An experienced patient researcher (MW) was a co-
applicant on the grant application for the HI-Light trial, 
acting also as a representative of The Vitiligo Society. 
Another patient representative of The Vitiligo Society 
(MS) acted as a lay member of the Trial Steering 
Committee (TSC). 
 
A patient researcher (MW) joined the trial team as a 
co-applicant and was a regular participant in Trial 
Development Group meetings during the funding 
application process. 
The presence of patient representatives on trial oversight committees was 
invaluable throughout the design and delivery of the trial, helping to ensure 
that patients remained at the forefront of trial objectives. 
Trial documentation Five patients with experience of vitiligo advised on the 
content and ease of use of Patient Information Sheets 
and treatment diaries. 
Feedback was incorporated into all aspects of patient facing trial 
documentation to ensure that it was both meaningful and informative to 
vitiligo patients. 
Data collection The patient researcher (MW) advised and commented 
on the development of the CRF, suggesting wording 
changes and amendments. 
 
Feedback from MW led to the following changes to the Case Report Form: 
• “uggested getti g o se  i stead of a ti e . 
• Questio ed the ea i g of dieta  e ui e e ts . 
• Suggested we try to capture information about traditional non-
western medicine. 
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Nine patient representatives were involved in the 
review and testing of the online follow-up 
questionnaires for the trial. 
• Suggested that a visual prompt i.e. drawing of a hand and foot, 
rather than a descriptive prompt may help when identifying patches during 
follow-up appointments. 
There were few reported problems with the online questionnaires from trial 
participants, and questionnaires that were completed were comprehensive. 
Recruitment and 
engagement activities 
The patient researcher (MW) and a young person with 
vitiligo and her mother assisted with the recording of 
a video to aid recruitment, and a video demonstration 
of how to use the light treatment (see images 1a and 
1b). These videos were used for training purposes. 
Site staff were encouraged to play the videos to 
participants at their baseline clinic appointment as a 
part of their intervention training. Participants were 
then given either a DVD of the training videos to take 
home, or a link that they could use to watch the 
videos online. 
 
The patient researcher and trial Chief Investigators 
gave presentations at The Vitiligo Society conferences 
to raise awareness of the trial. They also contributed 
pieces to The Vitiligo Society newsletter on an ongoing 
Participants reported feeling confident in their ability to use the treatments 
appropriately.  
 
Interviews carried out with trial participants as a part of the trial process 
evaluation suggested that, alongside the participant handbook, the videos 
were a useful tool to assist with the treatment regime. 
 
 
138 
 
 
basis, to update Society members about the progress 
of the trial and to help with trial recruitment 
Supporting analysis   
Providing blinded 
outcome assessment 
from the perspective 
of people with vitiligo 
Blinded assessment of baseline and post-treatment 
digital images were undertaken by 3 lay assessors 
(people with vitiligo) and 1 clinical assessor. 
Data provided by these blinded assessors were used to inform interpretation 
of the trial results. 
Process evaluation   
 A subset of HI-Light trial participants and their carers 
were interviewed once they had completed the trial. 
Questio s e plo ed the patie ts  e pe ie es i  usi g 
the treatments and possible barriers and facilitators to 
their use. 
Results of the process evaluation informed interpretation of the trial results 
and implementation planning for uptake of the treatments within the NHS. 
 
  
Interpretation   
 Four people with vitiligo attended the internal trial 
results reveal meeting. 
Patient partners were involved in producing and 
reviewing lay summaries of the trial findings, 
participant newsletters and social media 
communications. 
Having a strong patient presence at the internal results meeting ensured 
that interpretation of the results was appropriate and helped inform 
discussions around the clinical relevance of the observed treatment effects. 
Patient representatives also provided guidance on the delivery of trial 
results to the vitiligo community. 
Summaries of results were provided in accessible formats for multiple 
stakeholder groups 
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Figure 11 Stills from the HI-Light trial training videos.  
A patient researcher (a) and a young person with vitiligo and her mother (b) demonstrate the use of 
the NB-UVB handheld light device 
 
From stakeholder to participant 
During the delivery of the HI-Light trial, the patient researcher (MW) expressed an interest in being 
involved as a trial participant. In such instances, care should be taken to ensure that there is a clear 
distinction between being a member of the trial team (in this case a patient representative) and trial 
participation in order to protect the blinding and to preserve the equipoise of the research team. 
Following discussions between the research team and the patient researcher, it was decided that the 
prior role as a member of the research team should cease for the duration of her involvement as a 
trial participant. However, our patient researcher was able to provide valuable input at the trial 
results meeting, where she assisted with interpretation of the results and ongoing dissemination 
activities. 
Reflections from our stakeholders 
 
I feel very privileged to have been involved with the Hi-Light project from its inception. I was 
impressed by the way the trial was organised and conducted which involved patients in many 
aspects of trial design. I took part in videos, including the (NB)UVB training video, and other 
forms of publicity to encourage participation in the trial. My observation that small 
improvements in percentage repigmentation was not meaningful for patients led to the 
decision to develop a new scale for use as the primary outcome measure in the trial. I also 
commented on the wording of all patient-related study materials and on-line questionnaires 
to make them easier for patients to complete and I helped to develop the VNS scale. 
a b 
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Patient researcher and member of the Trial Management Group 
As I have vitiligo, and have experienced the difficulties in getting access to treatment. The 
trial seemed to provide a bit of hope for those wanting to treat their patches. If people have 
an opportunity to do this kind of voluntary work, I really recommend taking it. It s ee  eall  
interesting and I hope the lay volunteers have made a positive contribution to the trial 
overall. 
Blinded image assessor 
 
Being a vitiligo sufferer myself, I felt honoured to be asked to be part of this trial by looking 
at before and after treatment photos. It is exciting to see the research that is still being done 
and how the ways of treatment are still being explored. I would also be happy to take part in 
any future trials and participate in any further research. 
Blinded image assessor 
 
: As someone with vitiligo it is always pleasing to be asked to help in research. I have a PhD in 
pain control based on research I did in the NHS many years ago so I know how important it is 
to have people willing to give their support to research projects in a committed and 
consistent manner – I was more than happy to help. I would hope that if the results are in 
favour of a treatment effect then this treatment can then be offered to more people – but it 
a  o l  o k fo  so e a d ot at all fo  othe s so e d eed to t  it a d see o  a ase  
case basis. I look forward to learning more about this and thank you for allowing me to 
participate as an image reviewer. 
Blinded image assessor 
 
 I was delighted to be approached and take part in this trial. I agreed to take part because a) 
it felt like a professionally run trial and b) my role as a trustee of a related charity. 
I felt the organisation of the trial, the regular communications and reading materials were 
excellent. I felt part of the team and I recognised that extra effort that was made to include 
me in conversations/debates even though I was not a medical expert. As a senior manager in 
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business I was able to draw parallels with the formal board meetings and governance I have 
encountered in my day to day work. This felt like a series undertaking. 
I felt a little energy and momentum has been lost recently but that is also a recognition of the 
very high standards encountered at the beginning.  
Going forwards I would like to have sight of any publications relating to the research and 
would be delighted to support any further research relating to vitiligo.  
Patient member of the Trial Steering Committee 
When Ebony and I were approached to take part in the Hi-light trial, it gave us a great 
opportunity to be involved in research that was being undertaken in order to help those who 
were living with vitiligo. Both Ebony and I were happy to contribute to this trial as we 
believed that any outcome would be one step nearer to finding a cure for vitiligo or at least 
being able to manage the symptoms of living with vitiligo.  
I believe that during the trial the journey was made easier from the training tape that we 
were allowed to follow but also from the support that we were given during this time from 
those involved in the trial. 
Mother of child participant 
 
Maintaining communication 
A Trustee of The Vitiligo Society, who has vitiligo, actively contributed as a member of the Trial 
Steering Committee (TSC). This, along with the involvement of the patient researcher on the Trial 
Management Group, provided invaluable patient perspectives on key trial decisions. It also helped to 
maintain a connection between the trial management team and the community of people with 
vitiligo. The Chief Investigator and patient researcher attended meetings organised by The Vitiligo 
Society in order to keep the vitiligo community aware of trial progress and encourage participation 
in the trial. 
 
6.5 Discussion 
This report documents the diverse involvement of stakeholders in the development, delivery and 
dissemination of a large multicentre RCT. The importance of PPI and wider stakeholder involvement 
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in all aspects of research delivery were recognised by the trial funder, trial sponsor and research 
team. This shared passion helped to facilitate successful stakeholder involvement throughout the life 
cycle of the HI-Light trial. 
We have demonstrated significant impact from stakeholder involvement, particularly in prioritising 
the research question, defining the primary outcome, and informing the trial design. Involving a 
panel of people with vitiligo in the blinded assessment of the digital images was innovative and 
provided reassurance that the primary outcome was not influenced by accidental unmasking of the 
trial participants to their treatment allocation. Involvement of a range of key stakeholders during 
discussion of the trial results was key to understanding the clinical relevance of the findings, which 
demonstrated a statistically significant, but relatively small treatment effect. 
We used existing partnerships between people with vitiligo and the research team, in order to 
facilitate meaningful stakeholder contribution across all aspects of the trial, with almost 800 
individuals contributing overall. Given the large number of children involved in the trial, it is possible 
that greater impact could have been made by involving young people and parents of children with 
vitiligo. 
There was some criticism from stakeholders that communication towards the later stages of the trial 
was less evident and this most likely reflects the long time delay between the end of treatment at 9 
months, and the end of long-term follow-up after 21 months. For trials such as this with long-term 
follow-up, special efforts could helpfully be made to ensure that participants and stakeholders 
understand the reason for apparent inactivity and delays in hearing about the study results.  
6.6 Conclusion 
The NIHR-funded HI-Light trial had a strong stakeholder contribution in all aspects of trial design and 
delivery. With invaluable input from patients, patient carers and healthcare professionals, we were 
able to deliver the largest multi-centre vitiligo trial to date, and have successfully developed a 
patient-reported outcome and used it to assess a patient-led intervention. Our working relationship 
with the vitiligo patient community has proven to be mutually beneficial, and one that we hope 
continues to grow. 
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Chapter 7: Device Testing 
7.1 Introduction 
NB-UVB treatment is usually carried out in a hospital setting, although in some countries there are 
well-developed systems for allowing NB-UVB treatment to be carried out at home 75. For vitiligo, 
although treatment is usually administered in a hospital setting, there is increasing interest in hand-
held devices, which can be used at home to deliver NB-UVB to localised areas of vitiligo24, 76, 77. 
However, there are a number of evidence and knowledge gaps in the optimum use of localised NB-
UVB treatment for vitiligo23, 24. In particular, there is little evidence regarding the consistency of 
dosing delivered by localised NB-UVB units, the quality assurance measures that should be followed 
in their use, and whether there are any significant safety issues, especially when people with vitiligo 
use the units at home. 
• In preparation for the main trial, a pilot study was carried out that identified potential 
dosimetry issues that may arise during the use of hand-held NB-UVB units, which could have 
possible implications for maintaining adequate control of participant NB-UVB exposure. The 
following potential dosimetry issues were identified: 
• the a solute de i e output as lo e  tha  the a ufa tu e s spe ifi atio , hi h has 
implications for defining the treatment protocol exposure times 
• there was variation in device output , which could make it difficult to evaluate treatment 
effects 
• there was a change in tube output during use, with implications for defining the treatment 
protocol exposure times 
• short-term early life change in device output were observed, which suggests that a pre-burn 
of bulbs prior to delivery to a participant might be necessary. 
These issues have the potential to be critically important in the context of home-based treatment, 
without the usual degree of control over treatment that would be achieved in a hospital-based 
phototherapy unit. Furthermore, we wanted to minimise potential variance in trial outcomes caused 
by NB-UVB dosimetry issues. Therefore, it was clear that we needed to conduct a thorough analysis 
of device output prior to their use in the main trial. 
The aim of the work reported here was to ensure that the hand-held NB-UVB devices used in the HI-
Light Vitiligo Trial delivered a consistent and safe dose for all trial participants (addressing the issues 
identified above), so that any variance in trial outcomes attributable to variance in the output of the 
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NB-UVB devices would be kept to an absolute minimum. We planned to achieve this aim using the 
following objectives: 
1. To establish whether the device output was consistent with the outputs as specified by the 
manufacturer, and to quantify the variation in device output across all devices used. 
2. To quantify the likely drop in output over time and establish whether a pre-burn period was 
necessary prior to distribution of devices to trial participants. 
3. To provide quality control checks on all trial devices prior to distribution to ensure all issued 
devices had outputs within a pre-determined range. 
4. To develop a dosing schedule for use in the trial that ensured patient safety whilst delivering a 
clinically useful dose of NB-UVB. 
 
7.2 Materials and Methods 
Use of NB-UVB devices in the HI-Light Vitiligo Trial 
Before commencing trial recruitment, we undertook a photometric characterisation set of 
measurements as described in Study 1 below, in order to achieve objectives 1,2 and 4.  
The Hi-Light Vitiligo Trial recruited 517 participants (children aged over 5 years and adults) who were 
randomised into one of three parallel groups. 425 live devices and 175 placebo devices were tested. 
This was more than the number of participants due to some tested devices not being suitable for 
participants and anticipation of some devices requiring replacement during treatment. Participants 
(and their carers) were recruited at 16 secondary care sites around the UK and trained in how to use 
the NB-UVB device by watching a training video, and receipt of a written manual during a thorough 
face-to-face training with a research nurse. If a participant felt that the NB-UVB device was not 
working properly, they reported this to the co-ordinating clinical trials unit, and a replacement unit 
was sent out from the central trial pharmacy. Faulty devices were returned by the participant and 
replaced. The faulty devices were sent back to the manufacturer. 
Once the trial started recruitment, we performed the tests described in Study 2 below prior to 
issuing the devices, to achieve objective 3. All study tests were performed by a single team of 
scientists and technologists experienced in UV measurements. 
Devices and test equipment 
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The hand-held NB-UVB device used in the HI-Light trial was the Dermfix 1000MX unit (Androv 
Medical, Leatherhead, UK). This unit is provided with a suggested dosing schedule, to be used after 
consultation with a supervising medical professional. We sought to develop a simplified dosing 
schedule that could be used in the trial. Initially the manufacturer supplied 10 Dermfix 1000MX units 
and 2 fluorescent tubes for characterisation (LightTech LTC 9W/G23 and Philips PL-S 9W/01/2P 
tubes). Although there were small differences in spectral emissions [differing relative intensities at 
equivalent wavelengths] and a reduced output from the LightTech tube, the cost differential 
between the tubes was felt to outweigh these emission differences and so for all further 
characterisation and trial utilisation, LightTech tubes were used in the hand-held devices. This is the 
standard configuration for this unit. 
A Bentham DMc150 spectroradiometer (Bentham Instruments, Reading, UK), comprising a 
radiometer and double monochromator, was used to verify spectral outputs and an ILT 1700 
radiometer (International Light Technologies, Peabody, MA, USA) was used for instantaneous 
i adia e easu e e ts a d i teg ated dose easu e e ts. The spe t o adio ete s dou le 
monochromator and radiometer were calibrated against a mercury lamp with traceable spectral 
emissions. The ILT 1700 radiometer was field calibrated against the spectroradiometer. 
To ensure consistency of output measurements, a jig to hold the Bentham and ILT sensors was 
designed and built by the Clinical Engineering Department at Nottingham University Hospitals NHS 
Trust (Figure 12 and Figure 13). This ensured that the sensors were positioned over the centre of the 
lamp at the comb tip in order to consistently simulate desired clinical use. 
 
Figure 12 Elevation drawing of the measurement jig 
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Figure 13 Photos showing three differing views of the test jig 
7.3 Study 1: Photometric characterisation of the NB-UVB devices prior to their use in the trial 
In order to achieve objectives 1,2 and 4, we developed the following protocol to test the 
photometric characteristics [spectral output, actual irradiance, consistency of irradiance during 
warm-up, longer-term stability of the irradiance-time curve] of the device with the LightTech tubes: 
a. Measure the spectral output for 10 tubes and compare with the manufacturer s 
specification using the Bentham monochromator. 
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This test was to ensure that the tube emission spectrum was both as expected and consistent across 
tubes (Objective 1). 
b. Measu e the i adia e at  i utes follo i g s it h o  [to o pa e ith a ufa tu e s 
specification] and integrated dose at various time points [from 15s to 210s in 15s intervals], to 
calculate average dose-rate as a function of time for each LightTech tube, then calculate the mean 
values and variance across all LightTech tubes. 
We ca ied out these tests oth to e su e that the tu es et the stated a ufa tu e s output at  
minutes and also to investigate the irradiance changes during tube warm-up when the irradiance 
initially rises fairly rapidly, before dropping off more slowly. These tests evaluated whether the tube 
outputs were repeatable, thus allowing more confidence in any set treatment protocol (Objectives 
1,2,4). 
c. Measure irradiance to simulate various treatment regimen simulations [2 x 30% total; 2 x 
65% total; 2 x 100% total] following the skin type VI treatment protocol [longest treatment times] for 
three lesions, simulating actual usage. 
We carried out these tests to investigate whether the irradiance-time curve shape remained 
constant irrespective of usage. (Objectives 1,2,4) 
d. Measure integrated dose for 50% total, 2 x 50% total, 100% total in single exposures. The 
100% single exposure was conducted on two LightTech tubes. 
We a ied out this test to i estigate if f a tio atio  of total e posu e ha ged tu e 
characteristics (Objectives 2,4).  
Tests a and b were designed to test the absolute characteristics of the tubes and to assess the 
variability of performance. This helped us to develop cut-off tolerances for irradiance and integrated 
exposure when testing trial devices prior to issue to participants, excluding devices whose 
characteristics fell outside these tolerances. 
Tests c and d were designed to test the fall-off in irradiance and integrated dose, to ascertain if any 
pre-burn was required and to inform the trial treatment protocols. It also gave an insight into 
whether or not tests done on used devices following participant use could be used to determine 
treatment protocol adherence by the trial participants. 
 
7.4 Study 2: Quality assurance of devices prior to distribution to trial participants 
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Study 2 addressed Objective 3, ensuring consistency of performance for devices issued in the trial. 
For reasons of efficiency, devices were tested in batches of approximately 15-25 prior to release to 
participants. The tests undertaken included: 
• A spectral irradiance test to look for any gross fault or set-up error in the supplied device 
[such as an incorrect tube fitted] 
• Peak irradiance [3 minutes after start-up for all devices] to check if the device irradiance was 
within 20% of our validated irradiance values 
Due to the la ge a ia ilit  i  tu e i adia e at the a ufa tu e s spe ified ti e of  i utes post 
start-up, we measured irradiance at 3 minutes post-start-up, as we discovered that this was a more 
stable measure of individual tube performance (see results). 
7.5 Results 
Study 1 – Characterisation of Devices 
Ten tubes from the same manufacturing batch were tested for spectral irradiance. The results of 
these measurements are shown in Figure 3. The results show almost exact coincidence of the 
spe t al i adia e fo  all te  tu es. The  also sho  good oi ide e ith the a ufa tu e s 
specified spectral irradiance. The main irradiance was at 313 nm, with subsidiary peaks at 365nm, 
405nm and 435nm. There was a very small UVA component [365nm]. 
 
Figure 14 Spectral irradiance for the first batch of 10 tubes 
Table 32 shows the irradiance results from the sample of ten tubes. These results are to be 
o pa ed ith the a ufa tu e s spe ifi atio  [ t pi al i adia e at s ] at the tu e s id-point 
 
 
149 
 
at the comb tip of 7 mWcm-2. These results showed that most tubes would fall within our 
acceptance criteria of an output +/- 20% from the value used to inform the clinical treatment 
protocol. 
Table 32 Summary statistics for the characterisation of the irradiance  
Mean irradiance, 
mWcm-2 
 
Min irradiance, 
mWcm-2 
Max irradiance, 
mWcm-2 
Std. Dev. 
mWcm-2 
Ma ufa tu e s 
Specified 
irradiance 
mWcm-2 
4.02 3.58 4.50 0.26 7 
[Summary statistics for the characterisation of the irradiance measured at the comb tip midway 
along the tube at 120s post-start-up, fo  the i itial sa ple of te  LightTe h tu es [ f. Ma ufa tu e s 
specified irradiation at same time point, 7 mWcm-2] 
The ea  de i e output as o l  % of the a ufa tu e s spe ified output. For clinical protocol 
derivation a mean tube irradiance of 4 mWcm-2 was used. 
 
Figure 15 Tube irradiance (normalised to the maximum irradiance) as a function of time 
 
The results of simulating various participant protocols on the irradiance are shown in Table 33. 
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Table 33 Average irradiances following simulated treatment regimens for type VI skin.  
Treatment time [% of total 
fractions from the start] 
Average % Drop 
(from mean start maximum 
value) 
30% 23% [n=5] 
65% 31% [n=4] 
100% 37% [n=2] 
The values in parentheses in column 2 are the number of tubes that contributed to the average. 
The table shows the average irradiance and percentage drop from the initial maximum average 
irradiance at various time points during the treatment protocol for skin type VI for three lesions (the 
maximum number of lesions to be assessed in the trial). It allows for the repeated turning on and off 
of the device on different days and therefore includes multiple warm-up times, as would be the case 
for a real participant treatment regimen. 
Study 2 – Results of devices prior to issue to participants 
Although the spectral irradiance test in Study 2 was designed to ensure no devices with gross set-up 
errors (e.g. incorrect tube wavelength) were issued to participants, it also allowed us to track 
changes in tube manufacturing. The peak irradiance wavelength was noted to change from 313nm 
to 314nm after about a fifth of the batch processing. This slight change in the wavelength of the 
peak irradiance was not due to any calibration drift of our monochromator and was most likely due 
to changes in the phosphor composition of the fluorescent tubes. This change did not produce any 
significant change in the amount of UVA radiation. 
Twenty-one batches were tested and 9/21 (43%) batches had devices where one or more devices 
showed an irradiance outside the range 3.22 – 4.82 mWcm-2 (mean value +/- 20%). A total of 54 live 
devices were rejected out of a total tested of 425 (13%). One batch (24 live devices) was tested 
where all devices lay outside the required range. After confirming that this was not due to faulty 
bulbs, combs or voltage supply, it was assumed that a power supply fault was responsible and the 
devices were returned to the manufacturer. The batch sizes ranged from 15 to 25 units. 
 
7.6 Discussion 
The results of the characterisation tests on the LightTech tubes clearly showed a real output much 
lower than supplier information. This difference [a factor of approximately 0.6] would have required 
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an increase in treatment time of 75% to allow for the drop in output performance of the real-world 
tubes. These results show the importance of thoroughly characterising NB-UVB devices prior to use 
to ensure adequate treatment. Although the much lower output of the units could have potentially 
led to a reduction in efficacy, we accounted for the lower output by adjusting the treatment 
schedule used in the trial. Based upon our measurements, there is a need for cost-effective, higher 
irradiance tubes that can be used in such devices. 
The tube irradiance as a function of time (Figure 15) was broadly the same for all tubes tested. For 
all tubes there was a brief (within first 2 minutes) increase in output, followed by a decrease in 
output characterised by a reducing gradient with a plateau reached after about 50% of the 
treatment time. To pre-burn the tubes to enable a constant output would therefore have required a 
pre-burn time of many hours. This could have been done in the setting of a research study but would 
be costly and potentially impractical when using the devices in clinical practice. One alternative 
approach would be to adjust the treatment schedule in the early stages of treatment, making 
allowances for the gradual loss of output. However, this would have been complicated to calculate 
and would not have allowed us to use a simple treatment schedule with fixed increments between 
treatments. We also felt that asking participants to recalculate doses themselves would add further 
complexity to the treatment, which might have reduced adherence. Moreover, any gradual loss of 
output in the early life of a unit will simply require that it is used for slightly longer periods with each 
subsequent use in order to achieve the expected mild degree of skin erythema and subsequent 
therapeutic response, and this would be achieved by simply moving on to the next step of the dosing 
schedule. Therefore, as the trial was pragmatic, reflective of real-life clinical practice, we decided not 
to pre-burn the tubes but instead to use them from new and to ask participants to follow the 
planned treatment schedule that included a two- i ute sta ilisatio  pe iod fo  the de i e p io  to 
commencing treatment. 
The fact that 1 in 8 devices were rejected due to their output lying outside the +/-20% cut-off point 
shows the importance of testing the devices prior to use. This quality control reduced the variance in 
treatment exposure amongst trial participants attributable to device output. It also demonstrates 
the need to check the output of devices before they are used in clinical practice as part of quality 
assurance, as is current practice for clinic-based treatment units.  
Furthermore, as these devices may be purchased by members of the public, the output variation 
from specification and output variation between tubes shows the need for clinical supervision, 
backed up by robust quality assurance, during their use. Given these results we would recommend 
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any member of the public purchasing such a device directly from a supplier seek specialist 
dermatological advice before use. 
The device tests described in this paper require expensive ultraviolet test equipment and scientific 
and technical expertise to interpret the results. These staff and equipment are not available at all 
hospitals and so may support the development of specialist centres of expertise supporting many 
dermatology services [a hub and spoke model]. 
We hope that our findings regarding the dosimetry and performance of hand-held NB-UVB units will 
help to inform the design of community-based phototherapy services in the future. There are, 
however, some additional considerations regarding the external validity of the work. In the trial, 
each device was used by only one participant. In a clinical service each device is likely to be used by 
several patients in succession, so the clinical service would have to decide whether to reissue the 
unit with the same bulb or, whether it would be better to fit a new bulb prior to the unit being re-
issued. For the tubes used in this study the manufacturer states a useful tube life of 400 hours, 
which is far longer than the integrated treatment time for three lesions on a participant with skin 
type VI for 9 months, so a single tube could potentially be used for multiple patients, although 
protocols would have to be developed to ensure that devices were fit-for-purpose when re-issued. 
As the study team required detailed technical specifications of the devices and tubes, a close 
working relationship with the supplier was essential in order to access such information; we received 
good support from the manufacturer in this respect. This would also be an essential requirement in 
the future when setting up a home-based phototherapy service using the devices. 
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Chapter 8: Discussion and conclusion 
8.1 Main Findings 
The HI-Light Vitiligo trial was a large, pragmatic RCT of home interventions (potent TCS and NB-UVB 
light therapy) for people with active and limited vitiligo. The combination of hand-held NB-UVB plus 
potent TCS for 9 months was found to be superior to potent TCS used on their own, was well 
tolerated and was potentially cost-effective (£2,329 unadjusted or adjusted £1,932 per additional 
treatment success, though there is currently no evidence to indicate how much a decision maker 
would be willing to pay for an additional treatment success). NB-UVB used as monotherapy was not 
superior to potent TCS and had a higher incremental cost per additional successful treatment than 
combination treatment compared to TCS alone. 
Blinded evaluation of treatment success as assessed by a panel of three people with vitiligo 
supported the primary outcome, although treatment effects were larger and both NB-UVB and 
combination treatment were significantly better than TCS alone. It is unclear why blinded observers 
would value the treatments more than the participants in the trial, but it is possible that the trial 
participants balanced the observed treatment effects against the burden of adhering to treatment 
over 9 months.   
Results for investigator-assessed percentage repigmentation, using digital images of the vitiligo, 
were also consistent with the participant-reported primary outcome (VNS). Percentage 
repigmentation is the most commonly used outcome in vitiligo trials33, and so these results provide a 
useful context for comparison with other studies.  
Quality of life was high for all groups at baseline and no differences were observed between groups 
following treatment. 
Both NB-UVB and potent TCS were well tolerated. Erythema (grade 3 or 4) was a relatively common 
side-effect, but these episodes were limited to the small areas being treated and were managed 
effectively. The incidence of clinical skin thinning was rare despite the relatively long-term 
intermittent use of potent TCS, including on the face.  
Sensitivity analyses were supportive of the main findings and participants who adhered to the 
t eat e t egi e    % e e o e likel  to a hie e t eat e t su ess. The e as o diffe e e 
et ee  the t eat e t g oups a o di g to age adults e sus hild e  o  du atio  of itiligo  
years versus < 4 years). 
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In line with clinical experience, vitiligo patches on the hands and feet responded less well to 
treatment; this was true for whatever interventions were being used.  
At 3 months, over 90% of participants in all three groups showed onset of treatment response at the 
target patch, suggesting that all were effective in stopping the spread of vitiligo. However, onset of 
t eat e t espo se as defi ed as stopped sp eadi g stayed the same  o  i p o ed ), which 
could have resulted in an over-estimation of treatment effect if potential participants over reported 
recent changes to the target patch in order to gain access to treatment.  
 
I te p etatio  of esults fo  ai te a e of t eat e t espo se  e e li ited  lo  follo -up 
rates at 12 to 21 months. Nevertheless, the results suggest that treatment response may be lost 
quite rapidly once interventions are stopped and that maintenance therapy may be required to 
retain the pigmentation gained during treatment. 
Process evaluation findings suggested that patients and healthcare professionals were positive 
about the role of combination treatment in the management of vitiligo.  
Despite being time consuming and (potentially) complex, both participants and healthcare 
professionals indicated that, with appropriate support, combination treatment could be managed at 
home. Appropriate training and on-going monitoring, particularly in the early stages of treatment 
are essential, especially given concerns about potential side effects. 
People with vitiligo were perceived to have few treatment options, thus supporting the broader use 
of combination treatment in the NHS, with some caveats about which patients might benefit most. 
Those with a lifestyle that is incompatible with regular time-consuming treatments, unrealistic 
expectations of treatment, or poor levels of adherence to prior treatments may be poor candidates 
for combination treatment.  
Both healthcare professionals and commissioners recognised that the need for a developed 
infrastructure (including nursing support and medical physics provision) might be a barrier to 
broader NHS provision. Regional clinics might be a possible solution, as might some form of mixed 
economy approach, where patients purchase light-therapy devices alongside NHS support and 
training. 
 
Relevance to the wider literature 
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These results show that combination treatment with NB-UVB and potent TCS is more effective than 
a single intervention (in this case, TCS). This is consistent with previous research, which has shown 
that combination treatments are generally more effective than monotherapies in treating vitiligo, 
although overall response rates, both in our study and previous research, are generally modest.22, 25, 
26
 
 
Although there have not been any studies assessing the same interventions as those used in this 
study, the response rates are comparable with other studies. A meta-analysis of studies assessing 
phototherapy for vitiligo78, including 29 prospective studies of NB-UVB, epo ted a a ked 
espo se  > % repigmentation) in around 19% of participants after 6 months of NB-UVB 
monotherapy. This is similar to the rates of treatment success in our study, measured using the VNS 
(18% for NB-UVB only and 28% for combination at 6 months), although we observed lower success 
rates based on % repigmentation (5% for NB-UVB only and 11% for combination at 6 
months). The same meta-analysis reported better response rates for vitiligo on the head and neck, 
which is consistent with our study78.  
No other studies have compared the specific combination of NB-UVB and mometasone furoate with 
mometasone alone, so direct comparison is difficult. One study comparing the combination of NB-
UVB and clobetasol propionate (a more potent TCS) with NB-UVB alone79 was identified in the 
Cochrane systematic review of interventions for vitiligo22. This study suggested that combination 
treatment might be more effective than NB-UVB monotherapy, but the study was small and so 
lacked power to demonstrate any statistically significant difference between the intervention 
groups; the relative risk ratio for achieving >75% repigmentation was 1.38 (95% CI 0.71-2.68)79. 
No significant safety issues have been identified in previous small studies of home-based hand-held 
phototherapy devices for vitiligo, used instead of hospital NB-UVB therapy25, 26, and this is confirmed 
by the findings of our study. Long-term NB-UVB treatment (mean number of treatments = 211) in a 
study of patients with darker skin types conferred no increase in skin cancer risk, suggesting that NB-
UVB can safely be continued for longer periods than in our study, although most patients in that 
study were skin types IV-VI80. Large cohort studies of patients having long-term treatment with NB-
UVB have also shown no significant increase risk in skin cancer risk from this treatment39, 40. 
 Although combining NB-UVB and calcineurin inhibitors (e.g. tacrolimus) was discouraged in the past, 
due to concerns over a possible increased risk of skin cancer, a number of studies assessing this 
combination of treatment have been published over the last few years. A systematic review by Arora 
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et al81 identified three studies comparing a combination of NB-UVB and tacrolimus with NB-UVB 
monotherapy. Meta-analysis of two of these studies showed combination treatment to be more 
effective than NB-UVB monotherapy in achieving >75% repigmentation, although only just (RR 1.34; 
95% CI 01.05–1.71). It is possible that further studies comparing these interventions will provide 
sufficient data to make the confidence estimates stronger, but this remains to be seen. 
Strengths and Limitations 
This was a large, pragmatic trial that was designed and managed in collaboration with an accredited 
clinical trials unit. Using a patient-reported primary outcome meant that treatment success reflected 
the views of people with vitiligo and was supported by blinded outcome assessment using digital 
images for both VNS and percentage repigmentation; both of which have been recommended for 
inclusion in vitiligo clinical trials by people with vitiligo.35  
As found in other vitiligo trials22, retention throughout the trial was challenging. Just over 70% of 
participants provided primary outcome data at 9 months, and fewer than 50% provided data by 21 
months. This limited interpretation of some of the results, especially during the long-term follow-up 
phase.  
Since loss to follow-up was higher than originally anticipated, the trial lacked power to provide a 
high level of precision around the point estimates. 
Adherence to treatment regimens was quite low (see Table 6). This was most likely due to the time 
burden of treatments, particularly the active or dummy NB-UVB devices. This is a limitation of the 
study but this was a pragmatic trial  and treatments were delivered by the participant and / or their 
carers at home (with nursing support). It is possible that participants adhered more to trial 
interventions as a result of being in a trial, and this may have led to an overestimate of treatment 
effects. However, we think that overall, the level of use of the treatments is reflective of how they 
would be used in real life. 
We used a single, standardised treatment schedule, which we asked all participants to follow. This 
started at a very low dose and then built up to higher doses in small increments. This will have 
meant that for participants with darker skin types, the first few doses will have been lower than 
those used in conventional hospital-based phototherapy, where starting doses are determined by 
measuring the Minimum Erythemal Dose (MED) prior to starting treatment. However, participants 
would all move up the schedule to longer treatment times, and over the course of treatment (up to 
nine months), these smaller initial doses are not likely to have had a significant impact on the total 
NB-UVB dose received by those participants using active devices. 
 
 
157 
 
Participants were encouraged to choose a target patch that was genuinely the one in which they 
most wanted to see a difference. If they had two patches on different parts of the body which they 
were equally keen to see an improvement in, and if one of the patches was on the hands and feet, 
they were advised that the response may not be as good on the hands and feet, but they could still 
choose for the hand / foot patch to be their target patch. Many participants still chose a hand / foot 
patch as their target patch, but it is possible that some participants may have decided to change the 
target patch to one on the head and neck or rest of body. This could have introduced bias into the 
study findings. However, this is similar to the situation in clinical practice, where a patient may be 
advised that treatment of vitiligo in certain anatomical locations may be less effective, and that it 
may make more sense to concentrate on treating areas of vitiligo that are more likely to responds to 
treatment. 
Generalisability  
This trial has good external validity as it was a large, pragmatic trial with few exclusions, although all 
participants were required to have active vitiligo that affected less than 10% of their body surface 
area. People with more extensive vitiligo are unlikely to find these interventions helpful as the 
treatments would become overly burdensome.   
The trial included both children and adults and treated different body sites. Planned sub-group 
analyses explored the impact of these characteristics but found no evidence of differential 
treatment response by age or body site, other than the overall poorer response rates on the hands 
and feet. People with all skin types and ethnicities were included in the trial as this reflected the 
types of patients typically presenting for vitiligo treatment within the UK NHS. We did not exclude 
participants with lighter skin types (Types I and II), as vitiligo can cause considerable distress in such 
people as well as those with darker skin types16, 82. A post-hoc analysis by skin type found no 
differential treatment response in people with paler skin types (types I to III) or those with darker 
skin types (types IV to VI), although we would emphasise that this was an exploratory, post-hoc 
analysis and the study was not specifically powered for this analysis.  
The trial was designed to reflect normal clinical practice as far as possible. Hand-held NB-UVB 
devices such as those tested in this study are not widely available within the UK National Health 
Service at present, although a few sites do offer treatment with similar devices and they can also be 
pu hased o li e a d used at the use s o  isk. In the trial, nurses in secondary care dermatology 
departments delivered training on use of the treatments, and participants were reviewed every 3 
months during clinic visits. Additional support was provided by telephone as required, if participants 
had queries about use of the interventions or experienced side effects.  
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The process evaluation conducted alongside this study identified the importance of the support 
provided to participants, in order to enable them to use the treatments safely. Participants and 
investigators agreed that the complexity of the treatments meant that support and close monitoring 
were essential. Some participants had considered purchasing a light therapy device, but had decided 
against this due to a lack of the necessary support infrastructure. If the treatments were introduced 
into the NHS, the cost of providing this support infrastructure would need to be taken into account, 
and healthcare decision makers would have to decide how much they are willing to pay to achieve a 
successful treatment. The relative lack of other treatment options, and the likely high cost of newer 
drug treatments currently being developed, wounblinduld be important to consider when making 
such decisions.  
8.2 Conclusions 
Implications for healthcare 
The HI-Light Vitiligo Trial demonstrates that combination treatment with NB-UVB and potent TCS is 
superior to potent TCS alone, although the benefits are likely to be modest. Combination treatment 
was safe, well tolerated and cost-effective for people with limited vitiligo that had been active within 
the last 12 months. Given uncertainty about how much decision makers would be willing to pay to 
achieve an additional treatment success (as defined in this study) it is unclear whether combination 
treatment is cost-effective. 
Patients starting vitiligo treatments should be made aware of the considerable time commitment 
required, and the likely duration of treatment over many months. Clinical review at 3 months 
appears to be an appropriate time point at which to judge whether further treatment is likely to be 
beneficial.  
Our study confirmed that vitiligo on the hands and feet responds less well to treatment, so treating 
these anatomical areas may be difficult to justify when resources are limited.  
Hand-held, home NB-UVB therapy appears to be a useful treatment option for people with vitiligo 
and provides considerable advantages over hospital NB-UVB therapy (which requires hospital visits 
2-3 times per week). Home NB-UVB requires training and support from healthcare professionals with 
experience of delivering phototherapy services and is time intensive for patients.  
Use of mometasone furoate 0.1% ointment (a potent corticosteroid) as first-line treatment for 
vitiligo is supported, as it achieved treatment success in 1 in 6 individuals and was effective in 
stopping the spread of active vitiligo patches. Stopping the spread of vitiligo is an important 
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treatment outcome to people with the condition 21, 33. These trial results suggest that potent TCS is 
safe in both adults and children when used one week on, one week off for 9 months. 
Treatment effects were lost once interventions were stopped, suggesting that maintenance therapy 
is likely to be needed to prevent further loss of pigment. 
Compared to potent TCS, combination treatment had a lower incremental cost effectiveness ratio  
than NB-UVB monotherapy (meaning that an additional treatment success can be attained for a 
lower cost), although the mechanism for widespread implementation of a home-based NB-UVB 
service for skin disorders within the NHS has yet to be established.  
Qualitative findings from our mixed methods process evaluation study suggested that people with 
vitiligo and healthcare professionals who treat them would value the provision of home NB-UVB as a 
useful treatment option for the management of vitiligo, despite the relatively modest treatment 
effects. Both trial participants and healthcare professional suggested that so e fo  of i ed 
e o o  ight e ost effe ti e a  of p o idi g ho e light the ap . This ould pote tiall  
involve patients leasing or purchasing a phototherapy device, and the NHS providing the necessary 
training, quality assurance and support for patients. This would reduce the likely cost to the NHS 
(see sensitivity analysis in section 4.13) but would have equity implications in that treatment would 
only be accessible to those patients able to afford it. 
These findings need to be disseminated to a wide audience. People seeking treatment for vitiligo are 
unlikely to receive any treatment if they do not receive appropriate advice from health 
professionals. In the UK, people with vitiligo are likely to consult a GP initially, and research amongst 
members of the Vitiligo Society suggest people view their GP as their primary source of information, 
although GPs appear to have low awareness of vitiligo.83 The NICE CKS guideline suggests that 
people seeking treatment for vitiligo may be prescribed TCSs and/or referred to dermatology84. 
However, anecdotally, such management does not always seem to be followed. The safety data from 
this trial suggest that GPs can be reassured that adverse effects are rare if potent TCSs are used long-
term once daily on alternate weeks (one week on, one week off). 
Implications for research 
Participants in the HI-Light Trial reported relatively high quality of life scores at baseline using both 
generic and vitiligo-specific quality of life instruments. Despite having good quality of life, all 
participants were keen to access vitiligo treatments and were wiling to use them over many months, 
suggesting that something other than quality of life was motivating treatment choices. It is not clear 
whether this was because the trial focussed on people with limited vitiligo (which had limited impact 
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on their quality of life), or whether the quality of life instruments themselves were insufficiently 
sensitive to detect the impact of vitiligo, particularly in relation to psychological impact of the 
condition.  
Since home-based phototherapy services for the management of skin disorders are currently 
available in only a small number of specialist centres, further research is required to establish the 
best ways of implementing a home-based light therapy service across the UK. This might usefully 
involve a hub-and-spoke model whereby specialist medical physics units perform the testing and 
maintenance of devices for a number of departments. 
We used participant-reported treatment success as the primary outcome, based on the noticeability 
of the vitiligo (VNS), to ensure that vitiligo treatments were judged against criteria that are 
meaningful to people with vitiligo. Further work is required to establish the validity, responsiveness 
and interpretability of the VNS. In particular, it would be helpful to establish how patients value a 
pa tial t eat e t  espo se as easu ed  the VN“. 
The HI-Light Vitiligo Trial was designed to address two of the questions prioritised by healthcare 
professionals and people with vitiligo in the James Lind Alliance Vitiligo Priority Setting Partnership21. 
Many of the Top 10 priorities remain unanswered (Box 1). 
James Lind Alliance Vitiligo Priority Setting Partnership top 1021 
1. How effective are systemic immunosuppressants in treating vitiligo?  
2. How much do psychological interventions help people with vitiligo?  
3. Which treatment is more effective for vitiligo: light therapy or calcineurin inhibitors (e.g. 
tacrolimus, pimecrolimus)?  
4. How effective is UVB light therapy when combined with creams or ointments in treating vitiligo?  
5. What role might gene therapy play in the treatment of vitiligo?  
6. How effective are hormones or hormone related substances that stimulate pigment cells (MSH 
analogues, afamelanotide) in treating vitiligo?  
7. Which treatment is more effective for vitiligo: calcineurin inhibitors or steroid creams/ointments?  
8. Which treatment is more effective for vitiligo: steroid creams/ointments or light therapy?  
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9. How effective is the addition of psychological interventions to patients using cosmetic camouflage 
for improving their quality of life?  
10. How effective is pseudocatalase cream (combined with brief exposure to UVB light) in treating 
vitiligo?  
I  additio , t o t eat e t u e tai ties e e suggested as o es to at h , as these i te e tio s 
were still in an early investigative stage.  
1. How effective is piperine (black pepper) cream in treating vitiligo?  
2. What role might stem cell therapy play in treating vitiligo? 
Box 2 James Lind Alliance Vitiligo Priority Setting Partnership Top Research Priorities  
  
Future research priorities that have emerged from the HI-Light Vitiligo Trial include the need for: 
1. Development and testing of new vitiligo treatments with a greater response and longer-
lasting effects. 
2. Investigation of treatments suitable for people with widespread vitiligo.  
3. Research into different strategies to maintain treatment response once treatments are 
stopped 
4. Further development and validation of outcome instruments to be included in the vitiligo 
core outcome set, to facilitate combining of trial results in meta-analyses. 
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Appendix 1 Addendum to HI-Light Statistical Analysis Plan (SAP) Final Version 1.0 dated 15 October 2018 
Changes from protocol v5.0 Additional points of clarification are outlined below. These amendments provide additional information on how the outcomes were reported and analysed, but 
do not substantially change the outcomes as defined prior to database lock.  
 
Protocol  SAP Justification  
Digital image assessment of the target patch at 9 
months by independent assessors is described 
as a secondary analysis of the primary outcome. 
The digital image assessment of the target patch at 9 months by independent 
assessors will be reported as an additional secondary outcome.  
More appropriate as a secondary outcome as based on 
new data from a different source to the primary outcome. 
Maintenance of treatment response will be 
reported for each of the three body regions. 
Maintenance of treatment response will be reported for the target patch only. Due to lower than expected follow-up rates, there is 
insufficient data to present the maintenance of treatment 
response at 12, 15, 18 and 21 months for each body 
region. 
Patient reported treatment success by body 
region will be assessed at 3, 6 and 9 months. 
Patient reported treatment success by body region will be assessed at 9 months 
only. Treatment success at 3 and 6 months will be presented descriptively. 
Minimise risk of type I errors from multiple hypothesis 
testing 
Percentage repigmentation will be assessed at 3, 
6 and 9 months. 
Percentage repigmentation will be assessed using digital image assessment by a 
blinded clinical assessor at 9 months. Where available, data from nurse 
assessments at 9 months will be used for missing blinded assessor data. 
Assessments carried out by nurses at 3 and 6 months will be presented 
descriptively.   
Minimise risk of type I errors from multiple hypothesis 
testing 
Participant-reported treatment burden will be 
presented at 3, 6 and 9 months based on 
average duration and number of treatment 
sessions and adherence with the treatment 
schedule. To be presented for light therapy and 
topical corticosteroid therapy separately. 
Treatment burden will focus on the burden of light therapy and will be 
presented alongside adherence data as a process measure.  
Average session duration for those who received an active light device will be 
reported at 3, 6 and 9 months and the proportion of participants who reported 
difficulties with treatment (including time burden) with be presented over 9 
months.  
  
For TCS, average time per session will not be reported as the time required for 
this was felt to be minimal. However, treatment burden for those receiving 
active TCS will be presented for those who reported experiencing difficulties 
with treatment (including time burden) presented over 9 months. . 
Calculating the duration of light treatment based on 
placebo devices is not appropriate as the dosing schedule 
would always increase as no erythema will have been 
experienced during the dosing schedule, and so treatment 
times are likely to be longer.  
 
Data regarding the duration of treatment sessions was not 
collected for TCS treatment as the time required to apply 
ointment is minimal.  
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Appendix 2 Participant reported VNS treatment success at all assessed patches at 3 and 6 months 
 
TCS NB-UVB Combination 
Treatment success for head and neck 
At 3 months  
At 6 months  
 
13/73(18%) 
15/62(24%) 
 
15/71(21%) 
15/57(26%) 
 
19/73(26%) 
29/68(43%) 
Treatment success for hands and feet 
At 3 months  
At 6 months 
 
7/94(7%) 
10/81(12%) 
 
10/89(11%) 
11/73(15%) 
 
2/87(2%) 
10/74(14%) 
Treatment success for rest of body 
At 3 months  
At 6 months 
 
7/106(7%) 
11/91(12%) 
 
8/99(8%) 
13/86(15%) 
 
11/104(11%) 
25/91(27%) 
 
Appendix 3 Participant assessed onset of treatment response 
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Appendix 4 Target patch % repigmentation assessed by nurse at 3, 6, and 9 months 
 
TCS   NB-UVB   Combination 
 
Repigmentation of target patch at 3 months   
0-24% 
25-49% 
50-74% 
75-100% 
 
Repigmentation of target patch at 6 months   
0-24% 
25-49% 
50-74% 
75-100% 
 
Repigmentation of target patch at 9 months   
0-24% 
25-49% 
50-74% 
75-100% 
 
119(89%) 
7(5%) 
4(3%) 
4(3%) 
 
 
91(79%) 
6(5%) 
10(9%) 
8(7%) 
 
 
83(72%) 
16(14%) 
6(5%) 
10(9%) 
 
110(81%) 
13(10%) 
7(5%) 
6(4%) 
 
 
73(65%) 
24(21%) 
10(9%) 
6(5%) 
 
 
72(63%) 
14(12%) 
18(16%) 
11(10%) 
 
111(78%) 
15(10%) 
11(8%) 
6(4%) 
 
 
75(60%) 
17(14%) 
19(15%) 
14(11%) 
 
 
66(55%) 
18(15%) 
14(12%) 
21(18%) 
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Appendix 5 Summary of related AEs by preferred term name in MEDDRA coding  
 
 TCS 
(n = 33) 
NB-UVB 
(n = 69) 
Combination 
(n = 104) 
Total 
(n=206) 
Acne  0 1 2 3 
Application site 
pruritus  
0 2 0 2 
Blister  0 4 2 6 
Contusion  1 0 2 3 
Dry skin  3 0 5 8 
Erythema  3 29 45 77 
Folliculitis  0 0 1 1 
Haemangioma  0 1 0 1 
Hair growth 
abnormal  
5 2 4 11 
Herpes virus 
infection  
0 2 0 2 
Herpes zoster  0 0 1 1 
Koebner 
phenomenon  
0 1 0 1 
Lip dry  0 0 1 1 
Lip pain  0 0 1 1 
Melanocytic naevus  0 1 0 1 
Miliaria  0 0 2 2 
Night sweats  0 1 0 1 
Oral discomfort  0 0 1 1 
Oral herpes  1 4 6 11 
Pain in extremity  0 0 1 1 
Pain in jaw  1 0 0 1 
Pain of skin  1 0 0 1 
Paraesthesia  0 0 1 1 
Polymorphic light 
eruption  
0 1 0 1 
Pruritus  3 7 10 20 
Pustular psoriasis  0 0 1 1 
Rash  6 3 4 13 
Rash pruritic  1 2 6 9 
Rhinalgia  1 0 0 1 
Skin atrophy  5 1 1 7 
Skin depigmentation  1 0 0 1 
Skin exfoliation  0 5 0 5 
Skin 
hyperpigmentation  
0 0 2 2 
Skin papilloma  0 0 1 1 
Skin striae  1 0 0 1 
Spider vein  0 1 3 4 
Telangiectasia  0 0 1 1 
Vitiligo  0 1 0 1 
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Appendix 6 Utility and QALYs for participants aged 11 and over (available case data, Secondary 
Cost utility analysis) 
 
 NB-UVB only (n=148) TCS only (n=155) Mean difference (95% 
CI) 
 Mean Std dev Mean Std dev  
Devlin et al 2018 utility value  
Secondary outcomes 
EQ-5D-5L 
Baseline 
0.9300   0.1346 
(139) 
0.9456 0.0805 
(151) 
-0.0156  
(-0.0410 to 0.0098) 
EQ-5D-5L 
9 months 
0.9527  0.1108 (89) 0.9231   0.1240 (97) 0.0295  
(-0.0046 to 0.0637) 
QALYs at 9 
months 
0.7082  0.0699 (89) 0.6989 0.0694 (97) 0.0093 
(-0.0109 to 0.0295) 
 Combined (n=153) TCS only (n=155) Mean difference (95% 
CI) 
 Mean Std dev Mean Std dev  
Secondary outcomes 
EQ-5D-5L 
Baseline 
0.9247 0.1381 
(147) 
0.9456 0.0805 
(151) 
-0.0209  
(-0.0466 to 0.0048) 
EQ-5D-5L 
9 months 
0.9446 0.1057 (97) 0.9231   0.1240 
(97) 
0.0215 
(-0.0111 to 0.0540) 
QALYs at 9 
months 
0.7064 0.0757 (96) 0.6989 0.0694 
(97) 
0.0075 
(-0.0131 to 0.0282) 
 NB-UVB only (n=148) TCS only (n=155) Mean difference (95% 
CI) 
Mean Std dev Mean Std dev  
OHE 2018 utility value set  
Secondary outcomes 
EQ-5D-5L 
Baseline 
0.9299 0.1374 
(139) 
0.9461  0.0800 
(151) 
-0.0162 
(-0.0420 to 0.0095) 
EQ-5D-5L 
9 months 
0.9537 0.1101 (89) 0.9239 0.1245 (97) 0.0298  
(-0.0044 to 0.0639) 
QALYs at 9 
months 
0.7086 0.0696 (89) 0.6996 0.0690 (97) 0.0090 
(-0.0110 to 0.0291) 
 Combined (n=153) TCS only (n=155) Mean difference (95% 
CI) 
 Mean Std dev Mean Std dev  
Secondary outcomes 
EQ-5D-5L 
Baseline 
0.9250 0.1399 
(147) 
0.9461  0.0800 
(151) 
-0.0211 
(-0.0470 to 0.0048) 
EQ-5D-5L 
9 months 
0.9448 0.1059 (98) 0.9239 0.1245 
(97) 
-0.0209  
(-0.0118 to 0.0535) 
QALYs at 9 
months 
0.7068 0.0754 (96) 0.6996 0.0690 
(97) 
0.0073 
(-0.0132 to 0.0278) 
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Appendix 7 Survey of recruiting centre staff 
Introductory page: 
In anticipation of the Hi Light Trial Results day we would like to ask you some questions about your 
experience of providing hand-held phototherapy to the Hi Light participants.  
We are particularly interested to hear about any insight that you would like to share with those that 
might be thinking about providing a similar therapy to their patients. 
 
Context to these questions: 
Existing evidence points to the benefits of phototherapy (in combination with other treatments) in 
the management of vitiligo; existing evidence points to the potential for home-based phototherapy 
using hand-held devices. 
Some consideration of the clinical aspects of this (dosing, etc.) is manifest in the literature, but little 
has been said about service organisation and how best to delivery this type of therapy.  
The NHS is a distinct context for delivering this type of service.   
 
About you: 
Are you: a doctor / a nurse / a specialist dermatology nurse / other(?) 
 
Prior to Hi Light had you been involved in any form of phototherapy service? Y/N 
What was your role in the Hi Light trial? 
Are you already aware of the Hi Light trial results? Y/N 
 
Question 1: 
Do you agree that home-based phototherapy should be made more widely available for vitiligo 
patients? 
 strongly agree / agree / neutral / disagree / strongly disagree 
 
We appreciate that the Hi Light results will ultimately inform this decision, but at this point we 
would welcome your intuitive response. 
Can you explain your response? What is it about home-based phototherapy (and your experiences 
as part of Hi Light) that encourages, or discourages, you about its use? 
Free-te t espo se o …. 
 
Question 2: 
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Do you think that home-based phototherapy is appropriate for all vitiligo patients? 
All patients / most patients / some patients / few patients / no patients 
Could you explain your answer? What factors might influence whether a patient is appropriate for 
home-based phototherapy? 
We would be interested to hear if you think that there are types of vitiligo presentation which are 
more, or less, appropriate for home-based phototherapy. 
We would also be interested to hear if you think that lifestyle /personality/ personal circumstance 
are important in this decision.  
Free-te t espo se o …. 
 
Question 3: 
Do you agree that delivering a home-based phototherapy service is feasible in the NHS? 
 strongly agree / agree / neutral / disagree / strongly disagree 
We appreciate that ultimately this is a decision that commissioners will make, but we would invite 
your comment about the practical challenges that this might involve. 
What were the difficulties and challenges that you found in delivering the Hi Light trial? Do you have 
any suggestions that would make a home-based phototherapy service easier to deliver or manage? 
Free-text response o …. 
 
Question 4: 
Do you think that participants (and their families) found hand-held phototherapy easy to do at 
home?  
 Very easy / easy / neutral / difficult / very difficult 
We would be interested to hear about any difficulties or challenges that participants experienced 
with the hand-held phototherapy (and/or steroid cream).  
We would be interested to hear about any strategies or techniques that participants used to 
manage, and about the nature of support that you offered them in this. 
Free-text response o …. 
 
Question 5: 
How important do you think it is for any hand-held phototherapy devices to be provided and 
maintained by an NHS provider? 
 
Can you explain why you think this? 
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Do you have any thoughts about patients purchasing their own hand-held phototherapy unit? Via 
the NHS? Via a commercial provider? 
Free-te t espo se o …. 
 
Question 6: 
Do you have any other comments, or recommendations, that would help others to establish and run 
a home-based phototherapy service for vitiligo. 
Do you have any top-tips that you would like to share?  
Free-te t espo se o …. 
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